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Abstract 
Background: Antioxidants in plant foods have been proposed to reduce the risk of cardiovascular 
diseases (CVD) by reducing oxidative stress. The objective was to confirm prospective studies on 
CVD and traditional antioxidants (beta-carotene, alpha-tocopherol), and to investigate emerging 
antioxidants (alpha-carotene, gamma-tocopherol, cocoa flavanols), and oxidative stress (enzyme 
activity of glutathione peroxidase-3) with CVD risk.  
Methods: In cross-cultural studies, the Cretan (Greece) and Zutphen (The Netherlands) cohorts of 
Seven Countries Study were compared with respect to long-term mortality of coronary heart disease 
(CHD), diet, and indicators of oxidative stress. In prospective cohort studies, data were used from 
the Zutphen Elderly Study (~500 men aged 65-84 y), the ‘Survey in Europe on Nutrition and the 
Elderly: a Concerted Action’ (SENECA, 1168 men and women aged 70-75 y), and the Minnesota 
Heart Survey (270 men and women aged 26-85 y).  
Results: The comparison between the Cretan and Zutphen cohorts revealed a 3-fold lower 40-year 
CHD mortality rate in Crete. This lower mortality in Crete was paralleled by a higher consumption 
of fruit, tomatoes, and olive oil, amongst others, and by a lower consumption of meat, poultry, and 
dairy. Consequently, the Cretan men had higher intakes of carotenoids, alpha-tocopherol, vitamin C, 
and dietary fiber, and lower intakes of trans and saturated fatty acids. This was confirmed at the age 
of ≥80 years, when the Cretan men had higher plasma concentrations of major dietary antioxidants 
(major carotenoids and alpha-tocopherol), a lower iron status, and a lower level of oxidative stress. 
In the Zutphen Elderly Study, the relative risk (RR) of 15-y CVD mortality for 1 standard deviation 
(SD) increase in dietary intake was 0.81 [95% confidence interval (CI): 0.66-0.99] for alpha-
carotene and 0.80 (95% CI: 0.66-0.97) for beta-carotene. The intake of tocopherols was not related 
to CVD death. In SENECA, plasma concentrations of carotene (sum of alpha- and beta-carotene) 
were inversely related to CVD mortality (RR for 1 SD increase: 0.83; 95% CI: 0.70-1.00), but 
plasma concentrations of alpha-tocopherol were not. The daily use of 4 grams of cocoa, a rich source 
of flavanols, was related to a 3.7 mm Hg lower systolic (95% CI: –7.1 to –0.3) and a 2.1 mm Hg 
lower (95% CI: –4.0 to –0.2) diastolic blood pressure. The same amount of cocoa was also related to 
a 50% lower risk of 15-year CVD mortality (RR: 0.50; 95% CI: 0.32-0.78). Finally, in the 
Minnesota Heart Survey, the odds ratio of CVD mortality for the highest vs. the lowest quartile of 
glutathione peroxidase-3 activity was 0.42 (95% CI: 0.21-0.86). This inverse relation was confined 
to those with low concentrations of HDL cholesterol (odds ratio highest vs. lowest quartile: 0.17; 
95% CI: 0.06-0.47). 
Conclusion: The Cretan Mediterranean diet is rich in antioxidants, which may partly contribute to 
the low observed CHD mortality. The findings on beta-carotene support previous observational 
studies suggesting that this carotenoid relates to a lower CVD risk. We showed that alpha-carotene is 
correlated with beta-carotene in the diet, and alpha-carotene was also related to a lower CVD 
mortality. The results on alpha-tocopherol are in line with the outcomes of clinical trials and do not 
indicate a role for this vitamin in lowering CVD mortality in elderly populations.  
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Plant Foods, Antioxidants, and 
Cardiovascular Diseases 
 
 
 
 
Plant foods, in particular fruit and vegetables, are known to contain large amounts of 
antioxidants. In the early 1980s, antioxidants became promising compounds in preventing or, at 
least, lowering the risk of cardiovascular diseases. Vitamin E, beta-carotene, and to a lesser 
extent vitamin C were extensively studied. Later, other carotenoids than beta-carotene and also 
polyphenolic antioxidants became a topic of scientific interest. This thesis comprises cross-
cultural and prospective cohort studies on plant foods, antioxidants, and oxidative stress in 
relation to cardiovascular diseases. This introductory chapter describes what kinds of 
antioxidants are found in plant foods, how they are proposed to protect against cardiovascular 
diseases, the results of observational and intervention studies on antioxidants, and, finally, the 
rationale for the research in this thesis. 
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Plant foods and antioxidants 
Plant foods, such as fruit and vegetables, whole grains, nuts and seeds, and olive oil as the 
principle source of fat, form key components of traditional Mediterranean diets. Diets rich in 
plant foods may prevent a variety of chronic diseases, including cardiovascular diseases (CVD) 
(1,2). Compounds that are considered to contribute to the cardiovascular beneficial effects of 
plant foods include dietary fiber, unsaturated fatty acids, folate, potassium, and also 
antioxidants.  
Antioxidants are widely distributed in plant foods, in particular fruit and vegetables. 
Well-known antioxidants are vitamin C, vitamin E, carotenoids including beta-carotene, and 
polyphenols such as flavonoids. Their functions in plants are inherent to their immobility. Plants 
frequently have to cope with stressful environmental changes, such as drought, extreme 
temperatures, high levels of sunlight (radiation), and attacks by insects and pathogens (3). By 
synthesizing an impressive array of antioxidants, plants are able to protect themselves from 
these environmental threats. In general, antioxidants tend to concentrate in those parts of the 
plant that are most prone for oxidative damage (4). Vitamin C, for example, is in fairly high 
concentrations present in chloroplasts to protect the plant from reactive oxygen species that are 
developed during photosynthesis (4,5). Vitamin E is thought to protect plants against excess 
exposure to sunlight (6). Apart from absorbing light and transferring its energy to chlorophyll, 
carotenoids also protect plant tissues from photo-oxidative damage by losing excess of thermal 
energy and scavenging harmful oxygen species like triplet chlorophyll and singlet oxygen (6). 
Finally, phenolics, to which the flavonoids belong, possess antibacterial and antiviral effects (7). 
By consuming plant foods, humans ingest antioxidants. The amount of antioxidants in 
the diet depends on the consumed amount and the antioxidant content of the particular plant 
foods. A typical diet of adults in The Netherlands provides daily roughly 80 mg of vitamin C, 13 
mg of vitamin E, and about 1.3 mg of beta-carotene (8,9). There is no precise estimate of the 
average intake of flavonoids in The Netherlands, but it is likely to be about 180 mg per day 
(reference 10 and personal communication M. Bekkers).  
It is thought that a mild to moderate deficiency of certain antioxidants, although in the 
case of the vitamins not severely enough to cause classical deficiency diseases, may increase the 
risk of developing CVD (11). Therefore, high intakes of antioxidants may reduce CVD risk in 
humans. The mode of action is proposed to be similar as in plants: by preventing oxidative 
damage. More specifically, antioxidants are hypothesized to inhibit the main underlying process 
that leads to CVD, atherosclerosis. 
The oxidative modification hypothesis and its implications 
Atherosclerosis is a chronic inflammatory disease of the arterial wall in which lipid 
accumulation is accompanied by thickening and hardening of the vessel wall (12). One of the 
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first steps in the process of atherosclerosis is excessive uptake of LDL cholesterol by 
macrophages, which then become foam cells that compose the pre-atherosclerotic fatty streaks 
(13).  
In the late 1970s, Brown and Goldstein discovered that the rate at which macrophages in 
culture take up native LDL cholesterol is by far insufficient to load the cell with cholesterol (14). 
A second important observation they made was that patients totally lacking the native LDL 
receptor nevertheless accumulate large amounts of cholesterol in their macrophages (14). They 
proposed that instead of native LDL, it was some modified form of LDL that was taken up 
excessively by macrophages and gave rise to foam cells. In the early 1980s, the group of 
Steinberg found that native LDL was rapidly converted to a form that was taken up much more 
rapidly after it was incubated with cultured vascular endothelial cells or smooth muscle cells 
(15,16). Shortly there after, it was shown that the modification was basically oxidative damage 
of LDL (17,18). In 1989, Steinberg and colleagues published their landmark paper on the 
oxidative modification hypothesis of atherosclerosis (19). 
The oxidation modification hypothesis did not only explain the detrimental effect of 
cigarette smoking on CVD (by oxidizing LDL), but also implied that antioxidants may have an 
important role. It was postulated that antioxidants prevent LDL from oxidation, and 
consequently slowdown the atherosclerotic process and reduce the risk of cardiovascular 
diseases. Probucol, a powerful synthetic fat-soluble antioxidant, was shown in 1986 to block the 
oxidation of LDL in vitro (20). Later, probucol was found to inhibit atherogenesis in animal 
models. These results, amongst others, stimulated interest to conduct epidemiologic studies and 
randomized controlled intervention trials on antioxidants and cardiovascular diseases. With the 
benefit in hindsight, the conferees at a 1991 workshop on antioxidants convened by the National 
Heart, Lung and Blood Institute concluded that the evidence was sufficiently strong to justify 
starting clinical trials (21).  
While the randomized trials were ongoing and more findings from observational studies 
were published, antioxidants became very popular as dietary supplements. Especially vitamin E 
enjoyed ‘superstar status’ among the dietary supplements, particularly in the US (22). In the 
1990s, about 40% of the cardiologists in the US reported to use a supplement containing vitamin 
E (23), a percentage that makes one wonder what these cardiologists advised their patients. 
Perhaps it is not surprising that the largest increase in the use of vitamin supplements in the US 
between 1987 and 2000 was for vitamin E (24). 
Antioxidants and cardiovascular diseases: the evidence 
from early observational studies  
Gey and colleagues published the first observational study on antioxidants and CVD. In that 
study, of which the first findings were published in 1987 (25) and in more detail two years later 
Plant foods, antioxidants, and cardiovascular diseases 
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(26), blood concentrations of antioxidants as measured in randomly selected samples of 
residents of 12 different European regions were cross-sectionally related to regional mortality 
rates of coronary heart disease at the population level. A strong inverse relation was observed 
for concentrations of vitamin E, whereas no associations were seen for concentrations of beta-
carotene and vitamin C (26). Since then, numerous observational studies have been published. 
Two studies that particularly fuelled the enthusiasm to conduct large-scale trials with vitamin E 
were the Health Professionals’ Follow-up Study (27) and the Nurses’ Health Study (28). These 
two prospective cohort studies found that vitamin E, in particular from supplements, was related 
to a 40% lower risk of coronary heart disease. An indication that a high intake of carotenoids 
could lower coronary heart disease (CHD) risk was found in the Lipid Research Clinics’ 
Primary Prevention Trial, where men with serum carotenoid concentrations in the top quartile 
had a 36% lower risk of CHD (29). In support, male health professionals in the top quintile of 
carotene intake had a 30% lower risk of CHD compared to those in the lowest quintile (27). 
The evidence from early observational studies, in summary, suggested an inverse 
association between vitamin E and heart disease, possibly only at intakes that can be obtained 
from using vitamin E supplements. Beta-carotene could also lower heart disease risk. A similar 
role for vitamin C seemed unlikely given the inconsistent results from observational studies 
(30). However, evidence from randomized trials was needed to prove the efficacy of 
antioxidants in lowering CVD risk. 
The proof of the pudding: randomized controlled trials 
At present, a number of clinical trials reported on the efficacy of antioxidants on CVD. Most of 
them were randomized, double-blind, placebo-controlled trials, though differed with respect to 
type and dose of antioxidants, end points, duration, and study population (Table). The study 
populations participating in these trials varied, though generally consisted of subjects with 
established CVD, malignant disease, or who were at risk of these diseases.  
Unexpectedly, the vast majority of these trials showed that neither vitamin E (31,32), 
beta-carotene (31-34), nor vitamin C (32), either alone or in combination with each other 
(32,35), lowered the risk of cardiovascular events. These findings were similar for primary 
(33,36) (37,38) and secondary prevention (39,40) of CVD. Two relatively small trials reported 
that vitamin E (400-800 IU/day)  reduced the risk of cardiovascular diseases (41,42), but their 
results were outweighed by the null findings of the larger trials (43). Also, in one of the two 
smaller trials, the ‘Secondary Prevention with Antioxidants of Cardiovascular disease in 
Endstage renal disease’ (SPACE) trial, the study population consisted specifically of patients 
with end-stage renal disease (41). Although such patients are known to have oxidative stress 
(44,45), the apparent beneficial effect of vitamin E seen in the SPACE trial was not confirmed in 
patients with mild-to-moderate renal insufficiency enrolled in the Heart Outcomes Prevention 
(HOPE) Study (46).  
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Table: Randomized clinical trials of antioxidant supplementation and risk of cardiovascular diseases 
 
Study,  year 
(reference) 
 
 
Country 
 
 
Design 
 
 
Study population 
 
No. 
participants
 
Men, 
% 
Age 
range, 
y 
 
Duration, 
y 
 
 
End point 
 
Antioxidant 
supplementation
 
Dosage per 
day 
Relative risk  
(95% confidence 
interval) 
Trials included in a 2003 meta-analysis (43)         
ATBC Cancer 
Prevention 
Study, 1994 (31)
Finland 2×2 Male smokers not using 
anticoagulants 
29 133 100 50-69 6.1 CVD mortality 1. Beta-carotene 
2. Vitamin E 
3. Both combined 
20 mg 
50 IU 
 
1.11 (1.01-1.21) 
0.98 (0.89-1.07) 
NA 
CHAOS, 1996 
(42) 
United 
Kingdom 
Parallel Subjects with angiographically 
proven coronary artery disease 
2002 84 Mean, 
62 
1.4 1. Non-fatal MI 
alone; 
2. non-fatal MI 
and death from 
CVD combined 
Vitamin E 400 or  
800 IU 
0.23 (0.11-0.47) 
 
0.53 (0.34-0.83) 
PHS I, 1996 (33) United 
States 
Parallel * Physicians free of MI, stroke, or 
transient cerebral ischemia; 11% 
was current smoker at baseline 
22 071 100 40-84 12 Major CVD 
events 
Beta-carotene 25 mg 1.00 (0.91-1.09) 
CARET, 1996 
(34) 
United 
States 
Parallel Smokers, former smokers, or 
workers exposed to asbestos 
18 314 66 45-69 6 † CVD mortality Beta-carotene 
Retinol 
30 mg 
25 000 IU 
1.26 (0.99-1.61) 
GISSI-P Trial, 
1999 (48) 
Italy Parallel ‡ Subjects with previous MI, of 
whom 42% was current smoker 
at baseline 
11 324 85 Mean, 
59 
3.5 MI, stroke, and 
death from CVD 
combined 
Vitamin E 330 IU 0.98 (0.87-1.10) 
SPACE, 2000 
(41) 
Israel Parallel Hemodialysis patients with CVD 196 69 40-75 1.5 MI, stroke, PAD, 
and unstable 
angina pectoris 
combined 
Vitamin E 800 IU 0.46 (0.27-0.78) 
HOPE Study, 
2000 (40) 
19 countries Parallel § 
 
Subjects with previous CVD, or 
with diabetes and an additional 
CVD risk factor 
9541 73 ≥55 4.5¶ MI, stroke, and 
death from CVD 
combined 
Vitamin E 400 IU 1.05 (0.95-1.16) 
PPP, 2001 (37) Italy Parallel # Subjects free of CVD but with at 
least one major CVD risk factor 
4495  42 Mean, 
64 
3.6 MI, stroke, and 
death from CVD 
combined 
Vitamin E 330 IU 1.07 (0.74-1.56) 
HPS, 2002 (49) United 
Kingdom 
Parallel  Subjects with CVD, diabetes 
mellitus, or hypertension 
20 536 75 40-80 5 Major CHD 
events 
 
Beta-carotene 
Vitamin E 
Vitamin C 
20 mg 
660 IU 
250 mg 
1.02 (0.93-1.11) 
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Table (cont.): Randomized clinical trials of antioxidant supplementation and risk of cardiovascular diseases 
 
Study,  year 
(reference) 
 
 
Country 
 
 
Design 
 
 
Study population 
 
No. 
participants
 
Men, 
% 
Age 
range, 
y 
 
Duration, 
y 
 
 
End point 
 
Antioxidant 
supplementation
 
Dosage per 
day 
Relative risk  
(95% confidence 
interval) 
More recently published and ongoing trials         
HOPE Study, 
2004 (46) 
19 countries Parallel § Subjects with renal insufficiency 993 87 ≥55 4.5¶ MI, stroke, and 
death from CVD 
combined 
Vitamin E 400 IU 1.03 (0.79-1.34) 
SU.VI.MAX, 
2004 (50) 
France Parallel Apparently healthy adults, of 
whom 16% was current smoker 
at baseline 
13 017 39 35-60 7.5 Major CHD 
events 
Beta-carotene 
Vitamin E 
Vitamin C 
Selenium 
Zinc 
6 mg 
33 IU 
120 mg 
100 μg 
20 mg 
0.97 (0.77-1.20) 
WHS, 2005 (38) United 
States 
Parallel Female health professionals free 
of chronic diseases 
39 876 0 ≥45 4.1 MI, stroke, and 
death from CVD 
combined 
Beta-carotene†† 
Vitamin E 
25 mg 
300 IU 
1.14 (0.87-1.49) 
WACS, 2007 
(32)  
United 
States 
2×2×2 Female health professionals with 
CVD or at least 3 CVD risk 
factors 
8171 0 ≥40 9.4 MI, stroke, 
CABG/PTCA, 
and CVD 
mortality 
combined 
1. Beta-carotene 
2. Vitamin E 
3. Vitamin C 
4. Combined 
25 mg 
300 IU 
500 mg 
1.02 (0.92-1.13) 
0.94 (0.85-1.04) 
1.02 (0.92-1.13) 
No effects observed, 
except for fewer strokes 
for taking vitamins E and 
C (RR: 0.69; 95% CI: 
0.49-0.98) 
PHS II (51) United 
States 
2×2×2×2 Male physicians, of whom ~7500 
participated in PHS I 
15 000 100 ≥55  Important CVD 
events 
1. Beta-carotene 
2. Vitamin E 
3. Vitamin C 
4. A multivitamin 
25 mg 
200 IU 
500 mg 
 
Follow-up ended 
December 2007 
Abbreviations: IU, International Unit; ATBC, Alpha-Tocopherol Beta-Carotene; CVD, cardiovascular diseases; NA, not available (no interaction reported); CHD, coronary heart disease; MI, myocardial 
infarction; CHAOS, Cambridge Heart Antioxidant Study; CVD, cardiovascular diseases; PHS, Physicians’ Health Study; CARET, Beta-Carotene and Retinol Efficacy Trial; GISSI-P, Gruppo Italiano per 
to Studio della Sopravvivenza nell’Infarto miocardico Prevenzione; SPACE, Secondary Prevention of Antioxidants on cardiovascular diseases in End stage renal disease; HOPE, Heart Outcomes 
Prevention Evaluation; PPP, Primary Prevention Project; HPS, Heart Protection Study; SU.VI.MAX, SUpplémentation en VItamines et Minéraux AntioxYdants; WHS, Women’s Health Study; WACS, 
Women’s Antioxidant and Cardiovascular Study; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty.  
* In the Physicians’ Health Study, beta-carotene supplementation was one arm of a 2×2 factorial design for separate assessment of beta-carotene and aspirin use. 
† CARET was stopped prematurely because the active treatment group was found to have an increase in lung cancer and cardiovascular mortality. 
‡ In the GISSI-P Trial, vitamin E supplementation was one arm of a 2×2 factorial design for separate assessment of vitamin E and n-3 fatty acids. 
§ In the HOPE Study, vitamin E supplementation was one arm of a 2×2 factorial design for separate assessment of vitamin E and ramipril use. 
¶ After 4.5 y of follow-up, the follow-up on CVD events was stopped prematurely because the benefits of ramipril were conclusively shown and the effect of vitamin E was lacking. 
# In the PPP, vitamin E supplementation was one arm of a 2×2 factorial design for separate assessment of vitamin E and aspirin. 
†† Because of the null-findings in previous trials and the potential harmful effects that these trials indicate, beta-carotene supplementation was terminated after a median follow-up of 2.1 years. 
Plant foods, antioxidants, and cardiovascular diseases 
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Figure: Number of publications on antioxidants, oxidative stress, inflammation (panel A) and various antioxidants 
(panel B) in relation to cardiovascular diseases from 1970 to 2005. Publications were those registered in PubMed 
(http://www.ncbi.nlm.nih.gov/entrez, accessed October 2007). Values were determined as follows: number of results 
from the query “antioxidants” or “oxidative stress” or “inflammation” or “antioxidant X” AND “cardiovascular diseases” 
AND “year Y[dp]”. 
  
Apart from the largely null results, one trial suggested that antioxidants interfere with the 
efficacy of statin-plus-niacin therapy in coronary heart disease patients with low HDL 
cholesterol concentrations (35). It was suggested that antioxidants block the increase in the 
protective HDL-2 and apolipoprotein A1 subfractions of HDL cholesterol (47). 
The largely null-findings brought forward by the large-scale trials tempered the 
enthusiasm in antioxidants as preventive agents against CVD. In the popular and scientific press, 
antioxidants were seen as a ‘myth,’ a medical fairy tale (52), and it was questioned whether 
science was ‘back to square one’ (53). Especially vitamin E, the most extensively studied 
antioxidant, was degraded, with editorials entitled ‘Is there any hope for vitamin E’ (54) and 
‘Annus horribilis for vitamin E’ (22).  
As a consequence, the annual pile of scientific publications on antioxidants and CVD 
changed remarkably (Figure). After a sharp increase in the early 1990s, the number of reports 
on vitamin E dropped in the last 5 years, whereas those on carotenoids leveled off. The still 
increasing number of research publications on antioxidants is attributable to the interest in 
flavonoids; the number of reports on flavonoids has sharply increased since 1990. Oxidative 
stress is also still a topic of great interest. Inflammation, a condition that is hard to distinguish 
from oxidative stress, is even more popular. 
Rationale and outline of the thesis 
Despite the largely null-findings of the randomized trials, continuation of scientific research on 
antioxidants is important and even encouraged (55). Only by continuation of antioxidant 
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research it is possible to clarify the contradiction in results between the observational studies and 
the randomized trials and to assess whether oxidative stress, the oxidation modification 
hypothesis, and antioxidants are relevant to human atherosclerosis. 
This thesis aims to investigate the role of antioxidants and oxidative stress in the 
development of CVD from an epidemiological perspective. Specifically, the objective was [A] 
to confirm previous prospective cohort studies that found inverse associations of the traditional 
antioxidants beta-carotene and vitamin E with CVD risk, and [B] to investigate emerging 
antioxidants and oxidative stress in relation to CVD. These objectives were evaluated by cross-
cultural comparisons and prospective cohort studies. 
The cross-cultural studies used, in contrast to the vast majority of studies with this 
design, data of individuals with detailed information on possible confounding factors. In the 
prospective cohort studies, antioxidants in blood or diet and indicators of oxidative stress in 
blood were investigated. The data on dietary intake was collected repeatedly by using the dietary 
history method, thus representing the actual long-term intake. Chapters 2 and 3 present the 
cross-cultural studies in which the Cretan and Zutphen cohorts of the Seven Countries Study 
were compared with respect to long-term CHD mortality, diet and nutrient intake, and blood 
concentrations of antioxidants, fatty acids, iron status, and indicators of oxidative stress. 
Chapters 4 to 7 cover the prospective cohort studies. Because of the possibility that other dietary 
antioxidants, correlated with beta-carotene and alpha-tocopherol, may account for the inverse 
association in observational studies, Chapter 4 also describes associations for carotenoids and 
tocopherols. Chapter 5 covers a study aimed to confirm earlier published prospective cohort 
studies that suggested an inverse association of circulating levels of carotene and alpha-
tocopherol with CVD mortality. Given the interest in cocoa as a cardioprotective food ingredient 
(56), Chapter 6 describes a prospective cohort study about the associations of cocoa with blood 
pressure and CVD mortality. The relation between a scarcely investigated antioxidant enzyme, 
serum glutathione peroxidase 3, and CVD mortality is described in Chapter 7. Finally, the 
findings of the research in this thesis are discussed and put into context in Chapter 8. 
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Oxidative Stress, and Iron and 
Antioxidant Status in Elderly Men: 
Differences Between the 
Mediterranean South (Crete) and 
Northern Europe (Zutphen) 
 
Brian Buijsse, Edith J.M. Feskens, Joanna Moschandreas, Eugène H. Jansen, 
David R. Jacobs Jr., Anthony Kafatos, Frans J. Kok, and Daan Kromhout 
 
Background: Oxidative stress may accelerate ageing and increase the risk of chronic diseases, such as 
coronary heart disease (CHD). We assessed differences in oxidative stress, and iron and antioxidant status 
between elderly men living in Mediterranean southern Europe (Crete, Greece) and northern Europe (Zutphen, 
the Netherlands).  
Design: A cross-sectional study using data from two cohorts of the Seven Countries Study. 
Methods: Non-fasting blood samples were drawn in 2000 from 105 men from Crete and 139 men from 
Zutphen, all aged 79 years or over. All assays were performed in the same laboratory. 
Results: After multiple adjustments, serum levels of the markers of oxidative stress were lower in Cretan 
men than in men from Zutphen, as indicated by lower mean levels of hydroperoxides (33.2 versus 57.3 
μmol/l; P = .005) and gamma-glutamyltransferase (20.3 versus 26.1 U/l; P = .003). The most pronounced 
difference in iron status was a twofold lower mean serum ferritin level in Cretan men (69.8 μg/l) compared 
with men from Zutphen (134.2 μg/l; P < .0001). Men from Crete had consistently higher plasma levels of 
major plasma antioxidants than the Zutphen men, including a nearly fourfold higher mean level of lycopene 
(15.3 versus 4.1 μg/100 ml; P <.0001).  
Conclusions: Elderly men from Crete had consistently lower levels of the indicators of oxidative stress and 
iron status and higher concentrations of major antioxidants than men from Zutphen. These differences may 
contribute to the lower rate of CHD and total mortality that has been observed in this cohort of Cretan men.  
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Introduction 
Oxidative stress increases with ageing (1,2) and may be an independent risk factor for coronary 
heart disease(CHD) (3). Body iron stores also increase during the course of life (4), and a high 
iron status has been associated with an increased risk of age-related diseases, such as CHD (5). 
Like other transition metals, iron is thought to contribute to the development of oxidative stress 
by catalyzing reactions that produce oxidants. Antioxidants, on the other hand, may prevent 
oxidative stress by inhibiting reactions that would lead to the formation of oxidants, or by 
scavenging radicals. 
CHD mortality rates vary substantially across Europe. In adults, CHD mortality is the 
highest in northern and eastern Europe, whereas much lower rates are observed in European 
countries surrounding the Mediterranean Sea (6,7). In the Seven Countries Study (8), CHD 
mortality rates were the lowest in Crete, Greece, and four times higher in Zutphen, the 
Netherlands. Survival rates were also greater in Crete than in Zutphen (8). The lower CHD 
mortality rate in Cretan men compared with those from Zutphen cannot be completely explained 
by differences in traditional biological risk factors because differences in serum cholesterol and 
blood pressure levels between these populations were small (8). This suggests that other risk 
factors such as oxidative stress may play a role. 
At present, studies of the markers of oxidative stress, indicators of iron status, or 
circulating levels of antioxidants, have mostly investigated these parameters individually rather 
than ecologically, whereas most ecological studies lack individual data for detailed analysis. In 
the present study, we chose to measure indicators of oxidative stress, as well as iron and 
antioxidant status in the blood of elderly individuals, because they are likely to have high levels 
of oxidative stress. We evaluated our hypothesis that, consonant with their lower disease rates, 
elderly men in Crete have lower levels of the indicators of oxidative stress, a lower iron status, 
and higher levels of circulating antioxidants, compared with men of the same age from Zutphen, 
the Netherlands. 
Methods 
Study population 
For the present study, men aged at least 79 years living on Crete (Greece) and men of the same 
age living in Zutphen (the Netherlands) were selected. Both cohorts consisted of participants in 
the Seven Countries Study (9), a prospective cohort study that started in 1958. The original 
cohort in Crete consisted of 686 men, of whom 165 men were still alive in 2000. Of these men, 
152 were willing to participate and blood samples were drawn from 129 individuals. In 20 men, 
information on potential confounders was lacking, and in four men iron status could not be 
assessed, yielding information for 105 Cretan men for analysis (response rate 65%). The 
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Zutphen Elderly Study consisted of 939 men in 1985, approximately 50% of whom were first 
enrolled in 1960. For the examination in 2000, 240 men were still alive. Because 64 men were 
not willing to participate, 176 men enrolled in the study in 2000. Blood samples were taken from 
146 individuals. Because information on potential confounding factors was missing on four men 
and iron status could not be assessed in another three, 139 men were included in the present 
analysis (response rate 58%). The examination on Crete was conducted between May and 
August 2000, and in Zutphen between March and June 2000. The study was approved by local 
medical ethics committees. 
Blood collection 
Non-fasting blood samples were collected in the morning. In Crete, blood samples were allowed 
to stand for 2 h at room temperature, after which plasma and serum were obtained. In Zutphen, 
the samples were kept cool in a box with cool elements, and plasma and serum were obtained in 
the afternoon. Before transport within a few days of collection to the National Institute for 
Public Health and the Environment (RIVM), the Netherlands, samples were stored in Zutphen at 
– 30ºC and in Crete at – 80ºC. Samples from Crete were transported to the Netherlands on dry 
ice by plane. After arriving at the RIVM, all samples were stored at – 80ºC.  
Measurement of indicators of oxidative stress, iron status, and plasma 
antioxidants 
Serum indicators of oxidative stress 
We analysed two measures of in-vivo peroxidation. Total serum peroxides, primarily lipid 
peroxides, were measured enzymatically (OxyStat assay; Biomedica, Austria). 
Malondialdehyde, an end-product of lipid peroxidation, was measured by high-performance 
liquid chromatography (Chromsystems, Germany). Both assays were performed at the 
laboratories of the RIVM, Bilthoven, The Netherlands. Gamma-glutamyl-transferase (GGT), a 
possible marker of oxidative stress (10), was determined by a Technicon SMAC analyser 
(Technicon Instruments Corp., Tarrytown, New York, USA) at the Leiden University Medical 
Center.  
Iron status 
Serum iron, serum transferrin, serum ferritin and the unbound iron-binding capacity were 
determined at the laboratory of the RIVM by using a Hitachi 912 analyser (Roche Diagnostics, 
Indianapolis, Indiana, USA). The total iron-binding capacity was calculated by the sum of serum 
iron and unbound iron-binding capacity, and the proportion of transferrin saturation by dividing 
the concentration of serum iron by the total iron-binding capacity. Serum ferritin concentrations 
exceeding 300 μg/l in combination with a transferrin saturation exceeding 55% was taken as an 
indicator of iron overload (11). 
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Plasma antioxidant vitamins and serum endogenous antioxidants 
Plasma carotenoids and tocopherols were measured by high-performance liquid chromatography 
methods in the laboratory of the Division of Human Nutrition (Wageningen University, the 
Netherlands) according to a standardized protocol. All analyses were performed under subdued 
yellow light to prevent photo destruction. 
The endogenous antioxidants albumin, total bilirubin, and uric acid were measured in 
serum using a Technicon SMAC analyser at the Leiden University Medical Center. Control 
samples were determined during the assay for monitoring stability. 
Collection of data on lifestyle, biological risk factors, and history of chronic 
diseases 
Information on cigarette smoking, alcohol consumption, and the longest practised profession 
was collected by the same standardized questionnaires in Crete and Zutphen. The time spent in 
different physical activities was estimated in minutes per week with a validated questionnaire 
originally designed for retired men (12). Tertiles of physical activity were calculated based on 
the distribution of the total study population of 244 men. Subjects in the lowest tertile were 
defined as having a low physical activity. Information on whether subjects were using vitamin 
supplements or were on a diet prescribed by a doctor was obtained during an interview. 
During a physical examination, body weight was measured according to standardized 
procedures. Body mass index calculated by dividing weight (kg) by the square of height (m2), in 
which height measured around 1990 was used. The history of chronic diseases such as 
myocardial infarction, stroke, or cancer, and the presence of diabetes was ascertained by 
physical examinations of the subjects and by the use of questionnaires, and was verified by 
hospital records, information from general practitioners, and information from the previous 
surveys. 
Statistical analysis 
Analysis of covariance was used to assess possible differences in the mean values of variables 
between men from Crete and Zutphen, which allowed adjustment for potential confounders. For 
dependent variables with a positively skewed distribution, analyses were performed after natural 
logarithmic transformations; for these parameters, geometric means are presented. Besides 
adjustment for age (model 1), adjustments were made for body mass index and lifestyle factors 
such as smoking, alcohol consumption, physical activity, and the prevalence of chronic diseases 
(see subscript to Tables 2–4). All analyses were repeated after excluding subjects with a history 
of cardiovascular diseases, diabetes, or cancer. Means are presented with 95% confidence 
intervals, and reported P values are two-sided. All analyses were performed using the Statistical 
Analysis System, release 9.1 (SAS Institute Inc., Cary, North Carolina, USA). 
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Results 
General characteristics 
Selected characteristics of the study population are shown in Table 1. The mean age for both 
Cretan and Zutphen men was approximately 84 years (range 79.2–98.2). Elderly men from Crete 
were less likely to consume alcoholic beverages, and less often used a prescribed diet and 
vitamin or mineral supplements than elderly men from Zutphen. Furthermore, they had a lower 
body mean mass index and a lower mean C-reactive protein concentration. The proportion of 
men with a history of stroke and cancer was four times lower among men from Crete compared 
with those from Zutphen. 
 
Table 1: Selected characteristics of elderly men in Crete (Greece) and Zutphen (the Netherlands) in 2000 
Characteristic Crete Zutphen P value* 
Number of men 105 139  
Demographics and risk factors    
Age, y 84.5 (4.1) 84.0 (3.5) .33 
Cigarette smoking, % 0.5 0.1 .92 
Alcohol consumption, % 59.0 74.8 .009 
Low physical activity, % 31.4 32.4 .88 
Diet prescription, % 4.8 14.4 .01 
Use of vitamin supplements, % 2.9 18.0 .0002 
Body mass index, kg/m2 24.6 (4.2) 25.9 (3.7) .01 
Systolic blood pressure, mm Hg 150.2 (21.5) 145.7 (21.5) .11 
Diastolic blood pressure, mm Hg 76.9 (10.9) 74.4 (10.2) .06 
Serum total cholesterol, mmol/L 5.05 (0.93) 5.23 (0.98) .15 
Serum HDL cholesterol, mmol/L 1.21 (0.29) 1.23 (0.32) .65 
Serum C-reactive protein, mg/L, median [IQR] 2.8 [1.4, 5.5] 3.4 [2.0, 6.0] .03 
History of chronic diseases, %    
Myocardial infarction 16 (15.2) 23 (16.5) .78 
Stroke 6 (5.7) 23 (16.5) .01 
Diabetes 10 (9.5) 17 (12.2) .50 
Cancer 7 (6.7) 29 (20.9) .002 
Values are means (standard deviation) unless otherwise indicated. 
* P value for differences between Cretan and Zutphen elderly men based on unpaired t-test, Mann-Whitney U test, or Chi-square 
test. 
 
Serum indicators of oxidative stress 
After adjustment for potential confounders, Cretan elderly men had on average lower levels of 
serum hydroperoxides and GGT than elderly men in Zutphen (Table 2). Furthermore, the mean 
level of serum malondialdehyde was non-significantly lower in Cretan men, a result that 
persisted after the exclusion of men with chronic diseases (data not shown). 
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Table 2: Mean levels (95% CI) of serum indicators of oxidative stress in elderly men living in Crete and Zutphen in 
2000 
Age-adjusted   Multivariable-adjusted*   
Indicator of oxidative 
stress 
Crete 
(n=105) 
Zutphen  
(n=139) 
 
P 
 Crete 
(n=105) 
Zutphen  
(n=139) 
 
P 
Hydroperoxides, μmol/L† 34.6  
(26.3-45.3) 
55.6  
(43.9-70.4) 
.01  33.2  
(25.0-43.9) 
57.3  
(45.0-73.0) 
.005 
Malondialdehyde, mmol/L 98.4  
(94.3-102.5)‡ 
103.2  
(99.7-106.7) 
.08  98.1  
(94.0-102.3)‡ 
103.4  
(99.8-107.0) 
.07 
Gamma-glutamyl-
transferase, U/L† 
20.2  
(18.0-22.7)‡ 
26.1  
(23.6-28.8) 
.001  20.3  
(18.0-22.9)‡ 
26.1  
(23.5-28.9) 
.003 
*Adjusted for age (continuous), body mass index (continuous), smoking (yes or no), alcohol use (yes or no), physical activity 
(lowest tertile versus highest two tertiles), diet prescription (yes or no), history of myocardial infarction, stroke, diabetes, and cancer 
(all yes or no). 
† Geometric means and 95%CI. 
‡ Information on this variable was missing of one subject. 
 
Iron status 
Men from Crete had a lower iron status than men from Zutphen, as indicated by lower adjusted 
mean levels of serum iron and serum ferritin, a lower mean percentage of transferrin saturation, 
and a higher unbound iron-binding capacity (Table 3). The average serum transferrin and total 
iron-binding capacity did not differ between cohorts. There were few men with a possible iron 
overload, and its prevalence did not differ between Cretan and Zutphen men. Additional 
adjustment for serum C-reactive protein yielded similar results. Likewise, excluding subjects 
with a history of chronic diseases did not alter the results essentially. 
 
Table 3: Mean levels (95% CI) of serum indicators of iron status in elderly men living in Crete and Zutphen in 2000 
Age-adjusted   Multivariable-adjusted *   
Indicator of iron 
status Crete (n=105) 
Zutphen  
(n=139) 
 
P 
 Crete 
(n=105) 
Zutphen 
(n=139) 
 
P 
Serum iron, μmol/L 15.2  
(14.1-16.4) 
17.6  
(16.5-18.7) 
.02  15.4  
(14.1-16.6) 
17.6  
(16.5-18.6) 
.01 
Ferritin, μg/L 67.9  
(56.6-81.3) 
137.1  
(117.1-160.4) 
<.001  69.8  
(57.9-84.1) 
134.2  
(114.3-157.6) 
<.001 
Transferrin, g/L 2.61  
(2.52-2.70) 
2.54  
(2.46-2.61) 
.21  2.62  
(2.53-2.72) 
2.53  
(2.45-2.61) 
.12 
Total iron-binding 
capacity, μmol/L 
54.7  
(52.9-56.5) 
53.2  
(51.6-54.7) 
.20  55.1  
(53.2-56.9) 
52.9  
(51.3-54.5) 
.09 
Transferrin  
saturation, % 
28.9  
(26.6-31.3) 
33.8  
(31.7-35.9) 
.003  29.0  
(26.6-31.5) 
33.7  
(31.6-35.8) 
.007 
Unbound-iron binding 
capacity, μmol/L 
39.5  
(37.3-41.6) 
35.5  
(33.7-37.4) 
.007  39.7  
(37.4-41.9) 
35.4  
(33.4-37.3) 
.005 
Iron overload†, No. (%) 1 (1.0) 3 (2.2) .61  1 (1.0) 2 (1.4) .95 
*Adjusted for age (continuous), body mass index (continuous), smoking (yes or no), alcohol use (yes or no), physical activity 
(lowest tertile versus highest two tertiles), diet prescription (yes or no), history of myocardial infarction, stroke, diabetes, and cancer 
(all yes or no). 
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Plasma antioxidant vitamins and serum endogenous antioxidants 
Average plasma levels of the exogenous antioxidants beta-carotene, lycopene, zeaxanthin, 
lutein, and alpha-tocopherol were higher and that of gamma-tocopherol was lower in Cretan 
men than in Zutphen men (Table 4). Plasma beta-cryptoxanthin levels did not differ between 
cohorts. Plasma alpha-carotene was on average lower in Cretan men compared with men from 
Zutphen, despite a correlation coefficient between plasma alpha- and beta-carotene of 0.68. The 
most pronounced difference was a nearly fourfold higher mean level of lycopene in Cretan men. 
Plasma folic acid was on average higher in men from Crete. These findings were similar after 
excluding subjects with a history of chronic diseases. The multivariable-adjusted mean 
concentrations of the endogenous antioxidants albumin and total bilirubin were higher among 
 
Table 4: Mean levels (95% CI) of plasma and serum antioxidants in elderly men living in Crete and Zutphen in 2000 
Age-adjusted   Multivariable-adjusted *   
 
Parameter 
Crete 
(n=105) 
Zutphen 
(n=139) 
 
P 
 Crete 
(n=105) 
Zutphen 
(n=139) 
 
P 
Plasma antioxidant vitamins      
Carotenoids (μg/100 mL)      
Beta-cryptoxanthin 9.3 
(7.8-10.8) 
10.4 
 (9.0-11.7) 
.30  9.1 
(7.5-10.7) 
10.5 
(9.2-11.9) 
.20 
Lycopene 15.3 
(13.8-16.8) 
4.1 
(2.8-5.3) 
<.001  15.3 
(13.7-16.8) 
4.1 
(2.8-5.4) 
<.001 
Beta-carotene 26.1 
(22.8-29.4) 
16.3 
(13.4-19.2) 
<.001  25.0 
(21.5-28.5) 
17.1 
(14.1-20.1) 
.001 
Alpha-carotene 1.31 
(0.18-2.44) 
3.12 
(2.14-4.10) 
.02  0.97 
(0.00-2.15) 
3.38 
(2.37-4.39) 
.003 
Zeaxanthin 2.53 
(2.29-2.78) 
1.30 
(1.09-1.51) 
<.001  2.55 
(2.30-2.79) 
1.29 
(1.08-1.50) 
<.001 
Lutein 22.7 
(21.0-24.5) 
13.6 
(12.0-15.1) 
<.001  22.6 
(20.7-24.4) 
13.7 
(12.0-15.3) 
<.001 
Tocopherols (μg/100 mL)      
Alpha-tocopherol 1171 
(1118-1224) 
1052 
(1006-1098) 
.001  1186 
(1131-1240) 
1041 
(994-1088) 
.0002 
Gamma-tocopherol 72.9 
(66.5-79.3) 
94.0 
(88.5-99.6) 
<.001  75.0 
(68.4-81.6) 
92.4 
(86.7-98.1) 
.0002 
Folic acid (ng/mL) 6.44 
(5.82-7.11)† 
4.87 
(4.46-5.31) 
<.001  6.33 
(5.70-7.02)† 
4.92 
(4.51-5.39) 
.0006 
        
Serum endogenous antioxidants      
Albumin, g/L 41.6 
(41.0-42.1)† 
39.5 
(39.1-40.0) 
<.001  41.7 
(41.7-42.3)† 
39.4 
(38.9-39.9) 
<.001 
Total bilirubin, μmol/L 10.6 
(9.8-11.4) 
9.3 
(8.6-10.0) 
.02  10.6 
(9.8-11.5) 
9.3 
(8.6-10.0) 
.02 
Uric acid, mmol/L 387.9 
(371.7-404.6) 
365.6 
(351.5-379.6) 
.04  386.9  
(370.2-403.6) 
366.3 
(351.9-380.7) 
.08 
* Adjusted for age (continuous), body mass index (continuous), smoking (yes or no), alcohol use (yes or no), physical activity 
(highest tertile versus lowest two tertiles), diet prescription (yes or no), history of myocardial infarction, stroke, diabetes, and cancer 
(all yes or no). 
† Information on this variable was missing of one subject. 
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Cretan men. Serum uric acid was significantly higher in men from Crete after adjustment for 
age, although this difference attenuated slightly after additional adjustment. 
Discussion 
The present study compared markers of oxidative stress, and iron and antioxidant status in 
elderly men in Crete (Greece) with men in Zutphen (the Netherlands). Serum levels of total 
peroxides and GGT were lower in men from Crete, indicating a lower level of oxidative stress 
compared with men from Zutphen. Cretan men also had a lower iron status compared with men 
in Zutphen, with the most pronounced difference being a twofold lower average serum ferritin 
concentration. Finally, average plasma levels of major antioxidants were higher among Cretan 
men, including a nearly fourfold higher mean lycopene level. 
In the current study, the measurements of serum markers of oxidative stress, and iron and 
antioxidant status were performed at the same laboratory blinded by cohort identity of the 
samples, thereby excluding possible interlaboratory differences. Lifestyle factors, weight and 
height were assessed by using the same standardized procedures in Crete and Zutphen.  
The study does have certain limitations. We attempted to ascertain the history of chronic 
diseases by using information from different sources, including data from general practitioners, 
hospital discharge information, and information from repeated medical examinations. Despite 
the abundant body of information, we may have underestimated the prevalence of stroke and 
cancer in Cretan men because of underdiagnosis. However, the results did not change materially 
after the exclusion of subjects with a history of chronic diseases from the analysis, indicating 
that confounding by chronic diseases is not a major issue.  
The results of the present study may not be generalizable to younger populations. Our 
study population consisted of men aged 79 years and over, who differ from their younger 
counterparts who had died already. The findings also might not apply exactly to a future cohort 
of elderly men who might experience a higher survival rate. Also, because of the cross-sectional 
design of the study, it is not possible to draw conclusions as to whether the differences in 
oxidative stress and iron and antioxidant status actually contribute to the difference in CHD 
mortality and survival between the Cretan and Zutphen cohorts. 
Oxidative stress reflects an imbalance between reactive oxygen species and the 
antioxidative defense mechanisms of the body, in favor of the former. It is considered to be 
implicated in the ageing process and the development of many chronic diseases, including CHD. 
As there is no single valid marker for oxidative stress, it is recommended to measure different 
markers of oxidative stress simultaneously. We determined three markers of oxidative stress, 
including two markers of peroxidation, i.e. total hydroperoxides and malondialdehyde. Serum 
hydroperoxides were on average 40% lower in Cretan men, whereas mean levels of 
malondialdehyde did not differ between Cretan and Zutphen men. The validity of 
malondialdehyde as a biomarker has been questioned because of its instability and lack of 
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specificity (13). The association of serum malondialdehyde and serum hydroperoxides with the 
incidence of CHD remains to be established in prospective cohort studies.  
Moderately elevated levels of GGT are considered to indicate oxidative stress (10) and 
are shown to be an independent risk factor for hypertension (14, 15), diabetes (15,16), and 
cardiovascular diseases (17,18). It was recently found that atherosclerotic coronary plaques have 
GGT activity (19). Our observation that Cretan men have lower levels of GGT than men from 
Zutphen was independent of alcohol consumption, and corresponds with the results of these 
studies. Future studies should address whether GGT is related to cardiovascular diseases and 
which lifestyle and dietary factors besides alcohol modify GGT levels.  
We found that elderly men living on Crete had a substantially lower iron status than 
those in Zutphen, including lower iron body stores. The lower iron status in the men from Crete 
is probably the result of a life-long lower dietary intake of iron, and may partly explain the 
fourfold lower mortality rate of CHD of the Cretan men compared with the men in Zutphen. 
However, the role of iron in the development of oxidative stress and degenerative diseases, 
including CHD, is controversial. Although it was first thought that high iron body stores 
increased the risk of CHD (5), this was not found by later published studies (20–22). According 
to the current evidence, the risk reduction induced by a lower body iron store is considered to be 
small, if present at all. 
In the present study, plasma concentrations of alpha-tocopherol and major carotenoids 
were higher among Cretan men compared with men from Zutphen. These higher levels of 
antioxidants are probably the result of adherence to the traditional Mediterranean diet by the 
Cretan men, which is known for its abundance in fruit and vegetables and the use of olive oil. In 
contrast, plasma levels of alpha-carotene and gamma-tocopherol were higher in men from 
Zutphen. The finding for plasma alpha-carotene is unexpected given its known strong positive 
correlation with plasma beta-carotene. Although these differences may be caused by a different 
consumption of specific foods rich in alpha-carotene and gamma-tocopherol, various metabolic 
differences may exist between the Greek and Dutch populations. For example, it may be that 
carotenoids compete with each other and with vitamin E during absorption (23), and that the 
extent of this phenomenon may differ depending on the overall dietary context. 
Average plasma levels of folic acid were higher in Cretan men. Recent published 
intervention studies have indicated that this vitamin improves vascular function (24,25) and 
reduces pulse pressure and arterial stiffness (26) by a mechanism independent of homocysteine 
lowering. It is suggested that folic acid may increase the bioavailability of nitric oxide, which 
may explain its endothelial-dependent vasodilatory effects. However, the dose of folic acid used 
in the intervention studies was beyond that obtained by diet, and it is unclear whether dietary 
folate can improve vascular function.  
In conclusion, the present study shows that men aged 79 years and over from Crete have 
a lower level of oxidative stress, a lower iron status, and higher levels of major plasma 
antioxidants than men of the same age from Zutphen. These differences may contribute to the 
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lower CHD and total mortality rate and a higher survival that has been observed in the Cretan 
male population. 
References 
1. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956; 11:298–300. 
2. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000; 408:239–247. 
3. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine, 2nd ed. New York, USA: Oxford 
University Press; 1985. pp. 416–494. 
4. Johnson MA, Fischer JG, Bowman BA, Gunter EW. Iron nutriture in elderly individuals. FASEB J. 1994; 
8:609–621. 
5. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are 
associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992; 86:803–811. 
6. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of 
the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart 
J. 1997; 18:1231–1248. 
7. Kesteloot H, Sans S, Kromhout D. Evolution of all-causes and cardiovascular mortality in the age-group 75–84 
years in Europe during the period 1970–1996; a comparison with worldwide changes. Eur Heart J. 
2002;23:384–398. 
8. Kromhout D, Menotti A, Blackburn H, (eds). Prevention of coronary heart disease: diet, lifestyle and risk 
factors in the Seven Countries Study. Norwell, MA, USA: Kluwer Academic Press; 2002. 
9. Keys A, Aravanis C, Blackburn HW, van Buchem FSP, Buzina R, Djordjevic BS, et al. Epidemiological 
studies related to coronary heart disease: characteristics of men aged 40–59 in seven countries. Acta Med 
Scand. 1966;460 (Suppl.):1–392.  
10. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free 
Radic Res. 2004;38:535–539. 
11. 11 Heath AL, Fairweather-Tait SJ. Health implications of iron overload: the role of diet and genotype. Nutr 
Rev. 2003;61:45–62. 
12. Bijnen FC, Caspersen CJ, Feskens EJ, Saris WH, Mosterd WL, Kromhout D. Physical activity and 10-year 
mortality from cardiovascular diseases and all causes: the Zutphen Elderly Study. Arch Intern Med. 
1998;158:1499–1505. 
13. Griffiths HR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, et al. Biomarkers. Mol Aspects Med. 
2002;23:101–208. 
14. Miura K, Nakagawa H, Nakamura H, Tabata M, Nagase H, Yoshida M, Kawano S. Serum gamma-glutamyl 
transferase level in predicting hypertension among male drinkers. J Hum Hypertens. 1994;8:445–449. 
15. Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, Steffes M. Gamma-glutamyltransferase is a 
predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults 
(CARDIA) Study. Clin Chem. 2003;49:1358–1366. 
16. Perry IJ,Wannamethee SG, Shaper AG. Prospective study of serum gammaglutamyltransferase and risk of 
NIDDM. Diabetes Care 1998;21:732–737. 
17. Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyltransferase, self-reported alcohol drinking, 
and the risk of stroke. Stroke. 2000;31:1851–1855. 
18. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gammaglutamyltransferase as a risk factor for 
cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. 
Circulation. 2005;112:2130–2137. 
Oxidative stress, iron status, and antioxidant status in elderly men 
 31
19. Paolicchi A, Emdin M, Ghliozeni E, Ciancia E, Passino C, Popoff G, et al. Images in cardiovascular medicine. 
Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation. 
2004;109:1440. 
20. Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation. 
1999;99:852–854. 
21. Sempos CT, Looker AC, Gillum RF, McGee DL, Vuong CV, Johnson CL. Serum ferritin and death from all 
causes and cardiovascular disease. The NHANES II Mortality Study. Ann Epidemiol 2000; 10:441–448. 
22. Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart 
disease in men. Circulation 2001;103:52–57. 
23. Parker RS. Absorption, metabolism, and transport of carotenoids. FASEB J. 1996;10:542–551. 
24. Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, et al. Folic acid improves endothelial 
function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation. 
2002; 105:22–26. 
25. Doshi SN, McDowell IF, Moat SJ, Lang D, Newcombe RG, Kredan MB, et al. Folate improves endothelial 
function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler 
Thromb Vasc Biol. 2001; 21:1196–1202. 
26. Williams C, Kingwell BA, Burke K, McPherson J, Dart AM. Folic acid supplementation for 3 wk reduces 
pulse pressure and large artery stiffness independent of MTHFR genotype. Am J Clin Nutr. 2005; 82:26–31. 
  32 
Coronary heart disease, risk factors and diet  
 33
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Background: We examined correlates of the difference in 40-year CHD mortality rates between a 
Mediterranean and a Dutch cohort, differing in habitual diet. 
Methods: From 1960 through 2000 we followed two cohorts of men initially aged 40-59 years in Crete 
(Greece) and in Zutphen (The Netherlands). Major risk factors were assessed repeatedly in survivors. Food 
samples representing the average diet of each cohort in 1960 and 2000 were chemically analyzed for nutrient 
content. Blood samples obtained in 2000 were analyzed for biomarkers of fatty acid and antioxidant intake 
and indicators of oxidative stress.  
Results: After 40 years follow-up, all-cause mortality rates per 1000 person-years were 25.9 in Crete and 
33.3 in Zutphen. For coronary heart disease (CHD) mortality these rates were 1.8 and 8.9, respectively. Serum 
cholesterol, systolic blood pressure, and smoking combined explained about 30% of the cohort differences in 
CHD mortality. Body mass index, physical activity and resting heart rate did not help explain the cohort 
differences in CHD mortality. Ecologically, the Cretan Mediterranean diet was lower in trans and saturated 
fatty acids, and higher in oleic acid, fiber and antioxidants than the Zutphen diet. This was reflected in serum 
levels of fatty acids, antioxidants, and indicators of oxidative stress measured in 2000.  
Conclusions: Thirty percent of the 5-fold lower CHD mortality rate in Crete compared to Zutphen was 
explained by classical CHD risk factors. The difference in diet is a likely candidate to explain the remaining 
difference in CHD mortality. 
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Introduction 
The Seven Countries Study was initiated in 1958 to test whether the incidence of coronary heart 
disease (CHD) differed across populations with varying dietary intakes of fatty acids or other 
candidate risk factors (1). The age-standardized 25-year mortality rates from CHD and all causes 
in Crete (Greece) belonged to the lowest of the 16 included cohorts (2). By comparison, the age-
standardized mortality rate per 1000 men for CHD was 46 in Crete and 147 in the town of 
Zutphen (The Netherlands) and for all-cause mortality 314 and 480, respectively (2).  
Many factors have been suggested to explain the low mortality rates in Crete, including 
classical risk factors such as serum cholesterol, blood pressure and smoking. Other factors 
mentioned were diet, periods of fasting as recommended by the Greek Orthodox Church (3), 
high levels physical activity, the exceptional climate, and even the after-lunch siesta (4). 
Evidence is accumulating that the traditional Cretan Mediterranean diet lowers CHD 
risk. Intervention studies showed that adherence to a Mediterranean diet improved blood lipid 
levels and endothelial function, and lowered in vivo lipoprotein oxidation and inflammation (5-
9). Observational studies noted that adherence to a Mediterranean diet is associated with a lower 
mortality from CHD and prolonged survival (10-13).  
In the present study, we analyzed whether the differences in 40-year CHD mortality in 
originally middle-aged men in Crete and Zutphen could be explained by differences in classical 
risk factors. We chemically analyzed the habitual diets of both cohorts and explored its role in 
relation to CHD mortality in ecologic analyses. 
Methods 
Study population 
The present study was based on data from the Seven Countries Study in Crete (Greece) and 
Zutphen (the Netherlands). At baseline examinations in 1960, the men were aged between 40-59 
years. Repeated measurements among survivors took place in 1970, 1990/1991, and 2000. In 
Zutphen, an additional sample of men of the same age was added in 1985. This sample was, 
together with the survivors from 1960, used for the dietary assessment and blood sample 
collection that took place in 2000; all other analyses are based on the original 1960 cohort only. 
Assessment of lifestyle and risk factors 
Information on smoking was collected with standardized questionnaires. The percentage of 
cigarette smokers in Crete and Zutphen and the percentage of men who smoked only cigars or 
pipes in Zutphen (14) were calculated. There were no men in Crete who smoked cigars or pipes. 
For the present analysis, smoking was classified as either current smoking (including cigars or 
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pipes), former smoking (those who stopped smoking within 10 years), or never smoking (never 
smokers and those who stopped smoking for more than 10 years).  
Physical activity in 1960 was assessed using information on job-related physical activity 
(1). Men were classified in three categories: little, moderate or strenuous physical activity. In 
2000, physical activity was assessed using a validated questionnaire providing information about 
the number of minutes spent on different daily activities per week (15,16). 
Throughout the study, weight and height were measured and body mass index (BMI) 
was calculated in kg/m2. Systolic blood pressure was measured supine at the right arm using 
standardized methodology (1). Resting heart rate was derived from electrocardiograms. 
Serum obtained from casual blood samples was analyzed for total cholesterol using 
standardized methods (1,17). In 2000, serum samples were also analyzed for concentrations of 
major dietary antioxidants and indicators of oxidative stress (18). We also measured the 
composition of fatty acids in serum cholesteryl esters by HPLC (19). Serum concentrations of 
folate were measured by a CEDIA kit (Roche Diagnostics, Almere, The Netherlands). High-
sensitive C-reactive protein (hsCRP) concentrations were determined by a (latex) high-
sensitivity kit (Roche Diagnostics, Almere, The Netherlands), and soluble intercellular adhesion 
molecule-1 (sIACM1) by using an ELISA (Diaclone, Sangiun, Amsterdam, The Netherlands). 
Assessment of usual dietary intake 
Dietary intake was estimated in a sample of 30 men in Crete between 1960 and 1965 and of 45 
men in Zutphen in 1960 by using the seven-day weighed record method (20). Dietary intake was 
also assessed in all Zutphen men by using the cross-check dietary history method (21,22), which 
provides information about the habitual food consumption. This method was also used in the 
food consumption surveys conducted in Crete and Zutphen in 2000. 
The dietary records in 1960 were coded in 1986 by one dietician and summarized in 15 
homogeneous food groups (23). To describe the traditional Cretan Mediterranean diet, the same 
food grouping was used in a 1948 dietary survey independent of the Seven Countries Study 
using a seven-day food record and presented in Table 2 (24).  
Due to aging, total energy intake had decreased between 1960 and 2000. In the analyses 
on food patterns, the consumption of food groups was therefore standardized for a diet of 2500 
kcal. 
Chemical analysis of the average diet 
The nutrient content of food composites representing the average food consumption pattern of 
the Cretan and Zutphen men in 1960 and 2000 was chemically analyzed. For the 1960 food 
patterns this was done in 1987 (25) and for the 2000 food patterns in 2001. Oxalic acid was 
added to the composites to preserve the vitamin C content, and tertiary butyl hydroxyquinone 
was added to prevent fat oxidation. The food composites were homogenized and frozen at –20ºC 
until further analysis. 
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The nutrient analyses were performed with well-established procedures in 1987 and 
2001. These methods were subjected to regular proficiency schemes which guarantee stable 
performance. The total lipid fraction was isolated and determined by a procedure described by 
Folch (26), after which sub-fractions of fatty acids were determined by gas chromatography 
(27). In the 1960 diet in Zutphen, the trans fatty acids with more than 18 carbon atoms, derived 
from hydrogenated fish oils, were determined by infrared spectrometry (27). N-3 fatty acids 
were assessed by using food composition tables (28,29) due to unavailability of some kinds of 
the fish on the market at the time of food collection. Protein was determined as total nitrogen, 
using a conversion factor of 6.25 (30). Mono- and disaccharides were determined by enzymatic 
methods (30), and starch was measured as previously described (31). Glucose was subsequently 
determined enzymatically (32). Alcohol was determined by an enzymatic assay (33). Total 
dietary fiber was determined by the enzymatic-gravimetric AOAC method (31). Folates were 
analyzed as monoglutamates by HPLC (34). The vitamin C content was quantified by a 
fluorimetric method (35). Carotenoids (36) and tocopherols (37) were measured by reversed 
phase HPLC. Flavonols were determined by HPLC methods (38,39). Total energy intake was 
calculated by using Atwater factors (40). 
Morbidity and mortality data 
Information on the prevalence of myocardial infarction and diabetes was repeatedly collected by 
questionnaire and by information obtained from general practitioners or hospital registries. Vital 
status was verified approximately every five years during 40 years of follow-up. In Zutphen, two 
men were lost to follow-up and none in Crete. The final causes of death were coded by one 
clinical epidemiologist (A.M.) according the 8th Revision of the International Classification of 
Diseases of the World Health Organization (ICD-8). Death from CHD was defined as codes 
410-414 as the first cause of death or as sudden death (code 795) as the first cause of death 
combined with coronary heart disease as underlying cause of death. Survival time was 
calculated in years as the time from the first examination around 1960 to the date of death, loss 
to follow-up, or completion of the study in 2000, whichever came first.  
Statistical analysis 
All analyses were performed with SAS software (version 9.1, SAS Institute, Inc., Cary, North 
Carolina). Analysis of covariance was used to calculate mean values of and to test for mean 
differences between various biomarkers (18).  
For each cohort, Kaplan-Meier survival probabilities covering 40 years of follow-up 
were used to plot the distributions of time to death from CHD and all-causes. The log-rank test 
was used to test differences in survival between cohorts. Cox models were used to explain the 
difference in CHD mortality between Crete and Zutphen, estimated as the proportionate change 
in the regression coefficient for cohort after addition of serum cholesterol, systolic blood 
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pressure, smoking, BMI, heart rate and physical activity to the model (41). Statistical tests were 
based on two-sided probability and P-values less than 5% indicated statistical significance. 
Comparisons of diet between cohorts were ecologic, employing in Crete the independent 
set of observations in 1948, a subset of participants in 1960 and the surviving cohort in 2000, 
whereas in Zutphen diet data were available in all participants in 1960 and among survivors in 
2000. Chemical analysis of composite diets for 1960 and 2000 in Crete and Zutphen were 
presented.  
Results 
Risk and lifestyle factors 
In 1960, the cohort in Crete consisted mostly of farmers (75%) and in Zutphen of blue-collar 
workers (49%), white-collar workers (15%), professionals (18%), and small-business owners 
(15%). 
In 1960, the Cretan cohort had a more beneficial risk profile than the cohort of Zutphen 
(Table 1), as indicated by lower mean values of serum total cholesterol, systolic blood pressure, 
smoking, BMI, and resting heart rate (for all P <.0001). During follow-up, the differences in 
these risk factors shrunk. In 1990 and 2000, blood pressure values were higher in Crete than in 
Zutphen.  
In 1960, a high level of physical activity was observed for 62% of the Cretan men and 
11% of the Zutphen men. In 2000, when the men were between 80 and 99 years old, the age-
adjusted time spent on moderate-to-vigorous physical activities was twice as high in Crete (9.2 
hours/week in Crete versus 4.3 hours/week in Zutphen, P = .0006). The lower heart rate in Crete 
compared to Zutphen was consistent with greater physical activity in Crete. Both the Cretan and 
Zutphen men were moderate alcohol users (Table 2). 
Food consumption patterns and nutrient intakes 
Based on information collected in 1948 and 1960, the traditional Cretan food pattern was 
characterized by high intake of bread and cereals, legumes, fruit, tomatoes, and olive oil and low 
intake of fish, dairy and meat products (Table 2). The Zutphen diet in 1960 included high 
amounts of potatoes, dairy and meat products, solid fats, and sugar. Survivors in Crete largely 
kept their traditional food pattern until 2000, although the consumption of bread and tomatoes 
decreased and the meat consumption doubled. In Zutphen, the consumption of bread, potatoes 
and solid fats decreased substantially, but a twofold increase was observed in fish consumption 
and a four-fold increase in fruit and orange juice consumption. 
In 1960 the diet of both cohorts was high in fat, but the fatty acid composition differed 
markedly (Table 3). Whereas the Cretan diet was low in saturated and trans fatty acids and high 
in the oleic acid, the diet in Zutphen was high in saturated, trans and linoleic acid. In 1960 the
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Table 1: Risk and lifestyle factors in the Cretan and Zutphen cohorts of the Seven Countries Study from 1960 to 2000 
 Crete Zutphen 
Risk factor 1960 1970 1991 2000 
 
1960 1970 1990 2000 
Number examined (response rate 
%) 
686 (98) 611 (95) 256 (67) 152 (94)  878 (81) 646 (84) 235 (75) 76 (72) 
Age, yrs 49.0 (5.5) 58.9 (5.4) 77.8 (4.7) 84.6 (4.3)  49.5 (5.5) 59.1 (5.4) 76.0 (4.5) 84.6 (3.6) 
Serum total cholesterol, mmol/l 5.34 (1.07) 6.03 (1.11) 5.75 (1.10) 5.03 (0.96)  6.09 (1.15) 6.18 (1.10) 6.09 (1.12) 5.42 (1.02) 
Systolic BP, mm Hg 137.0 (20.0) 137.2 (23.4) 162.9 (22.9)* 150.7 (21.6)  144.4 (19.8) 147.0 (21.2) 152.8 (20.4) 151.2 (21.0) 
Body mass index, kg/m2 22.9 (3.0) 24.1 (3.5) 24.6 (3.6) 24.1 (4.1)  24.0 (2.7) 25.1 (2.7) 25.0 (3.2) 25.1 (3.2) 
Resting heart rate, beats/min† 61.8 (11.7) NA 67.8 (13.6) 71.5 (11.8)  72.6 (12.7) NA 75.7 (14.7) 73.8 (11.1) 
Cigarette smoking, % 57.3 59.2 17.0 10.6  74.5 52.7 28.3 14.5 
Only cigar or pipe smoking, % 0 0 0 0  14.3 21.1 9.7 0 
Prevalence of diabetes, % 0.6 2.8 4.3 8.5  0.9 2.9 15.0 15.8 
Prevalence of myocardial 
infarction, % 
0.2 0.8 5.0 12.7  1.3 6.6 22.2 19.4 
Abbreviation: NA, not available. 
* Due to missing values on systolic blood pressure based on n=188. 
†Information on heart rate in Crete was obtained for 642 men in 1960, 214 men in 1991, and 107 men in 2000, and in Zutphen for 812 men in 1960. 
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Table 2: Average daily food consumption per person in Crete (1948, 1960-1965, and 2000) and Zutphen (1960 and 2000), standardized for a 2500 kcal diet 
  Crete    Zutphen  
Daily dietary intake 1948 1960-1965 2000  1960 1960 2000 
Population* 128 families 30 men 152 men  45 men 878 men 122 men 
Assessment method 7-day record 7-day record Dietary history  7-day record Dietary history Dietary history 
Period of assessment Sept-Oct Sept-Oct July-Aug  May-July May-July March-June 
Energy intake, kcal† 2547 2820 2220  2756 3107 2019 
Daily food intake per 2500 kcal        
Bread, g 231 336 141  229 212 158 
Cereals, g 111 26 95  15 14 31 
Potatoes, g 159 168 84  229 275 132 
Legumes, g 44 26 59  1 9 9 
Vegetables, g 254 169 185  206 162 157 
tomatoes, g 112 110 64  19 3 7 
Fruit and orange juice, g 258 410 317  74 90 305 
oranges, g NA 65 97  NA 25 36 
orange juice, g NA NA 19  NA NA 40 
Meat, g 31 31 60  125 89 122 
Poultry, g 5 13 17  0 0 17 
Fish, g 25 16 31  11 16 26 
Snails, g 7 0 2  0 0 0 
Eggs, g 7 23 13  25 27 18 
Milk products, g 32 208 200  416 428 417 
yoghurt, g 0 41 38  25 32 57 
Cheese, g 9 11 21  28 25 35 
Edible fats, g 83 84 79  71 72 47 
olive oil, g 80 84 78  0 0 1 
Sugar products, g 15 18 16  76 66 64 
Ethanol, g 4 10 14  3 3 14 
Abbreviation: NA, not available. 
* In 1948 in Crete, dietary intake per capita as estimated in 128 families is shown (24). Otherwise, dietary intake in men participating in the Seven Countries Study is presented. 
† Total energy was based on food composition tables (Crete 1948, and Zutphen dietary history in 1960) or chemical analyses in equivalent food composites (Crete 1960-1965 and 2000, and Zutphen 
food record in 1960 and dietary history in 2000). 
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Table 3: Chemical analyses of the nutrient content of food composites representing the average daily consumption in the Cretan and Zutphen cohorts of the 
Seven Countries Study in 1960 and 2000 
 Crete  Zutphen  
1960 (food record)  2000 (dietary history)  1960 (food record)  2000 (dietary history)   
 
Dietary factor 
Daily 
intake 
 
En% 
 Daily 
intake 
 
En% 
 Daily  
intake 
 
En% 
 Daily 
intake 
 
En% 
 
Energy and energy-delivering nutrients             
Total energy, kcal 2975 100.0  2220 100.0  2810 100.0  2019 100.0  
Protein, g 90 12.1  71 12.8  92 13.1  75 14.9  
Carbohydrates, g 331 44.5  220 39.6  281 40.0  220 44.2  
Fat, g 135 40.8  108 43.8  145 46.4  81 36.1  
Saturated fatty acids 29 8.8  28 11.4  62 19.9  38 17.0  
Trans fatty acids 0.6 0.2  1.4 0.6  26 8.3  1.1 0.5  
Monounsaturated fatty acids 86 26.0  66 26.8  42 13.5  27 12.0  
Oleic acid 79 24.0  63 25.5  30 9.6  24 10.7  
Polyunsaturated fatty acids 13 3.9  11 4.5  21 6.7  15 6.7  
n-6  
Linoleic acid, C18:2n-6 11 3.3  8.1 3.3  13 4.2  13 5.8  
n-3  
Alpha-linolenic acid, C18:3n-3 1.2 0.4  1.1 0.4  2.2 0.7  1.4 0.6  
Fish fatty acids EPA + DHA* 0.09 <0.1  0.16 <0.1  0.09 <0.1  0.19 <0.1  
Fiber, folate, and antioxidants             
Dietary fiber, g 44   26   26   23   
Folate, μg NA   198   NA   153   
Carotenoids, μg NA   4450   NA   3857   
Beta-carotene NA   730   NA   1927   
Lycopene NA   1723   NA   193   
Alpha-tocopherol, mg 22.0   19.7   8.8   9.6   
Beta- and gamma-tocopherol, mg 6.8   4.6   12.1   8.1   
Vitamin C, mg 140   153   112   76   
Flavonols, mg 16   16   33   24   
* The intake of EPA (eicosapentaenoic acid, C20:5) and DHA (docosehexaenoic acid, C22:6) were estimated by using food composition tables (28). 
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Serum markers of oxidative stress, inflammation, and endothelial function 
Mean gamma-glutamyltransferase activity and serum concentrations of hydroperoxides and 
malondialdehyde were lower in Cretan compared to Zutphen men, although the latter finding 
reached only borderline significance. Mean concentrations of hsCRP and sICAM1 were also 
lower in Cretan men. 
All-cause and coronary heart disease mortality 
After 40 years of follow-up, the all-cause mortality rate per 1000 person-years was 25.9 in Crete 
and 33.3 in Zutphen. For CHD mortality these rates were 1.8 in Crete and 8.9 in Zutphen. 
Kaplan-Meier survival curves for CHD and all-cause mortality differed significantly between 
cohorts (P < .0001; Figure 1). The median survival time for all-cause mortality was 32 years in 
Crete (95% CI: 31 to 33 years), and 26 years in Zutphen (95% CI: 24 to 27 years).  
Plots of the log-minus-log survival function against log-time showed a decrease in 
parallelism in curves between cohorts with increasing follow-up for mortality (Figure 2). 
Therefore, follow-up time was split at 30 years. Baseline serum cholesterol, systolic blood 
pressure and smoking explained for about 30% of the cohort differences in CHD mortality for 
both 30 and 40 year of follow-up (Table 5). BMI, physical activity and resting heart rate did not 
contribute additionally either to the prediction of CHD death or to explaining the difference in 
death rates between the cohorts. Separate models for the last 10 years showed that the difference 
in all-cause mortality between cohorts was no longer present. However, serum cholesterol, 
systolic blood pressure and smoking still contributed to the difference in CHD mortality between 
the cohorts. In explaining the differences in mortality rates, models using the baseline risk 
factors were superior compared to time-dependent models. 
Discussion 
In the present study, the 40-year all-cause mortality rate was substantially lower in Crete 
compared to Zutphen. This was partly explained by a lower CHD mortality rate in Crete, which 
was 1/5 that in Zutphen. In the 1960s the Cretan men had lower average serum total cholesterol 
and systolic blood pressure levels and a lower prevalence of smokers. The difference in CHD 
mortality could partly be explained by baseline levels of these risk factors. A substantial part of 
the residual difference in CHD mortality may be explained by the baseline difference in diet 
between Crete and Zutphen. 
The strengths of the present study include the nearly complete mortality follow-up from 
middle-age onwards, and the comprehensive long-term assessment of risk factors and diet. Also, 
rather than using food composition tables like many studies, we directly analyzed the nutrient 
content of the diet in food composites representing the average food consumption pattern of the 
men in Crete and Zutphen.  
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Table 4: Serum fatty acid composition, serum antioxidants and vitamins, and markers of oxidative stress, inflammation and endothelial function in 2000 at the 
age 80-99 years in the Cretan and Zutphen cohorts of the Seven Countries Study 
 Age-adjusted Multivariable-adjusted * 
Serum variable Crete Zutphen P 
 
Crete Zutphen P 
Number 105 139   105 139  
Fatty acid composition, %        
C18:1 (n-9) 29.3 (28.7-29.9) 16.1 (15.8-16.6) <.0001  29.2 (28.6-29.8) 16.1 (15.6-16.7) <.0001 
C18:2 (n-6) 41.1 (40.1-42.0) 53.6 (52.8-54.5) <.0001  41.1 (4.0-42.1) 53.6 (52.8-54.5) <.0001 
C18:3 (n-3) 0.41 (0.39-0.44) 0.57 (0.55-0.60) <.0001  0.41 (0.38-0.43) 0.58 (0.55-0.60) <.0001 
C20:5 (n-3) 0.84 (0.71-0.97) 1.22 (1.11-1.34) <.0001  0.85 (0.72-0.99) 1.21 (1.09-1.33) .0003 
C22:6 (n-3) 0.59 (0.53-0.65) 0.71 (0.65-0.76) .004  0.60 (0.54-0.66) 0.70 (0.64-0.75) .03 
Others 27.8 (27.2-28.4) 27.8 (27.3-28.3) .92  27.8 (27.2-28.5) 27.7 (27.2-28.3) .81 
Antioxidants and folic acid        
Total carotenoids (µg/100 ml) 77.3 (70.7-83.9) 48.7 (42.9-54.5) <.0001  75.5 (68.5-82.4) 50.1 (44.1-56.0) <.0001 
Beta-carotene (µg/100 ml) 26.1 (22.8-29.4) 16.3 (13.4-19.2) <.0001  25.0 (21.5-28.5) 17.1 (14.1-2.1) .001 
Lycopene (µg/100 ml) 15.3 (13.8-16.8) 4.1 (2.8-5.3) <.0001  15.3 (13.7-16.8) 4.1 (2.8-5.4) <.0001 
Alpha-tocopherol (µg/100 ml) 1244 (1189-1299) 1146 (1098-1194) .009  1261 (1204-1317) 1134 (1085-1182) .001 
Folic acid (ng/ml) 7.5 (6.8-8.2) 5.5 (4.9-6.1) <.0001  7.4 (6.6-8.1) 5.6 (5.0-6.3) .0007 
Markers of oxidative stress,  
inflammation, and endothelial function 
       
Malondialdehyde (mmol/l) 98.4 (94.3-102.5) 103.2 (99.7-106.7) .08  98.1 (94.0-102.3) 103.4 (99.8-107.0) .07 
Hydroperoxides (µmol/l) 34.6 (26.3-45.3) 55.6 (43.9-70.4) .01  33.2 (25.0-43.9) 57.3 (45.0-73.0) .005 
Gamma-glutamyl transferase (U/l) 20.2 (18.0-22.7) 26.1 (23.6-28.8) .001  20.3 (18.0-22.9) 26.1 (23.5-28.9) .003 
hsCRP (mg/l) 2.7 (2.3-3.2) 3.6 (3.2-4.0) .004  2.8 (2.4-3.2) 3.6 (3.2-3.9) .01 
sI-CAM1 (ng/ml) 626 (587-665) 708 (674-742) .002  622 (581-663) 710 (675-746) .002 
Abbreviations: hsCRP, high-sensitive C-reactive protein; sICAM-1, soluble intercellular adhesion-molecule. 
* Adjusted for age, BMI, smoking (yes/no), alcohol consumption (yes/no), physical activity, diet prescription (yes/no), and prevalence of diabetes (yes/no), myocardial infarction (yes/no), stroke 
(yes/no), or cancer (yes/no). 
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Figure 1: Kaplan-Meier survival curves for 40-year all-cause (left) and CHD mortality (right) in the Cretan 
and Zutphen cohorts of the Seven Countries Study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Log-minus-log survival curves for 40-year all-cause (left) and CHD mortality (right) in the 
Cretan and Zutphen cohorts of the Seven Countries Study. 
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Table 5: Hazard ratios (95% confidence intervals) for coronary heart disease mortality for risk factors measured at baseline, by duration of follow-up* 
 Coronary heart disease  mortality  
Variable 0-30 year 0-40 year 30-40 year  
Age, per y 1.10 (1.07-1.13) 1.08 (1.05-1.11) 1.02 (0.97-1.08)  
Serum cholesterol – per mmol/l 1.33 (1.17-1.51) 1.28 (1.15-1.43) 1.15 (0.91-1.44)  
Systolic BP – per 20 mm Hg 1.35 (1.19-1.54) 1.34 (1.19-1.51) 1.29 (0.97-1.70)  
Tobacco smoking     
Current smokers vs. non-smoker† 1.44 (0.92-2.24) 1.24 (0.86-1.79) 0.96 (0.49-1.90)  
Recent ex-smokers vs. non-smokers† 0.94 (0.50-1.77) 0.93 (0.56-1.79) 1.00 (0.42-2.41)  
Cohort – Zutphen vs. Crete     
Adjusted for age 8.83 (5.27-14.79) 5.43 (3.79-7.80) 2.49 (1.44-4.30)  
Adjusted for age, serum cholesterol, 
systolic blood pressure, and smoking 
6.41 (3.78-10.85) 4.09 (2.81-5.94) 2.11 (1.17-3.82)  
Abbreviation: BP, blood pressure. 
* Hazard ratios were adjusted for all other mentioned variables, unless otherwise indicated. 
† Non-smokers were defined as never smokers and long-term ex-smokers (for details see text).
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the intake of dietary fiber 18g/day was higher in Crete. Also the intake of antioxidants, including 
carotenoids, alpha tocopherol and vitamin C was higher. These differences became smaller 
during follow-up but were still present in 2000. 
Only a part of the difference in CHD mortality between Crete and Zutphen could be 
explained by traditional risk factors such as serum cholesterol, blood pressure, and smoking. 
This is in accord with the results of the Lyon Diet Heart Study (42). In this trial, a large effect of 
a Mediterranean diet enriched with alpha-linolenic acid was observed on CHD events, even 
though serum cholesterol, blood pressure, and BMI remained unaffected. Taken together, these 
findings suggest that other mechanisms are involved in lowering CHD mortality. Our findings of 
lower levels of oxidative stress, inflammation, and a more favorable endothelial function in 
Cretan men at old age suggest that these are important candidate mechanisms. Intervention 
studies have shown that the Mediterranean diet is likely to favorably influence these novel risk 
factors (5-9).  
Based on the results of the Cretan cohort of the Seven Countries Study in the 1960s and 
of the study performed on Crete by the Rockefeller Foundation in 1948 (24), it is possible to 
characterize the traditional Cretan Mediterranean diet. This diet has olive oil as its principal 
source of fat and is rich in whole-meal bread and cereals, legumes, fruit and tomatoes and low in 
fish, poultry, meat and dairy products. The main characteristics of this diet were kept by the 
survivors in Crete in 2000. However, this traditional dietary pattern is rapidly disappearing from 
Crete and this is likely to have detrimental effects on the health status of the population of Crete 
(43).  
We conclude from the findings of the present study that the difference in CHD mortality 
between Crete and Zutphen can partly be explained by differences in baseline serum cholesterol, 
blood pressure and smoking. It is likely that another part of the difference in CHD mortality is 
explained by the traditional Mediterranean diet. This diet is a prototype of a healthy diet with its 
low content of saturated and trans fatty acids and its high content of dietary fiber and 
antioxidants. 
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Both Alpha- and Beta-Carotene, 
but Not Tocopherols and  
Vitamin C, Are Inversely Related to 
15-Year Cardiovascular Mortality  
in Dutch Elderly Men 
 
Brian Buijsse, Edith J.M. Feskens, Lemogang Kwape, Frans J. Kok, and Daan 
Kromhout 
 
The role of beta-carotene, alpha-tocopherol, and vitamin C in the prevention of cardiovascular diseases (CVD) 
is controversial. Prospective studies on gamma-tocopherol and carotenoids other than beta-carotene are sparse. 
We assessed relations between the intake of different carotenoids, alpha- and gamma-tocopherol, and vitamin 
C with 15-y CVD mortality in elderly men who participated in the Zutphen Elderly Study. Information on diet 
and potential confounding factors was collected in 1985, 1990, and 1995. In 1985, 559 men (mean age ~72 y) 
free of chronic diseases were included in the current analysis. After 15 y of follow-up, comprising 5744 
person-years, 197 men had died from CVD. After adjustment for age, smoking, and other potential lifestyle 
and dietary confounders, relative risks (RR) (95% CI) of CVD death for a 1-SD increase in intake were 0.81 
(0.66–0.99) for alpha-carotene and 0.80 (0.66–0.97) for beta-carotene. Carrots were the primary source of 
alpha- and beta-carotene and their consumption was related to a lower risk of death from CVD (adjusted RR, 
0.83; 95% CI: 0.68–1.00). Intakes of carotenoids other than alpha- and beta-carotene were not associated with 
CVD mortality, nor were vitamin C and alpha- and gamma-tocopherol. In conclusion, dietary intakes of alpha-
carotene and beta-carotene are inversely associated with CVD mortality in elderly men. This study does not 
indicate an important role for other carotenoids, tocopherols, or vitamin C in lowering the risk of CVD death. 
 
Published in The Journal of Nutrition 2008;138:344-350. 
Reprinted with permission from The American Society for Nutrition. 
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Introduction 
During the past 25 y, there has been considerable interest in the role of antioxidants in the 
prevention of cardiovascular diseases (CVD). In particular, vitamin E (1) and beta-carotene (2) 
received much attention and, to a lesser extent, also vitamin C.  
Findings from in vitro studies indicate that these antioxidants directly scavenge reactive 
oxygen and nitrogen species (3). In addition, depletion of vitamin E in humans leads to 
increased susceptibility of LDL to in vitro oxidation (4) and a reduction of LDL in vitro 
oxidation is observed after supplementation of alpha-tocopherol (5–8,9). Although there are 
indications that support a similar role for vitamin C (10), the evidence is equivocal (8). One 
intervention study, however, suggests that this antioxidant improves endothelial function (11) 
and a cross-sectional observational study in persons free of CVD found inverse associations of 
vitamin C with circulating markers of inflammation and endothelial function (12). Finally, in 
addition to their role as scavengers of free oxygen and nitrogen species, observational studies on 
carotenoids suggest that they also may have anti-inflammatory properties (13,14) and may 
improve endothelial function (14). 
Early reports of prospective cohort studies have suggested that a high intake of vitamin E 
(15–17), carotene (15), fruit and vegetables rich in carotene (18), or carotenoids (17) lowers the 
risk of coronary heart disease. In sharp contrast, large-scale trials conducted in high-risk 
populations have not shown protective effects of these antioxidants against CVD (19,20). 
Likewise, intervention studies on the progression of atherosclerosis have in general not shown 
an effect of antioxidant supplementation either (21). Meanwhile, findings from observational 
studies continue to show inverse associations of dietary intake (22,23) or tissue levels (24,25) of 
especially beta-carotene with CVD risk. 
The precise reason for the contradictory results between observational studies and large-
scale intervention trials is yet unclear. One of the possibilities is that other carotenoids and 
tocopherols account for the inverse associations of beta-carotene and alpha-tocopherol with 
CVD in observational studies. Prospective studies on dietary carotenoids other than beta-
carotene have only been published sparingly (22) and those on specifically dietary gamma-
tocopherol are lacking. Therefore, we evaluated whether dietary intakes of 6 different 
carotenoids, alpha- and gamma-tocopherol, and also vitamin C were related to CVD mortality in 
elderly men living in the town of Zutphen, the Netherlands. 
Materials and Methods 
Study population. The Zutphen Elderly Study is a prospective population-based cohort study and 
is a continuation of the Zutphen Study, the Dutch contribution to the Seven Countries Study 
(26). Baseline data were collected between March and June in 1985 and repeated measurements 
were carried out in the same months in 1990 and 1995 (27). In 1985, 555 men of the original 
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cohort who were still alive and a random sample of 711 other men of the same age and also 
living in Zutphen were selected. Of these 1266 men aged 65–84 y, 939 participated (response 
74%) in the study. Information on dietary intake in 1985 was collected from 876 men. Because 
men with known CVD, diabetes, and cancer may have changed their dietary habits, we excluded 
prevalent disease cases at baseline, yielding a study population of 559 men. In 1985 and 1990, 
the study was approved by the Medical Ethics Committee of Leiden University Medical Centre, 
the Netherlands, and in 1995 and 2000 by the Medical Ethics Committee of the Netherlands 
Organization for Applied Scientific Research. 
Dietary assessment 
Information on habitual food consumption was collected in 1985, 1990, and 1995 by using a 
cross-check dietary history method adapted to Dutch conditions (28). All subjects were 
interviewed about their dietary habits during the month preceding the interview. Experienced 
dieticians conducted the interviews, which took place at the subjects’ homes in the presence of 
the person who usually prepared the hot meal. The habitual consumption of foods per day was 
estimated with a checklist and verified by estimating the quantities of foods bought per week for 
the whole family. In case this verification raised uncertainties about the consumption of a 
particular food, the participant was asked for more details. 
 Based on the information of the dietary histories in 1985, 1990, and 1995, the 
intake of nutrients and energy was calculated using the Netherlands food composition table from 
1987–1988, 1989–1990, and 1996, respectively. The 2001 version of this table includes detailed 
information on the content of carotenoids, tocopherols, and folate in foods (29). Therefore, this 
release was used to calculate the intake of these nutrients in each survey year. Apart from the 
individual tocopherol levels, this food composition table also provides alpha-tocopherol 
equivalents (alpha-TE) in foods according to the formula alpha-tocopherol intake × 1.00 + beta-
tocopherol × 0.40 + gamma-tocopherol × 0.10 + delta-tocopherol × 0.01 (29) [this conversion to 
a-TE differs from the conversion that was commonly used in the US, i.e. alpha-TE = mg alpha-
tocopherol × 1.0 + mg beta-tocopherol × 0.5 + mg gamma-tocopherol × 0.1 + mg delta-
tocopherol × 0.03 + mg alpha-tocotrienol × 0.3 + mg beta-tocotrienol × 0.05 (30).] The intake of 
trans fatty acids in every survey year was calculated by using previously collected information 
on the content of these fatty acids in foods consumed by the Zutphen elderly (31). 
Collection of risk factor and morbidity data 
During a medical exam, weight and height were measured while subjects wore light underwear. 
BMI was calculated by dividing weight by height squared (kg/m2). Information on cigarette 
smoking, socioeconomic status, prescribed diet by a physician, and the use of aspirin, 
antihypertensive medication, and anticoagulants was collected using a questionnaire. All 
subjects were also asked whether they used (yes or no) multivitamin supplements or vitamin C 
or E supplements. Physical activity of walking, cycling, hobbies, sports, and gardening was 
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estimated in min/wk by using a validated questionnaire originally designed for retired men (32). 
In addition, socioeconomic status was assessed based on longest occupation. The highest 
occupational status included professionals, managers, and teachers. 
The history of previous myocardial infarction, stroke, and cancer was ascertained using a 
questionnaire and was verified with information from general practitioners or hospital discharge 
information. Information on the history of diabetes mellitus was obtained from a standardized 
questionnaire. 
Ascertainment of follow-up events 
Municipal registries provided information on vital status and were checked at 5-y intervals. Two 
men were lost to follow-up during the study. Their time to follow-up was censored after their 
last physical exam. Information on the cause of death during 15 y of follow-up was obtained 
from hospital discharge data, cancer registries, and/or general practitioners. One clinical 
epidemiologist ascertained the final causes of death. The underlying causes of death were coded 
according to the Ninth Revision of the International Classification of Diseases (ICD-9). CVD 
cover ICD-9 codes 390–459. This included ischemic heart disease (ICD-9 codes 410–414) and 
stroke (codes 430–438) as main causes and also other diseases of the circulatory system. The 
first, 2nd, and 3rd cause of death was used to identify mortality from CVD. Information on the 
cause of death was lacking for 2 men and their follow-up was censored after they had died. 
Data analysis 
Relative risks (RR) and 95% CI were calculated for a 1-SD increase of antioxidants from diet 
only by using Cox regression models. To check the assumption on linearity, we also performed 
analyses for tertiles of antioxidant intake. Because this yielded similar findings, we report only 
RR based upon continuous analysis. In time-dependent analysis, we analyzed the cumulative 
mean intake of antioxidants using methods for repeated measurements (33). Specifically, 
mortality between 1985 and 1990 was related to the intake reported in 1985; mortality between 
1990 and 1995 was related to the mean intake of 1985 and 1990 and mortality from the period 
1995 to 2000 was related to the mean intake of 1985, 1990, and 1995. The intake of antioxidants 
and other dietary variables was adjusted for total energy intake by using the residual method 
(34).  
We also investigated the total intake of vitamin C and alpha-tocopherol from diet and 
vitamin supplements. Because the information on dosage of vitamin supplements was not 
collected, we performed analyses in tertiles of intake, in which users of vitamin C were forced 
into the highest tertile of vitamin C, users of vitamin E in the highest tertile of alpha-tocopherol, 
and users of multivitamin supplements in the highest tertile of vitamin C and alpha-tocopherol. 
In these analyses, the lowest tertile served as the reference category. 
Finally, we assessed whether a diet rich in 3 major antioxidants was related to CVD 
mortality by constructing a dietary antioxidant score, i.e. the sum of carotenoids, the sum of 
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alpha-tocopherol and gamma-tocopherol, and vitamin C. First, tertiles of intake (1 to 3) were 
computed for each of the 3 antioxidants. These 3 tertile variables were then summed, yielding a 
score that ranged from 3 (indicating a diet poor in antioxidants) to 9 (indicating a diet rich in 
antioxidants). Tertiles of the antioxidant score were computed and entered in the Cox regression 
models, in which the lowest tertile served as the reference. At baseline, the antioxidant score in 
the lowest tertile ranged from 3 to 5, the middle tertile consisted of men with a score of 6, and 
the score in the highest tertile ranged from 7 to 9.  
 
 
All analyses were adjusted for age and total energy intake. We then adjusted additionally 
for current and former cigarette smoking. This model was extended with nondietary covariates, 
including BMI (kg/m2), physical activity (min/wk), alcohol consumption (yes or no), diet 
prescription (yes or no), vitamin supplement use (yes or no), socioeconomic status (high vs. 
low), and the use of antihypertensive medication (yes or no), aspirin (yes or no), and 
anticoagulants (yes or no). The final model included additional adjustments for the intake of 
dietary fiber, folate, saturated fat, polyunsaturated fat, and trans fatty acids. Physical activity and 
nutrient intakes were entered in the models as cumulative means. Effect modification by 
smoking, alcohol consumption, physical activity, BMI, and socioeconomic status was evaluated 
by including product terms into the multivariable model B and were considered significant at P 
< .05. All analyses were performed with SAS version 9.1 (SAS Institute) and reported P-values 
are 2-sided. 
Results 
Characteristics of the study population 
Characteristics of the study population in 1985, 1990, and 1995 are shown in Table 1. At 
baseline, the mean age of the men was ~72 y. During the study, the proportion of smokers 
decreased from one-third at baseline to one-fifth 10 y later. The use of vitamin supplements was 
~15% throughout the study. The mean intake of most nutrients remained stable throughout the 
study, although the intake of lycopene increased and the intake of trans fatty acids decreased 
substantially during 10 y.  
At baseline, vegetables contributed 82% to the intake of beta-carotene, with carrots 
(40%) and leafy vegetables (33%) as major sources. Carrots provided 94% of the amount of 
alpha-carotene. Main sources of vitamin E were margarines (43% contribution to the intake of 
alpha-tocopherol, 36% to gamma-tocopherol). For vitamin C, major sources were fruits (44%) 
and vegetables (23%). 
Intakes of several dietary antioxidants were associated (P < .05) with each other. 
Examples are alpha-carotene and beta-carotene (Spearman r = 0.74), beta-cryptoxanthin and 
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zeaxanthin (r = 0.65), alpha-tocopherol and gamma-tocopherol (r = 0.56), and vitamin C with 
beta-cryptoxanthin (r = 0.64) and zeaxanthin (r = 0.60). 
 
Table 1: Selected characteristics of the study population in 1985, 1990, and 1995 
 Study year 
Characteristic 1985 1990 1995 
Number of men participating 559 375 202 
Demographic and risk factor data  Mean ± SD  
Age, y 71.8 ± 5.2 75.7 ± 4.5 80.1 ± 4.3 
Body mass index, kg/m2 25.6 ± 3.1 25.4 ± 3.2 25.1 ± 3.4 
Current smoking, % 32.7 24.3 18.8 
Physical activity, min/wk, median [IQR] 465 [225, 870] 480 [210, 750] 300 [110, 630] 
Current alcohol consumption, % 432 (77) 284 (75) 159 (79) 
Diet prescription, % 16.3 14.4 14.4 
Use of vitamin C supplements, % 6.1 9.3 8.4 
Use of multivitamin supplements, % 7.3 5.9 6.9 
Aspirin, % 12.2 12.0 10.4 
Antihypertensive medication, % 10.6 12.3 12.4 
Anticoagulant medication, % 8.1 9.9 5.0 
Dietary intake*    
Total energy, kJ/d 9572 ± 2096 8925 ± 1969 9001 ± 1904 
Saturated fatty acids, g/d 44.3 ± 8.6 37.0 ± 8.5 39.1 ± 8.0 
Trans fatty acids, g/d 11.2 ± 5.5 6.9 ± 3.4 4.5 ± 1.5 
Monounsaturated fatty acids, g/d 27.5 ± 6.1 27.1 ± 4.7 27.8 ± 5.7 
Polyunsaturated fatty acids, g/d 17.4 ± 7.0 16.4 ± 7.6 16.6 ± 7.2 
Fiber, g/d 24.8 ± 6.1 23.4 ± 6.3 23.5 ± 5.5 
Folate, µg/d 187 ± 54 183 ± 57 189 ± 47 
Vitamin E, mg α-TE/d 12.5 ± 5.1 13.5 ± 6.2 13.4 ± 5.2 
Alpha-tocopherol, mg/d 9.1 ± 4.6 9.1 ± 4.9 7.5 ± 3.5 
Gamma-tocopherol, mg/d 9.3 ± 6.2 7.7 ± 6.0 7.9 ± 5.8 
Vitamin C, mg/d 88 ± 38 94 ± 47 96 ± 45 
Beta-carotene, µg/d 2766 ± 1474 2179 ± 1360 2487 ± 1408 
Alpha-carotene, µg/d, median [IQR] 428 [136, 767] 231 [86, 622] 414 [148, 778] 
Beta-cryptoxanthin, µg/d 47 ± 75 64 ± 86 109 ± 173 
Lutein, µg/d 2477 ± 1490 1836 ± 1114 1853 ± 1107 
Zeaxanthin, µg/d 109 ± 43 99 ± 49 99 ± 47 
Lycopene, µg/d, median [IQR] 104 [39, 305] 166 [50, 579] 194 [59, 639] 
Values are presented as mean ± SD, n (%), or median [IQR]. 
* Shown are dietary intakes; contributions from vitamin supplements were not included. 
 
Dietary antioxidants and CVD mortality 
After 15 y of follow-up, comprising 5744 person-years, 383 men had died (68.5%). CVD were 
the cause of death in 197 men. Major cardiovascular causes of death were ischemic heart disease 
(n = 89) and stroke (n = 52). In time-dependent analysis and after adjustment for age and total 
energy intake, a-carotene and beta-cryptoxanthin were significantly related to a lower CVD 
mortality (Table 2). After further adjustment for smoking, BMI, physical activity, alcohol use, 
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Table 2: Relative risks* of 15-y cardiovascular mortality by intake of dietary antioxidants in the Zutphen Elderly Study 1985-2000 
Adjusted for age and 
energy intake‡ 
Adjusted for age, energy 
and smoking§ 
Multivariable- adjusted 
model A¶ 
Multivariable- adjusted 
model B# 
 
 
Antioxidant 
 
Mean ± SD daily intake at 
baseline (1985)† RR 95% CI RR 95% CI RR 95% CI RR 95% CI 
Total carotenoids 6372 ± 3201 µg 0.90 0.76-1.05 0.92 0.79-1.08 0.90 0.77-1.06 0.82 0.69-0.98 
Alpha-carotene 541 ± 586 µg  0.81 0.67-0.99 0.84 0.69-1.02 0.81 0.66-0.98 0.81 0.66-0.99 
Beta-carotene 2766 ± 1474 µg  0.89  0.75-1.05 0.91 0.77-1.08 0.88 0.74-1.05 0.80 0.66-0.97 
Luteine 2477 ± 1490 µg  1.08 0.93-1.25 1.08 0.93-1.24 1.06  0.92-1.22 0.95 0.81-1.12 
Lycopene 442 ± 1112 µg  0.85 0.71-1.02 0.87 0.73-1.04 0.88 0.73-1.05 0.91 0.76-1.08 
Beta-cryptoxanthin 47 ± 75 µg  0.84 0.71-0.99 0.85 0.72-1.00 0.85 0.72-1.01 0.86 0.72-1.03 
Zeaxanthin 109 ± 43 µg  0.94 0.81-1.09 0.95 0.82-1.10 0.92 0.79-1.07 0.88 0.70-1.10 
Vitamin C 88 ± 38 mg 0.89 0.76-1.04 0.92 0.78-1.07 0.91 0.78-1.07 1.02 0.85-1.23 
Vitamin E** 12.5 ± 11.9 mg alpha-TE 0.93 0.79-1.10 0.93 0.79-1.10 0.92 0.78-1.09 0.92 0.76-1.12 
Alpha-tocopherol 9.1 ± 4.6 mg 0.98 0.85-1.14 0.99 0.85-1.14 1.00 0.86-1.16 0.96 0.82-1.12 
Gamma-tocopherol 9.3 ± 6.2 mg 1.04 0.90-1.20 1.02 0.88-1.18 1.01 0.87-1.18 0.94 0.79-1.12 
* Shown are relative risks and 95%CI for a 1-SD increase in intake of dietary antioxidants; the intake from vitamin supplements was not included. 
† Shown are mean intakes ± SD from diet; contributions by vitamin supplements were not included.  
‡ Adjusted for age (continuous), and energy intake (continuous). 
§ Adjusted for age (continuous), energy intake (continuous), and smoking (indicator variables of current and former smoking). 
¶ Adjusted for age (continuous), energy intake (continuous), smoking (indicator variables of current and former smoking), body mass index (continuous), physical activity (continuous), alcohol 
consumption (yes or no), socioeconomic status (high versus medium and low), use of multivitamin supplements (yes or no), use of vitamin C supplements (yes or no), use of aspirin (yes or no), use of 
antihypertensive drugs (yes or no), use of anticoagulants (yes or no). 
# As Model A, with additional adjustment for diet prescription, intake of fiber, β-carotene, vitamin C, α-tocopherol, folate, saturated fatty acids, trans fatty acids, polyunsaturated fatty acids. Intake of all 
carotenoids was not adjusted for other carotenoids and no adjustment was made for the antioxidant under investigation.   
** Alpha-tocopherol Equivalents (alpha-TEs) as calculated by alpha-tocopherol + beta-tocopherol × 0.40 + gamma-tocopherol × 0.10 + delta-tocopherol × 0.01. 
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socioeconomic status, the use of medications, vitamin supplements, and dietary factors, a 1-SD 
increase in intake of alpha- and beta-carotene was associated with ~20% lower RR of death from 
CVD. An association of similar strength was observed for the consumption of carrots, the major 
source of alpha- and beta-carotene, in relation to 15-y CVD mortality (multivariate-adjusted RR 
= 0.83; 95% CI = 0.68-1.00). Intakes of carotenoids other than alpha- and beta-carotene were not 
significantly associated with CVD mortality, nor were intakes of vitamin C and vitamin E 
analyzed as alpha-TE, alpha-tocopherol, or gamma-tocopherol. 
To assess whether the relations of alpha- and beta-carotene with CVD mortality differed 
by levels of established CVD risk factors, we performed stratified analyses. We did not find 
significantly different associations for smokers and nonsmokers, for users and nonusers of 
alcoholic beverages, for those in the highest or lowest 2 tertiles of minutes of physical activity, 
for men with BMI < 25 and ≥25 kg/m2, or between levels of socioeconomic status (P > .05 for 
all). 
To avoid bias from change in diet and lifestyle due to nonfatal cardiovascular events, 
analyses were performed in which we stopped updating the information on diet and physical 
activity if subjects reported a nonfatal myocardial infarction or stroke (whichever came first) 
during the follow-up of the study, comprising 136 men. This, however, did not change our 
findings. We also analyzed the associations in nonusers of vitamin supplements (n = 504) and 
found virtually the same results. We finally performed analyses without possible subclinical 
CVD cases at baseline by excluding men who died within the first 2 y of follow-up (n = 15). 
This strengthened the multivariate-adjusted RR for a 1-SD increase to 0.72 (95% CI = 0.57-
0.90) for alpha-carotene and 0.74 (0.60-0.91) for beta-carotene. 
 
 
Table 3: Relative risks* of 15-y cardiovascular mortality by intake of antioxidant vitamins C and E from diet and 
supplements in the Zutphen Elderly Study 1985-2000 
 Tertiles of total intake 
Antioxidant vitamin Lowest Middle Highest 
P for linear 
trend 
Vitamin C     
Adjusted for age and energy 1.00 0.83 (0.58-1.20) 0.67 (0.46-0.98) .03 
Adjusted for age, energy, and 
smoking 
1.00 0.84 (0.58-1.20) 0.70 (0.48-1.02) .06 
Multivariate-adjusted model A† 1.00 0.83 (0.57-1.20) 0.70 (0.48-1.03) .07 
Multivariate-adjusted model B‡ 1.00 0.95 (0.64-1.42) 0.86 (0.57-1.30) .45 
Vitamin E     
Adjusted for age and energy 1.00 0.75 (0.52-1.08) 0.65 (0.44-0.94) .03 
Adjusted for age, energy, and 
smoking 
1.00 0.75 (0.52-1.08) 0.65 (0.45-0.95) .03 
Multivariate-adjusted model A† 1.00 0.76 (0.52-1.10) 0.67 (0.46-0.98) .05 
Multivariate-adjusted model B‡ 1.00 0.82 (0.56-1.21) 0.73 (0.49-1.08) .12 
* Shown are relative risks (95% CIs) for cardiovascular mortality by tertiles of total antioxidant intake. Users of vitamin supplements 
were forced into the highest tertile; for details see text.  
† Adjusted for age (cont.), energy (cont.), body mass index (cont.), physical activity (cont.), alcohol consumption (yes or no), 
socioeconomic status (high versus medium and low), use of aspirin (yes or no), use of antihypertensive drugs (yes or no), use of 
anticoagulants (yes or no). 
‡ As Model A, with additional adjustment for diet prescription, intake of fiber, beta-carotene, folate, saturated fatty acids, trans fatty 
acids, polyunsaturated fatty acids. The intake of vitamin C was adjusted for the intake vitamin E, and vice versa. 
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Total intake of vitamins C and E, and CVD mortality 
The total intake of vitamin C and vitamin E, i.e. from diet and vitamin supplements together, 
was studied in tertiles. After adjustment for age, energy intake, and lifestyle not including 
dietary factors (Model A), total vitamin E intake was significantly and total vitamin C intake 
borderline significantly associated with CVD mortality, indicating ~30% lower CVD mortality 
risk in the highest tertile compared with the lowest (Table 3). Further adjustment for dietary 
factors (Model B), especially trans fatty acids, attenuated these relations to yield nonsignificant 
findings (P for trend > .10 for both). 
Dietary antioxidant score and CVD mortality 
A diet high in 3 major antioxidants, i.e. carotenoids, vitamin E, and vitamin C, was related to a 
lower CVD mortality, although this finding was borderline (P for trend = .05) at the customary 
level of significance (Table 4). To investigate the importance of alpha- and beta-carotene in this 
antioxidant score, we reassessed the score in which alpha- and beta-carotene were not included. 
This alternative score was composed of the sum of carotenoids other than alpha- and beta-
carotene, vitamin C, and the sum of alpha- and gamma-tocopherol. RR (95% CI) according to 
the multivariable-adjusted model B for increasing tertiles of this antioxidant score were 1.00, 
1.02 (0.71-1.47), and 0.80 (0.55-1.16) (P for trend = .34). 
Discussion 
In this prospective cohort study in Dutch elderly men, dietary alpha-carotene and beta-carotene 
were inversely related to CVD mortality. Carrots were the primary source of both alpha- and 
beta-carotene and their consumption was also associated with a lower risk of CVD death. In 
contrast, the intake of 4 other carotenoids and that of vitamin E and vitamin C were not 
associated with mortality from CVD. 
 
 
Table 4: Relative risks* of 15-y cardiovascular mortality by dietary antioxidant score in the Zutphen Elderly Study 
1985-2000 
 Tertiles of total intake 
Model Lowest Middle Highest 
P for linear 
trend 
Adjusted for age and energy 1.00 0.94 (0.66-1.34) 0.74 (0.53-1.03) .04 
Adjusted for age, energy, and 
smoking 
1.00 0.96 (0.68-1.37) 0.78 (0.56-1.08) .08 
Multivariate-adjusted model A† 1.00 0.94 (0.66-1.34) 0.75 (0.54-1.05) .06 
Multivariate-adjusted model B‡ 1.00 0.87 (0.60-1.25) 0.73 (0.60-1.05) .05 
* Shown are relative risks (95% CIs) by tertiles of dietary antioxidant score, contributions by vitamin supplements were not included 
(for details see text). 
† Adjusted for age (cont.), energy (cont.), body mass index (cont.), physical activity (cont.), alcohol consumption (yes or no), 
socioeconomic status (high versus medium and low), use of multivitamin supplements (yes or no), use of vitamin C supplements 
(yes or no), use of aspirin (yes or no), use of antihypertensive drugs (yes or no), use of anticoagulants (yes or no). 
‡ As Model A, with additional adjustment for diet prescription, intake of fiber, folate, saturated fatty acids, trans fatty acids, 
polyunsaturated fatty acids. 
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The strengths of this study include its prospective design, the nearly complete mortality 
follow-up, and the relatively high CVD mortality rate. Also, the use of cumulative means of 
repeated measurements of diet and physical activity better reflect long-term exposure and reduce 
within-person variation (33). This study also has limitations. First, the credibility of 
observational studies is often criticized because of the potential of residual confounding due to 
measurement error and unmeasured variables (35). In this study, men with higher intakes of 
alpha- and beta-carotene were less likely to smoke, more often used multivitamin supplements, 
and had a higher socioeconomic status. Although the relation of alpha- and beta-carotene with 
CVD mortality did not differ between levels of these variables, we cannot exclude the possibility 
of residual confounding by these or other factors. Second, as many dietary carotenoids, 
especially alpha- and beta-carotene, were correlated with each other, their independent 
association with CVD mortality was difficult to establish. Third, the sample size of the study 
population limited the power to detect small effects of antioxidants and their dietary sources. 
Finally, information about the dose and frequency of vitamin supplement use was not collected 
in this study. Although we forced users of vitamin supplements in the highest tertile of 
antioxidant intake, this may have resulted in some misclassification. 
Several prospective cohort studies on dietary carotenoids showed an inverse relation 
between the intake of beta-carotene or total carotenoids and the risk of coronary heart disease 
(22,36), although sometimes only in subgroups (15). This is in line with the inverse relation 
between the intake of beta-carotene and CVD mortality in the current study. The Nurses’ Health 
Study also confirmed the inverse relation for alpha-carotene (22).  
Findings from observational studies that addressed relations between circulating 
carotenoids and intermediaries for CVD and clinical CVD are inconsistent. Subjects with high 
blood concentrations of a- or b-carotene had less atherosclerosis compared with subjects with 
low concentrations (37,38), although this finding is not consistent in all studies (39,40). Yet, 
circulating levels of either alpha- and beta-carotene, or both, are inversely associated with future 
CVD in some (24,41) but not all studies (13,42).  
In this study, we constructed an antioxidant score combining 6 carotenoids, 2 
tocopherols, and vitamin C, in which each of these 3 antioxidants was given the same weight. 
Such an approach may be preferable to studying 1 antioxidant at a time, as single antioxidants 
are less likely to lower CVD risk (19–21), whereas a diet rich in multiple antioxidants may do 
so. However, the weak inverse association between the antioxidant score and CVD mortality in 
this study was driven by alpha- and beta-carotene and did not clearly support the hypothesis that 
a diet rich in multiple antioxidants lowers CVD risk. To our knowledge, only 1 other study has 
applied a score in which dietary antioxidants were included (43). In that study population, which 
consisted of male smokers, an oxidative balance score based on the dietary intake of beta-
carotene, vitamin C, and iron was not related to CVD mortality (43). 
Alpha and beta-carotene are considered to be important antioxidants. It has been 
hypothesized that lipoprotein oxidation induced by reactive nitrogen species within the arterial 
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wall preferably depletes these carotenes compared with other fat-soluble antioxidants (44). 
When the diet no longer provides sufficient amounts of these carotenes, their concentrations in 
LDL and plasma will decrease and lipoproteins will become more prone to oxidation. However, 
although it has been shown that in vitro lipoprotein oxidation induced by reactive nitrogen 
species depletes a- and b-carotene (44), it is yet not clear whether reactive nitrogen species are 
an important cause of in vivo lipoprotein oxidation. Also, recently it was shown that circulating 
carotenoids, including alpha- and beta-carotene, are inversely associated with inflammation and 
oxidative stress and positively associated with markers of endothelial function (14), which 
suggests that they may influence CVD risk through different pathways. Alternatively, it may 
also be that other nutrients and dietary bioactive compounds, correlated with dietary alpha- and 
beta-carotene, may account for the observed inverse association of these 2 carotenoids with 
cardiovascular mortality. 
Research on vitamin E has been mainly focused on alpha-tocopherol, whereas scientific 
interest in gamma-tocopherol was raised only recently (45). Gamma-tocopherol constitutes 
~70% of the vitamin E in the typical American diet (46) and 50% in the diet consumed by the 
population in this study. Our findings do not support a role of vitamin E in lowering mortality 
from CVD. Observational studies on vitamin E and CVD have yielded conflicting results, 
whereas large-scale trials with vitamin E largely produced null results (19). The most 
conspicuous study is the Alpha-Tocopherol Beta-Carotene trial, in which 50 mg/d synthetic 
vitamin E did not affect primary and secondary prevention of CVD in male Finnish smokers 
(47,48), but baseline serum levels of alpha-tocopherol were, paradoxically, inversely related to 
CVD mortality (49). 
Despite the possibility that vitamin C may exert anti-inflammatory effects (11) and may 
improve endothelial function (12), dietary vitamin C intake was not related with CVD mortality 
in this study or in large prospective cohort studies on dietary vitamin C intake and 
cardiovascular events (15,50–53). Although in a recent meta-analysis of large prospective cohort 
studies vitamin C from foods and supplements was related to a lower risk of coronary heart 
disease (54), the few trials that have investigated the efficacy of vitamin C supplementation on 
mortality do not support a role for this antioxidant in reducing overall mortality (55). 
In summary, intakes of alpha- and beta-carotene, especially from carrots, were inversely 
related to a CVD death in elderly men. More observational studies on the intake of individual 
carotenoids and their specific sources, as well as foods correlated with their intake, in relation to 
CVD are warranted. Our findings on dietary vitamin C and alpha- and gamma-tocopherol do not 
support a role for these antioxidants in lowering CVD mortality. 
References 
1. Guallar E, Hanley DF, Miller ER III. An editorial update: annus horribilis for vitamin E. Ann Intern Med. 
2005;143:143–5. 
Antioxidant intake and cardiovascular mortality 
 60 
2. Voutilainen S, Nurmi T, Mursu J, Rissanen TH. Carotenoids and cardiovascular health. Am J Clin Nutr. 
2006;83:1265–71. 
3. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. 
Arch Biochem Biophys. 1989;274:532–8. 
4. Winklhofer-Roob BM, Rock E, Ribalta J, Shmerling DH, Roob JM. Effects of vitamin E and carotenoid status 
on oxidative stress in health and disease. Evidence obtained from human intervention studies. Mol Aspects 
Med. 2003;24:391–402. 
5. Jialal I, Fuller CJ, Huet BA. The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-
response study. Arterioscler Thromb Vasc Biol. 1995;15:190–8. 
6. Princen HM, van DuyvenvoordeW, Buytenhek R, van der Laarse A, van Poppel G, Gevers Leuven JA, van 
Hinsbergh VW. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and 
women. Arterioscler Thromb Vasc Biol. 1995;15:325–33. 
7. Porkkala-Sarataho EK, Nyyssonen MK, Kaikkonen JE, et al. A randomized, single-blind, placebo-controlled 
trial of the effects of 200 mg alpha-tocopherol on the oxidation resistance of atherogenic lipoproteins. Am J 
Clin Nutr. 1998;68:1034–41. 
8. Porkkala-Sarataho E, Salonen JT, Nyyssonen K, Kaikkonen J, Salonen R, Ristonmaa U, Diczfalusy U, 
Brigelius-Flohe R, Loft S, Poulsen HE. Long-term effects of vitamin E, vitamin C, and combined 
supplementation on urinary 7-hydro-8-oxo-2#-deoxyguanosine, serum cholesterol oxidation products, and 
oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vasc Biol. 2000;20:2087–93. 
9. Jialal I, Grundy SM. Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene 
on low-density lipoprotein oxidation. Circulation. 1993;88:2780–6. 
10. Huang HY, Appel LJ, Croft KD, Miller ER III, Mori TA, Puddey IB. Effects of vitamin C and vitamin E on in 
vivo lipid peroxidation: results of a randomized controlled trial. Am J Clin Nutr. 2002;76:549–55. 
11. Esposito K, Nappo F, Giugliano F, Giugliano G, Marfella R, Giugliano D. Effect of dietary antioxidants on 
postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects. Am J Clin Nutr. 
2003;77:139–43. 
12. Wannamethee SG, Lowe GD, Rumley A, Bruckdorfer KR, Whincup PH. Associations of vitamin C status, fruit 
and vegetable intakes, and markers of inflammation and hemostasis. Am J Clin Nutr. 2006;83:567–74. 
13. Walston J, Xue Q, Semba RD, Ferrucci L, Cappola AR, Ricks M, Guralnik J, Fried LP. Serum antioxidants, 
inflammation, and total mortality in older women. Am J Epidemiol. 2006;163:18–26. 
14. Hozawa A, Jacobs DR Jr, Steffes MW, Gross MD, Steffen LM, Lee DH. Relationships of circulating 
carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: 
The Coronary Artery Risk Development in Young Adults (CARDIA)/Young Adult Longitudinal Trends in 
Antioxidants (YALTA) Study. Clin Chem. 2007;53:447–55. 
15. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the 
risk of coronary heart disease in men. N Engl J Med. 1993;328:1450–6. 
16. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the 
risk of coronary disease in women. N Engl J Med. 1993;328:1444–9. 
17. Knekt P, Reunanen A, Jarvinen R, Seppanen R, Heliovaara M, Aromaa A. Antioxidant vitamin intake and 
coronary mortality in a longitudinal population study. Am J Epidemiol. 1994;139:1180–9. 
18. Gaziano JM, Manson JE, Branch LG, Colditz GA, Willett WC, Buring JE. A prospective study of consumption 
of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol. 
1995;5:255–60. 
19. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of 
cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017–23. 
Antioxidant intake and cardiovascular mortality 
 61
20. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant 
supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 
2007;297:842–57. 
21. Bleys J, Miller ER III, Pastor-Barriuso R, Appel LJ, Guallar E. Vitamin-mineral supplementation and the 
progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2006;84:880–7. 
22. Osganian SK, Stampfer MJ, Rimm E, Spiegelman D, Manson JE, Willett WC. Dietary carotenoids and risk of 
coronary artery disease in women. Am J Clin Nutr. 2003;77:1390–9. 
23. Tavani A, Gallus S, Negri E, Parpinel M, La Vecchia C. Dietary intake of carotenoids and retinol and the risk 
of acute myocardial infarction in Italy. Free Radic Res. 2006;40:659–64. 
24. Buijsse B, Feskens EJ, Schlettwein-Gsell D, Ferry M, Kok FJ, Kromhout D, de Groot LC. Plasma carotene and 
alpha-tocopherol in relation to 10-y all-cause and cause-specific mortality in European elderly: the Survey in 
Europe on Nutrition and the Elderly, a Concerted Action (SENECA). Am J Clin Nutr. 2005;82:879–86. 
25. Kabagambe EK, Furtado J, Baylin A, Campos H. Some dietary and adipose tissue carotenoids are associated 
with the risk of nonfatal acute myocardial infarction in Costa Rica. J Nutr. 2005;135:1763–9. 
26. Keys A, Aravanis C, Blackburn HW, van Buche FSP, Buzina R, Djordjevic BS, Dontas AS, Fidanza F, 
Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu V, Taylor HL. Epidemiological studies related to coronary 
heart disease: characteristics of men aged 40–59 in seven countries. Acta Med Scand Suppl. 1966;460 Suppl:1–
392. 
27. Buijsse B, Feskens EJ, Kok FJ, Kromhout D. Cocoa intake, blood pressure, and cardiovascular mortality: the 
Zutphen Elderly Study. Arch Intern Med. 2006;166:411–7.  
28. Bloemberg BP, Kromhout D, Obermann-De Boer GL, Van Kampen-Donker M. The reproducibility of dietary 
intake data assessed with the cross-check dietary history method. Am J Epidemiol. 1989;130:1047–56.  
29. NEVO Foundation. Netherlands Food Composition Table 2001. The Hague, The Netherlands; Netherlands 
Nutrition Center; 2001. 
30. Dietary Reference Intakes for vitamin C, vitamin E, selenium, and carotenoids. Institute of Medicine, 
Washington DC; 2000. 
31. Oomen CM, Ocke MC, Feskens EJM, Erp-Baart MAJv, Kok FJ, Kromhout D. Association between trans fatty 
acid intake and 10-year risk of coronary heart disease in the Zutphen Elderly Study: a prospective population-
based study. Lancet. 2001;357:746–51. 
32. Bijnen FC, Caspersen CJ, Feskens EJ, Saris WH, Mosterd WL, Kromhout D. Physical activity and 10-year 
mortality from cardiovascular diseases and all causes: the Zutphen Elderly Study. Arch Intern Med. 
1998;158:1499–505. 
33. Hu FB, Stampfer MJ, Rimm E, Ascherio A, Rosner BA, Spiegelman D, Willett WC. Dietary fat and coronary 
heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary 
measurements. Am J Epidemiol. 1999;149:531–40. 
34. Willett WC, Stampfer M. Implications of total energy intake for epidemiologic analysis. In: WillettW, ed. 
Nutritional epidemiology. 2nd ed. New York: Oxford University Press; 1998. 
35. Lawlor DA, Davey Smith G, Kundu D, Bruckdorfer KR, Ebrahim S. Those confounded vitamins: what can we 
learn from the differences between observational versus randomised trial evidence? Lancet. 2004;363:1724–7. 
36. Klipstein-Grobusch K, Geleijnse JM, den Breeijen JH, Boeing H, Hofman A, Grobbee DE, Witteman JC. 
Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 
1999;69:261–6. 
37. D’Odorico A, Martines D, Kiechl S, Egger G, Oberhollenzer F, Bonvicini P, Sturniolo GC, Naccarato R, 
Willeit J. High plasma levels of alpha- and beta-carotene are associated with a lower risk of atherosclerosis: 
results from the Bruneck study. Atherosclerosis. 2000;153:231–9. 
Antioxidant intake and cardiovascular mortality 
 62 
38. Dwyer JH, Paul-Labrador MJ, Fan J, Shircore AM, Merz CN, Dwyer KM. Progression of carotid intima-media 
thickness and plasma antioxidants: the Los Angeles Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 
2004;24:313–9. 
39. Klipstein-Grobusch K, Launer LJ, Geleijnse JM, Boeing H, Hofman A, Witteman JC. Serum carotenoids and 
atherosclerosis. The Rotterdam Study. Atherosclerosis. 2000;148:49–56. 
40. de Waart FG, Smilde TJ, Wollersheim H, Stalenhoef AF, Kok FJ. Smoking characteristics, antioxidant 
vitamins, and carotid artery wall thickness among life-long smokers. J Clin Epidemiol. 2000;53:707–14. 
41. Ito Y, Kurata M, Suzuki K, Hamajima N, Hishida H, Aoki K. Cardiovascular disease mortality and serum 
carotenoid levels: a Japanese population-based follow-up study. J Epidemiol. 2006;16:154–60. 
42. De Waart FG, Schouten EG, Stalenhoef AF, Kok FJ. Serum carotenoids, alpha-tocopherol and mortality risk in 
a prospective study among Dutch elderly. Int J Epidemiol. 2001;30:136–43. 
43. Van Hoydonck PG, Temme EH, Schouten EG. A dietary oxidative balance score of vitamin C, beta-carotene 
and iron intakes and mortality risk in male smoking Belgians. J Nutr. 2002;132:756–61. 
44. Kontush A, Weber W, Beisiegel U. Alpha- and beta-carotenes in low density lipoprotein are the preferred 
target for nitric oxide-induced oxidation. Atherosclerosis. 2000;148:87–93. 
45. Devaraj S, Traber MG. Gamma-tocopherol, the new vitamin E? Am J Clin Nutr. 2003;77:530–1. 
46. Jiang Q, Christen S, Shigenaga MK, Ames BN. Gamma-tocopherol, the major form of vitamin E in the US 
diet, deserves more attention. Am J Clin Nutr. 2001;74:714–22. 
47. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Randomised trial of 
alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous 
myocardial infarction. Lancet. 1997;349:1715–20. 
48. Virtamo J, Rapola JM, Ripatti S, Heinonen OP, Taylor PR, Albanes D, Huttunen JK. Effect of vitamin E and 
beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch 
Intern Med. 1998;158:668–75. 
49. Wright ME, Lawson KA,Weinstein SJ, Pietinen P, Taylor PR, Virtamo J, Albanes D. Higher baseline serum 
concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr. 2006;84:1200–7. 
50. Kushi LH, Folsom AR, Prineas RJ, Mink PJ,Wu Y, Bostick RM. Dietary antioxidant vitamins and death from 
coronary heart disease in postmenopausal women. N Engl J Med. 1996;334:1156–62. 
51. Osganian SK, Stampfer MJ, Rimm E, Spiegelman D, Hu FB, Manson JE, Willett WC. Vitamin C and risk of 
coronary heart disease in women. J Am Coll Cardiol. 2003;42:246–52. 
52. Fletcher AE, Breeze E, Shetty PS. Antioxidant vitamins and mortality in older persons: findings from the 
nutrition add-on study to the Medical Research Council Trial of Assessment and Management of Older People 
in the Community. Am J Clin Nutr. 2003;78:999–1010. 
53. Lawlor DA, Ebrahim S, Kundu D, Bruckdorfer KR, Whincup PH, Smith GD. Vitamin C is not associated with 
coronary heart disease risk once life course socioeconomic position is taken into account: prospective findings 
from the British Women’s Heart and Health Study. Heart. 2005;91:1086–7. 
54. Knekt P, Ritz J, Pereira MA, O’Reilly EJ, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans G, 
et al. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am J Clin Nutr. 
2004;80:1508–20. 
55. Ness A, Egger M, Smith GD. Role of antioxidant vitamins in prevention of cardiovascular diseases. Meta-
analysis seems to exclude benefit of vitamin C supplementation. BMJ. 1999;319:577. 
Plasma carotene and tocopherol and mortality in the eldery 
 63
 
Plasma Carotene and Alpha-
Tocopherol in Relation  
to 10-Year All-Cause and  
Cause-Specific Mortality in European 
Elderly: the Survey in Europe on 
Nutrition and the Elderly, a Concerted 
Action (SENECA) 
 
Brian Buijsse, Edith J.M. Feskens, Daniela Schlettwein-Gsell, Monique Ferry, 
Frans J. Kok, Daan Kromhout, and Lisette C.P.G.M. de Groot 
 
Background: Only a few observational studies have related plasma carotene and alpha-tocopherol to 
mortality in elderly subjects.  
Objective: The objective was to study the association of plasma carotene (alpha- and beta-carotene) and 
alpha-tocopherol with all-cause and cause-specific mortality in elderly subjects who participated in a 
European prospective study. 
Design: Plasma concentrations of carotene and alpha-tocopherol were measured in 1168 elderly men and 
women. After a follow-up period of 10 y, 388 persons had died. The association between plasma antioxidants 
and mortality was analyzed by using Cox proportional hazard models. To put our results in context, we 
performed a meta-analysis of 5 studies on plasma antioxidants and all-cause mortality in elderly populations. 
Results: Plasma carotene concentrations were associated with a lower mortality risk [adjusted rate ratio (RR) 
for an increment of 0.39 μmol/L: 0.79; 95% confidence interval (CI): 0.70, 0.89]. This lower mortality risk 
was observed for both cancer (RR: 0.59; 95% CI: 0.44, 0.79) and cardiovascular disease (RR: 0.83; 95% CI: 
0.70, 1.00). The lower risk in cardiovascular death risk was confined to those with a body mass index (in 
kg/m2) <25 (RR: 0.67; 95% CI: 0.49, 0.94). Plasma concentrations of alpha-tocopherol were not associated 
with all-cause or cause-specific mortality. The results for both plasma antioxidants and all-cause mortality 
were confirmed by the meta-analysis. 
Conclusions: This prospective study suggests that high plasma concentrations of carotene are associated 
both with a lower mortality from all causes and with cancer in the elderly. For cardiovascular mortality, the 
inverse association was confined to elderly with body mass indexes <25. 
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Introduction 
Aging is associated with higher levels of oxidative stress (1), which are likely to play an 
important role in the development of cardiovascular disease (CVD) (2) and cancer (3). Oxidative 
stress is lower among subjects with a high antioxidant status (4). Therefore, elderly subjects with 
a high antioxidant status may have a lower risk of these chronic diseases.  
Carotene and vitamin E are 2 fat-soluble antioxidants that have received much scientific 
attention during the past decade. Observational studies relating plasma or serum concentrations 
of beta-carotene to CVD and cancer and relating vitamin E to CVD are mainly conducted in 
middle-aged populations. A high status of beta-carotene was related to a lower risk of CVD in 
most (5–8) but not all (9) observational studies. A few studies of vitamin E status found an 
inverse association with CVD (10,11), but most others did not (5,7,11,12,13). A high beta-
carotene status was strongly related to a low risk of cancer, especially lung cancer (14).  
Studies of beta-carotene and vitamin E status in elderly populations are limited to a few 
observational studies that related plasma concentrations of these antioxidants to mortality (15–
19). Most of these studies focused on all-cause mortality and had a small sample size. Although 
several studies found an inverse association of serum beta-carotene or total carotenoid 
concentrations with all-cause (15,18,19) and cardiovascular mortality (15,18), this association 
was in most cases not significant. One study did not find a relation between plasma beta-
carotene and all-cause mortality (17). Plasma alpha-tocopherol was not associated with either 
all-cause (15–18) or cardiovascular mortality (15,16,18) in elderly subjects. Only one study 
investigated the relation of plasma carotenoids and vitamin E to cancer mortality in an elderly 
population, and it found no association (15).  
 Measures of overweight and obesity, such as body mass index, are consistently 
found to be inversely associated with levels of plasma beta-carotene (20–22), whereas their 
association with plasma alpha-tocopherol is less clear (20,22,23). Obesity has been shown to be 
associated with systemic low-grade inflammation (24) and oxidative stress (25). Taken together, 
these observations could indicate that plasma beta-carotene in particular is depleted because of 
oxidative stress in obese subjects.  
We have studied whether plasma concentrations of carotene and alpha-tocopherol were 
associated with all-cause and cause-specific mortality in apparently healthy elderly subjects who 
participated in a prospective European study. We examined whether these associations were 
modified by body mass. Finally, to put our results in context, we performed a meta-analysis of 
observational studies of both plasma antioxidants in relation to all-cause mortality in elderly 
populations. 
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Subjects and methods 
Study population 
The Survey in Europe on Nutrition and the Elderly, a Concerted Action (SENECA) is a 
prospective study investigating whether diet and lifestyle influence the health of elderly people 
in various European countries (26). Subjects were excluded if they were psycho-geriatric 
patients living in nursing homes, did not speak the country’s language fluently, or were not able 
to answer questions independently.  
Between December 1988 and March 1989, baseline measurements took place in a 
random age-gender stratified sample of European elderly aged 70-75 y (27). Nine study centers, 
in which 2038 subjects were examined, collected blood samples for antioxidant measurements 
and provided information about vital status and causes of death. Participation rates varied 
between 34% and 62% (27). Plasma antioxidants were actually measured in 1682 subjects. We 
excluded 102 participants with missing information on important variables and another 392 with 
a history of myocardial infarction, stroke, diabetes, or cancer. In addition, 16 participants were 
excluded because information on follow-up time was lacking, and 4 participants were excluded 
because their plasma antioxidant concentrations exceeded the mean by >9 times the SD. This 
study is therefore based on 1168 European elderly.  
All participants gave written informed consent. Approval of the study was obtained from 
the participating SENECA centers. 
Antioxidant and lipid measurements 
Blood samples were obtained by venipuncture after an overnight fast. Plasma and sera were 
stored at –80 ºC before transport to the Division of Human Nutrition at Wageningen University 
for measurement of serum total and HDL cholesterol. For plasma antioxidant measurements, 
plasma samples were then send to the laboratories of Hoffmann-La Roche Ltd (Basel, 
Switzerland). Plasma concentrations of carotene and alpha-tocopherol were determined by 
HPLC methods (28,29). For the present study the sum of alpha- and beta-carotene was reported 
by the laboratory. CVs for the day-to-day variance of duplicate assays of one sample were 3.0% 
for carotene and 1.8% for alpha-tocopherol. Total and HDL cholesterol and triacylglycerols 
were measured in sera by using enzymatic calorimetric methods in the standardized lipid 
laboratory of Wageningen University (30).  
Lifestyle assessment and health status 
Baseline information on smoking, years spent in full-time education, the use of vitamin 
supplements, alcohol consumption, and the prevalence of diabetes, myocardial infarction, stroke, 
and cancer was obtained by using questionnaires (31). Alcohol consumption was categorized as 
use and nonuse. Household, sports, and leisure time physical activities were estimated by using a 
Plasma carotene and tocopherol and mortality in the elderly 
 66 
validated questionnaire (32). Physical activity was classified in the total study population by 
sex-specific tertiles. 
Body weight was measured to the nearest 0.5 kg on a calibrated scale. Subjects were 
weighed in the morning after breakfast and after emptying the bladder; they were wearing light 
underclothing. Height was measured to the nearest 0.1 cm while subjects were standing erect 
and wearing no shoes. Body mass index (BMI) was calculated by dividing body weight (in kg) 
by the square of height (m2).  
Case ascertainment 
Information on vital status was collected in 1999–2000. One experienced clinical epidemiologist 
coded the causes of death by using the ninth revision of the World Health Organization 
International Classification of Diseases (ICD9) (33). CVD is covered by ICD9 codes 390–459, 
and cancer is covered by codes 140–209. The cause of death was unknown for 104 subjects. For 
the analysis of cause-specific mortality, the follow-up time of these subjects was censored. Only 
4 subjects were lost to follow-up; their follow-up time was censored after 5 y. After 10 y of 
follow-up, 388 had died–38% of CVD and 25% from cancer.  
Statistical analysis 
Descriptive analyses were performed with stratification for cohort and tertiles of plasma 
carotene and alpha-tocopherol. Because the distribution of plasma carotene was skewed to the 
right, values were log transformed and, therefore, geometric means and geometric SDs are 
presented. 
Cox proportional hazards models were used to obtain rate ratios (RR) and 95% CIs for 
the association between a 1-SD increment in plasma antioxidant concentration and mortality. 
Although women had a higher average concentration of both plasma carotene and alpha-
tocopherol, all analyses were done for men and women combined because the associations with 
mortality did not differ between men and women. Analyses were adjusted for age (continuous) 
and sex (Model 1); in additional multivariate analyses, they were also adjusted for other 
covariates [Model 2: BMI (continuous), serum total cholesterol (continuous), serum HDL 
cholesterol (continuous), current smoking (yes or no), alcohol consumption (yes or no), physical 
activity (low versus medium and high tertiles), and SENECA center (indicator variables)]. All 
analyses were further adjusted for either plasma carotene or plasma alpha-tocopherol (Model 3).  
Plasma carotene and alpha-tocopherol were measured 5 y later in a subsample of 644 
participants. Using Pearson’s coefficient for correlation between the measurements at baseline 
and 5 y later, we adjusted our risk estimates for measurement error and within-person variance 
(regression dilution bias) (34). 
To examine the roles of body mass, smoking, and sex, stratified analyses were 
performed. Possible interactions of plasma concentrations of antioxidants with body mass or 
smoking for mortality were studied by entering product terms in the Cox regression models. 
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We performed a meta-analysis of observational studies of the association of plasma 
(beta-)carotene or alpha-tocopherol with all-cause mortality in subjects aged ≥60 y, including 
the current study. We performed a systematic, computerized literature search by using a 
combination of the Medical Subject Heading terms “aged,”  “beta-carotene,” “carotenoids,” 
“vitamin E,” “antioxidants,” and “mortality.” References lists of selected articles were inspected. 
In addition to 3 studies which measured plasma beta-carotene (17–19), we included one study 
that measured plasma carotenoids (15). Reported adjusted RRs were used to calculate new 
mortality rates in the lowest and highest category of plasma antioxidant. On the basis of these 
event rates, RRs were calculated in which the lowest plasma category was taken as the 
reference. We used a random-effects model to combine the results of all studies (35). 
Heterogeneity was assessed by inconsistency squared (I2), which describes the percentage of 
total variation between studies that is due to heterogeneity rather than to chance; higher values 
indicated greater heterogeneity (36).  
All data were analyzed by using SAS software (version 9.1; SAS Institute, Cary NC, 
USA). Statistical tests were 2-sided, and P values < .05 were considered significant.  
Results 
Plasma carotene varied from 0.28 μmol/L in Belgian subjects to 0.69 μmol/L in Swiss subjects. 
Plasma alpha-tocopherol ranged from 25.3 μmol/L in the Belgians to 35.6 μmol/L in the Swiss. 
Selected characteristics of the participants from the SENECA centers are shown in Table 1. 
Plasma concentrations of carotene and alpha-tocopherol were positively associated with serum 
total and serum HDL cholesterol and inversely associated with smoking (Table 2 and Table 3). 
Plasma carotene was inversely related to serum triacylglycerols and physical activity, whereas 
plasma alpha-tocopherol was positively associated with serum triacylglycerols and years spent 
in full-time education. 
After multivariate adjustment, subjects with BMI s ≥ 25 had lower mean plasma carotene 
concentrations compared than did subjects with BMIs < 25 (0.47 μmol/L and 0.60 μmol/L, 
respectively; P < .0001). Plasma alpha-tocopherol was not associated with BMI. Women had 
higher concentrations of both plasma alpha-tocopherol and plasma carotene than did men (P < 
.0001 for both after multivariate adjustment). 
Plasma antioxidants and mortality 
As shown in Table 4, plasma carotene concentrations were inversely associated with mortality 
due to all causes, CVD, and cancer. The strongest inverse association was observed for mortality 
due to cancer. Additional adjustment for plasma alpha-tocopherol yielded similar results. 
Excluding subjects with subclinical CVD and cancer by omitting the first 2 y of follow-
up resulted in similar associations. The inverse association with cancer mortality became 
stronger (RR for an increment of 0.39 μmol/L plasma carotene: 0.50; 95% CI: 0.35, 0.72),
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Table 1: Baseline characteristics of apparently healthy participants (n=1168) by SENECA study center 
 
 
 
Characteristic 
 
Hamme, 
Belgium 
(n=137) 
 
Roskilde, 
Denmark 
(n=122) 
 
Haguenau, 
France 
(n=144) 
 
Romans, 
France 
(n=107) 
 
Padua, 
Italy 
(n=156) 
 
Culemborg, 
Netherlands 
(n=149) 
Villa 
Franca, 
Portugal 
(n=112) 
 
Betanzos, 
Spain 
(n=118) 
 
Yverdon, 
Switzerland 
(n=123) 
Demographics and lifestyle          
% Men 57 49 53 50 49 45 52 47 46 
Age (years) 73.0 (1.8) 72.9 (3.1) 72.9 (1.7) 73.1 (1.8) 73.5 (1.7) 72.8 (1.7) 72.4 (1.6) 72.7 (1.9) 72.9 (1.7) 
Body Mass Index (kg/m2) 26.3 (3.9) 25.4 (4.2) 27.2 (4.2) 26.0 (3.8) 25.5 (4.0) 27.0 (3.8) 26.9 (4.1) 27.9 (3.9) 26.6 (4.1) 
Education (years) 9.0 (2.4) 10.3 (3.4) 9.4 (2.7) 8.2 (3.0) 8.9 (4.7) 8.6 (2.8) 2.6 (2.7) 6.7 (3.7) 9.4 (2.2) 
% Smoker 27 43 17 7 23 23 8 19 14 
% Alcohol use 62 81 85 79 84 65 45 52 72 
% Low physical activity 41 33 39 59 24 29 21 29 24 
% Vitamin supplement use 3 59 0 0 15 23 6 0 9 
Plasma antioxidants and serum 
lipoproteins 
         
Plasma carotene (μmol/L) * 0.28 (0.21) 0.50 (0.35) 0.49 (0.37) 0.67 (0.47) 0.67 (0.49) 0.50 (0.26) 0.59 (0.49) 0.43 (0.32) 0.69 (0.44) 
Plasma alpha-tocopherol (μmol/L) 25.3 (8.3) 30.4 (8.1) 31.7 (8.7) 30.8 (8.2) 32.9 (8.5) 29.9 (7.2) 28.9 (8.5) 30.8 (8.6) 35.6 (8.1) 
Plasma alpha-tocopherol (μmol/L) † 24.6 (0.5) 30.0 (0.6) 32.7 (0.5) 30.6 (0.6) 33.4 (0.5) 29.8 (0.5) 29.9 (0.6) 31.5 (0.6) 33.7 (0.6) 
Serum total cholesterol (mmol/L) 6.5 (1.3) 6.5 (1.3) 6.1 (1.1) 6.4 (1.1) 6.3 (1.0) 6.4 (1.1) 6.2 (1.2) 6.2 (1.1) 6.8 (1.1) 
Serum HDL cholesterol (mmol/L) 1.30 (0.35) 1.43 (0.40) 1.36 (0.37) 1.42 (0.38) 1.53 (0.41) 1.31 (0.35) 1.23 (0.34) 1.36 (0.38) 1.39 (0.38) 
Serum triacylglycerols (mmol/L) 1.4 (0.7) 1.3 (0.8) 1.4 (0.8) 1.4 (0.6) 1.5 (0.7) 1.4 (0.7) 1.3 (0.7) 1.4 (1.3) 1.4 (0.8) 
Values are means (SD) unless otherwise indicated. 
*Geometric mean (geometric SD). 
† Mean plasma alpha-tocopherol (SE), adjusted for total serum cholesterol. 
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Table 2: Baseline characteristics of the study population (n=1,168) by tertiles of plasma carotene 
Tertiles of plasma carotene  
 
Characteristic 
Lowest tertile 
(n=385) 
Medium tertile 
(n=390) 
Highest tertile 
(n=393) 
 
P value* 
Plasma carotene, μmol/L† 0.22 (0.12) 0.54 (0.09) 1.12 (0.39)  
Plasma carotene, μmol/L‡ 0.23 (0.22-0.24) 0.54 (0.52-0.56) 1.10 (1.06-1.14)  
Demographics and lifestyle     
Age, y 73.0 (2.3) 73.0 (1.7) 72.8 (1.8) .32 
% Men 70 47 34 <.0001 
Body Mass Index, kg/m2 27.3 (4.0) 26.8 (4.2) 25.6 (3.8) <.0001 
Education, y 8.0 (3.7) 8.2 (3.5) 8.5 (4.2) .18 
% Smoker 34 18 11 <.0001 
% Alcohol use 75 70 65 .02 
% Low physical activity 36 36 26 .004 
% Vitamin supplement use 12 11 16 .11 
Plasma tocopherol and serum 
lipoproteins 
    
Plasma alpha-tocopherol, μmol/L 26.5 (8.2) 31.5 (7.9) 34.0 (8.1) <.0001 
Plasma alpha-tocopherol, μmol/L§ 28.1 (0.35) 31.4 (0.34) 32.6 (0.34) <.0001 
Serum total cholesterol, mmol/L 6.0 (1.1) 6.4 (1.1) 6.7 (1.2) <.0001 
Serum HDL cholesterol, mmol/L 1.29 (0.37) 1.35 (0.37) 1.48 (0.38) <.0001 
Serum triacylglycerols, mmol/L 1.5 (1.0) 1.4 (0.7) 1.3 (0.6) .002 
Values are means (SD) unless otherwise indicated. 
* P value based on analysis of (co)variance or Chi-square test. 
† Geometric mean (geometric SD).   
‡ Geometric mean (95% CI), adjusted for gender. 
§ Mean plasma alpha-tocopherol (SE), adjusted for total serum cholesterol. 
 
though the association with cardiovascular mortality was slightly attenuated (RR: 0.89; 95% CI: 
0.74, 1.07).  
The inverse association between plasma carotene and risk of death due to CVD was 
confined to subjects with a low body mass. Persons with BMIs < 25 had RRs of 0.67 (95% CI: 
0.49, 0.94), whereas those with a BMIs ≥ 25 had RRs of 0.97 (95% CI: 0.79, 1.20) (P for 
interaction = .033; based on model 3 without adjustment for BMI). The association between 
plasma carotene and CVD death did not differ between men and women (P for interaction = 
.65), and nor did between smokers and non-smokers (P for interaction = .63).  
After adjustment for age, sex, and other potential confounders, plasma alpha-tocopherol 
was not significantly associated with mortality due to all causes, CVD, or cancer. These results 
did not differ significantly by strata of BMI, smoking, or sex (data not shown).  
With the use of Pearson’s correlation coefficients between baseline and follow-up 
measurements of plasma carotene (r = 0.73) and alpha-tocopherol (r = 0.68; P < .0001 for both), 
we adjusted for measurement error and within-person variation of both plasma antioxidants. For 
associations between plasma carotene and mortality, this resulted in age- and sex-adjusted RRs 
that were 7– 16% lower than those obtained by using only baseline information of plasma 
carotene. 
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Table 3: Baseline characteristics of the study population (n=1168) by tertiles of plasma alpha-tocopherol 
Tertiles of plasma alpha-tocopherol  
 
Characteristic 
Lowest tertile 
(n=371) 
Medium tertile 
(n=399) 
Highest tertile 
(n=398) 
 
P value* 
Plasma alpha-tocopherol, μmol/L 21.8 (4.4) 29.9 (2.0) 39.9 (6.0)  
Plasma alpha-tocopherol, μmol/L† 21.9 (21.4-22.3) 29.9 (24.4-30.3) 39.8 (39.4-40.3)  
Demographics and lifestyle     
Age, y 72.9 (1.8) 73.0 (2.2) 73.0 (1.8) .63 
% Men 65 50 24 <.0001 
Body Mass Index, kg/m2 26.3 (4.1) 26.6 (4.1) 26.7 (4.0) .37 
Education, y 7.9 (3.9) 8.3 (3.9) 8.6 (3.5) .03 
% Smoker 27 21 15 <.0001 
% Alcohol use 70 71 68 .64 
% Low physical activity 37 32 30 .09 
% Vitamin supplement use 10 13 16 .07 
Plasma carotene and serum 
lipoproteins 
    
Plasma carotene, μmol/L‡ 0.35 (0.27) 0.55 (0.37) 0.70 (0.45) <.0001 
Serum total cholesterol, mmol/L 5.6 (1.0) 6.3 (0.8) 7.2 (1.0) <.0001 
Serum HDL cholesterol, mmol/L 1.3 (0.3) 1.4 (0.4) 1.4 (0.4) <.0001 
Serum triacylglycerols, mmol/L 1.2 (0.8) 1.3 (0.6) 1.7 (0.9) <.0001 
Values are means (SD) unless otherwise indicated. 
* P value based on analysis of (co)variance or Chi-square test. 
† Mean plasma alpha-tocopherol (95%CI), adjusted for gender. 
‡ Geometric mean (geometric SD). 
 
Meta-analysis on plasma antioxidants and all-cause mortality 
We identified 5 observational studies, including the current study, that reported associations of 
plasma (beta)-carotene, plasma vitamin E, or both with all-cause mortality in elderly 
populations. For the current study, multivariate adjusted RRs for the highest versus the lowest 
antioxidant quartile were used. After combining all studies, elderly subjects with high 
concentrations of plasma carotene had a RR of 0.72 (95% CI: 0.59, 0.87; Figure 1) compared 
with those with low plasma carotene concentrations, whereas high plasma vitamin E 
concentrations were not associated with all-cause mortality (RR: 1.07; 95% CI 0.94, 1.22; 
Figure 2). Heterogeneity between studies was moderate, varying from 36% for studies of 
vitamin E status to 50% for those of carotene status. 
Discussion 
In this prospective study conducted in European elderly subjects, plasma carotene 
concentrations were associated with lower mortality risks due to all causes, cancer and CVD. 
The inverse relationship with CVD mortality was, however, confined to subjects with a BMI < 
25.  Plasma concentrations of alpha-tocopherol were not associated with both all-cause or cause-
specific mortality.  
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Table 4: Relative risks and 95%CIs for the association of plasma antioxidants with all-causes and cause specific 
mortality among participants of the SENECA study (n=1,168) 
RR (95%CI)  
Causes of mortality 
Number of 
deaths (%) Plasma carotene* Plasma alpha-tocopherol† 
 
All-causes 388 (33.2)    
Crude model  0.67 (0.60-0.75) 0.81 (0.73-0.90)  
Model 1 ‡  0.76 (0.68-0.85) 0.90 (0.81-0.99)  
Model 2 §  0.79 (0.70-0.89) 0.96 (0.84-1.10)  
Model 3║  0.79 (0.70-0.89) 1.01 (0.88-1.15)  
Cardiovascular diseases 148 (12.7)    
Crude model  0.74 (0.63-0.87) 0.81 (0.69-0.95)  
Model 1 ‡  0.83 (0.70-0.98) 0.89 (0.75-1.05)  
Model 2 §  0.82 (0.68-0.98) 0.83 (0.67-1.03)  
Model 3║   0.83 (0.70-1.00) 0.87 (0.70-1.07)  
Cancer 96 (8.2)    
Crude model  0.52 (0.39-0.67) 0.82 (0.67-1.00)  
Model 1 ‡  0.62 (0.47-0.80) 0.94 (0.76-1.15)  
Model 2 §  0.60 (0.45-0.80) 1.01 (0.77-1.32)  
Model 3║  0.59 (0.44-0.79) 1.11 (0.85-1.44)  
Other causes 53 (4.5)    
Crude model  0.59 (0.43-0.82) 0.85 (0.64-1.11)  
Model 1 ‡  0.67 (0.48-0.93) 0.94 (0.71-1.24)  
Model 2 §  0.71 (0.50-1.01) 1.01 (0.72-1.42)  
Model 3║  0.70 (0.49-1.01) 1.07 (0.77-1.49)  
Unknown causes 104 (8.9)    
Crude model  0.72 (0.59-0.88) 0.76 (0.62-0.92)  
Model 1 ‡  0.79 (0.65-0.97) 0.82 (0.67-1.00)  
Model 2 §  0.94 (0.75-1.17) 0.97 (0.75-1.27)  
Model 3║  0.94 (0.75-1.17) 0.99 (0.76-1.29)  
Data are relative risks for a 1-standard deviation change of *0.39 μmol/L plasma carotene and †8.5 μmol/L plasma alpha-
tocopherol. 
‡Adjusted for age (continuous) and gender.  
§As model 1, but with additional adjustment for body mass index (continuous), serum total cholesterol (continuous), serum HDL 
cholesterol (continuous), current smoking (yes/no), alcohol consumption (yes/no), physical activity (lowest versus the medium and 
highest tertile), and SENECA center (indicator variables).  
║As model 2 but with additional adjustment for either plasma alpha-tocopherol or plasma carotene (both continuous). 
 
The strengths of our study are the performance of all assays of plasma antioxidant 
concentrations in one laboratory, the wide range in plasma concentrations of carotene and alpha-
tocopherol, the longitudinal study design, and the standardized and validated methods to assess 
lifestyle factors and anthropometric variables (27). The limitations of this study also must be 
considered. First, although vital status follow-up was nearly complete, there were 104 deceased 
subjects for whom the cause of death could not be ascertained, which limited our power to study 
cause-specific associations. Second, baseline plasma values of carotene and alpha-tocopherol are 
assumed to be stable in persons during the years of follow-up, but these concentrations could 
change over time. However, concentrations of both plasma antioxidants at baseline correlated 
strongly with those 5 y later. 
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Figure 1: Meta-analysis of the association of high and low carotene status with all-cause mortality in elderly 
subjects. USA, United States of America; NL, Netherlands; UK, United Kingdom; EU, Europe; I 2, inconsistency 
squared. *This study investigated plasma carotenoids. **This study investigated plasma alpha- and beta-carotene. 
The P value represents the result of the chi-square test for heterogeneity. 
 
In the current study, plasma carotene was strongly inversely associated with mortality 
from all causes, whereas no association was observed between plasma alpha-tocopherol and all-
cause mortality. Previous observational studies in elderly subjects related plasma carotene, 
carotenoids, or vitamin E to all-cause mortality (15–19), but the sample size of most of these 
studies was relatively small. Therefore, we performed a meta-analysis, including the current 
study, with all-cause mortality as the endpoint. Plasma carotene was strongly associated with a 
lower risk of all-cause mortality, whereas plasma alpha-tocopherol was not associated with all-
cause mortality. 
We observed an inverse association of plasma carotene with cancer and cardiovascular 
mortality. Together with results from other observational studies, these findings are in sharp 
contrast with those from large-scale supplementation trials (37–40), which makes it very 
unlikely that pharmacological doses of beta-carotene are effective in preventing CVD and caner. 
It was argued that the inverse associations between antioxidants and chronic disease in 
observational studies could be confounded by smoking or by socioeconomic status (41). We 
adjusted our analyses for current smoking. An alternative adjustment for smoking, the use of 
information of former smoking, did not result in different risk estimates. In our study, the 
number of years spent in full-time education was not significantly related to plasma carotene, 
and it did not confound the relation between plasma carotene and all-cause mortality. However, 
residual confounding by smoking, socioeconomic status, or other factors can not be excluded. 
Plasma carotene was inversely associated with cancer mortality in the current study. This 
relation became stronger after excluding subclinical cancer cases and adjustment for errors in 
Study Country Study population Age 
range 
(y) 
High 
carotene 
status 
(deaths/N) 
Low 
carotene  
status 
(deaths/N) 
All-cause mortality 
risk (95% CI) 
Sahyoun 
et al (15)* 
USA 725 community-
dwelling subjects 
60-101 37/145 48/145  
De Waart 
et al (17) 
NL 638 community-
dwelling subjects 
65-85 50/213 51/213  
Fletcher et 
al (18) 
UK 1214 community-
dwelling subjects 
75-84 44/227 57/227  
Hu et al 
(19) 
USA 672 high-functioning 
subjects 
70-79 59/330 93/342  
Current 
study** 
EU 1168 mainly non-
institutionalized 
subjects 
70-75 64/303 129/287  
Combined   RR: 0.72 (95% CI: 0.59-0.87)  
   P for heterogeneity = 0.09; I 2 = 49.6% 
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Study Country Study population Age 
range 
(y) 
High 
vitamin E 
status 
(deaths/N) 
Low 
vitamin E 
status 
(deaths/N) 
All-cause mortality 
risk (95% CI) 
Sahyoun 
et al (15) 
USA 725 community-
dwelling subjects 
60-101 47/145 38/145  
Marniemi  
et al (16) 
Fin 344 community-
dwelling subjects 
65-80+ 77/115 70/115  
De Waart 
et al (17) 
NL 638 community-
dwelling subjects 
75-84 49/213 55/213  
Fletcher  
et al (18) 
UK 1214 community-
dwelling subjects 
70-79 59/228 49/228  
Current  
study 
EU 1168 mainly non-
institutionalized 
subjects 
70-75 107/301 106/291  
Combined   RR: 1.07 (95% CI: 0.94-1.22)  
   P for heterogeneity = 0.18; I 2 = 36.3% 
 
 
 
Figure 2: Meta-analysis of the association of high and low vitamin E status with all-cause mortality in elderly 
subjects. USA, United States of America; Fin, Finland; NL, Netherlands; UK, United Kingdom; EU, Europe; I 2, 
inconsistency squared. The P value represents the result of the chi-square test for heterogeneity. 
 
measurement of and biological fluctuation in plasma carotene. Because large-scale trials did not 
show that pharmalogical doses of beta-carotene prevent cancer, the question remains whether 
lower doses of beta-carotene would reduce the incidence of cancer in susceptible populations. 
An alternative explanation is that other factors related to plasma carotene are responsible for the 
inverse associations found in observational studies (42). Plasma carotene may also be a marker 
of a concerted effect of multiple other nutrients in fruit and vegetables. 
In the current study, the inverse association between plasma carotene and CVD mortality 
was confined to subjects with BMIs < 25. A possible explanation for this difference in 
association between plasma carotene and CVD mortality by BMI could be the relationship with 
inflammation. It has been shown that BMI is positively associated to C-reactive protein (24), an 
indicator of inflammation. Our data suggest that, in persons with BMIs < 25, who are likely to 
have a low level of inflammation, plasma beta-carotene is inversely related to CVD mortality. 
However, in overweight and obese subjects, who are characterized by a high level of 
inflammation, this relation was not observed. These results therefore suggest that, in the 
presence of a low inflammation burden, carotene may be protective against CVD.  
Results of observational studies on plasma vitamin E in relation to CVD mortality in 
elderly subjects are inconsistent. In British elderly subjects, a nonsignificantly lower risk of 
CVD death was observed for subjects in the 2 upper quintiles of plasma alpha-tocopherol (18), 
whereas in elderly living in the United States, plasma alpha-tocopherol was positively associated 
with heart disease mortality (15). In the current study, plasma alpha-tocopherol was not related 
to CVD mortality or to all-cause mortality. This observation was confirmed by our meta-
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analysis as well as by a meta-analysis of trials, in which vitamin E supplementation did not 
reduce all-cause mortality and high doses of vitamin E were even found to increase the risk of 
all-cause mortality (43). 
In conclusion, in the current study, conducted in European elderly, plasma 
concentrations of carotene were associated with a lower risk of death due to all causes and that 
due to cancer. Subjects with a high plasma carotene concentration and a BMI < 25 had also a 
lower risk of CVD death. The relationship between plasma carotene, BMI, and CVD merits 
further study.  
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Cocoa Intake, Blood Pressure, and 
Cardiovascular Mortality: the 
Zutphen Elderly Study 
 
Brian Buijsse, Edith J.M. Feskens, Frans J. Kok, and Daan Kromhout 
 
Background:  Small, short-term, intervention studies indicate that cocoa-containing foods improve 
endothelial function and reduce blood pressure. We studied whether habitual cocoa intake was cross-
sectionally related to blood pressure and prospectively related with cardiovascular mortality.  
Methods:  Data used were of 470 elderly men participating in the Zutphen Elderly Study and free of chronic 
diseases at baseline. Blood pressure was measured at baseline and 5 years later, and causes of death were 
ascertained during 15 years of follow-up. Habitual food consumption was assessed by the cross-check dietary 
history method in 1985, 1990, and 1995. Cocoa intake was estimated from the consumption of cocoa-
containing foods.  
Results:  One third of the men did not use cocoa at baseline. The median cocoa intake among users was 2.11 
g/d. After adjustment, the mean systolic blood pressure in the highest tertile of cocoa intake was 3.7 mm Hg 
lower (95% confidence interval [CI], –7.1 to –0.3 mm Hg; P = .03 for trend) and the mean diastolic blood 
pressure was 2.1 mm Hg lower (95% CI, –4.0 to –0.2 mm Hg; P = .03 for trend) compared with the lowest 
tertile. During follow-up, 314 men died, 152 of cardiovascular diseases. Compared with the lowest tertile of 
cocoa intake, the adjusted relative risk for men in the highest tertile was 0.50 (95% CI, 0.32-0.78; P = .004 for 
trend) for cardiovascular mortality and 0.53 (95% CI, 0.39-0.72; P < .001) for all-cause mortality.  
Conclusion:  In a cohort of elderly men, cocoa intake is inversely associated with blood pressure and 15-
year cardiovascular and all-cause mortality.  
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Introduction 
Cocoa has a rich history, covering a period of more than 2600 years (1). In ancient history, 
numerous positive properties to human health have been ascribed to cocoa and chocolate. 
Already in the 18th century, cocoa was believed to strengthen the heart and reduce angina 
pectoris (2), but these benefits were not based on scientific evidence. After the finding that cocoa 
and chocolate contain phenolic compounds (3), scientific interest was triggered. Cocoa is a rich 
source of flavan-3-ols, also known as flavanols or catechins, a subclass of flavonoids. The 
flavan-3-ols in cocoa are present as monomers (4), and as oligomers and polymers, better known 
as procyanidins (5).  
In the past few years, the results of several small randomized trials were published in 
which the effects of cocoa-containing foods were studied on intermediate end points of 
cardiovascular diseases (CVDs). Consumption of chocolate or cocoa drinks rich in flavan-3-ols 
lowered blood pressure (6-8) and improved endothelial function (8-11) and insulin sensitivity 
(7,8). Although these results are promising, most studies (6-10) used chocolate or cocoa that 
contained much higher amounts of flavan-3-ols than commercially available products. 
Furthermore, the question remains whether the observed effects are long-standing or transitory, 
and whether they extend to clinical CVDs.  
To our knowledge, observational studies examining the association of cocoa intake with 
blood pressure or CVD have not been published. We, therefore, have estimated the intake of 
cocoa from the habitual consumption of cocoa-containing foods and evaluated whether cocoa 
intake was inversely related to blood pressure and cardiovascular mortality in elderly men living 
in Zutphen, the Netherlands.  
Methods 
Study population 
The Zutphen Elderly Study is the continuation of the Zutphen Study, the Dutch contribution to 
the Seven Countries Study (12). Baseline examinations took place between March 9 and June 
25, 1985, and repeated examinations took place in the same period in 1990 and 1995. At 
baseline, 367 of the 555 men in the original cohort who were still alive participated. In addition, 
a random sample of 711 other men of the same age and also living in Zutphen was selected. In 
total, 1266 men aged 65 to 84 years were invited, of whom 939 (74.2%) participated in the 
study. In 876 men, dietary intake was estimated. Information on risk factors and chronic disease 
prevalence was available for 790 men. Men with a history of CVDs, diabetes mellitus, or cancer 
at baseline (n = 266) or those who were taking antihypertensive medication (n = 54) were 
excluded from the analysis. Therefore, our study population consisted of 470 men.  
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Assessment of diet and cocoa intake 
The habitual dietary intake of the subjects in the month preceding the interview was estimated in 
1985, 1990, and 1995 by experienced dieticians using a cross-check dietary history method 
adapted to the Dutch situation (13). All subjects were interviewed at home for about 1 hour in 
the presence of the person who usually prepared the meals. The habitual consumption of foods 
during the whole week was determined, and verified with the quantities of foods bought per 
week. Also, information on the type of diet prescribed by a physician was collected.  
The intake of calories (energy) and nutrients in 1985, 1990, and 1995 was calculated 
using the Netherlands' food composition table from 1987/1988, 1989/1990, and 1996, 
respectively. The most recent version of this table (14) was used to calculate the intake of 
magnesium, vitamin E, beta carotene, and folate in all examination years, because only this 
version contains information on these nutrients. Earlier collected information on trans fatty acids 
in foods consumed in the Zutphen Elderly Study was used to calculate the intake of these fatty 
acids (15).  
We identified 24 cocoa-containing foods that were reported by the Zutphen elderly 
subjects. For each examination year, the consumption of these foods was multiplied with their 
individual cocoa content, which was derived from the Conversion Model for Consumer Foods to 
Primary Agricultural Products (16) or from food labels. The intake of cocoa from individual 
foods was summed to yield actual cocoa in grams per day for each subject.  
The reproducibility of the dietary history method was tested 3 and 12 months after the 
start of the study in a sample of the present study (13). For the consumption of sugar 
confectionary, which is the most important source of cocoa in the present study, the 3- and 12-
month reproducibility was r = 0.72 and r = 0.76, respectively (13). Baseline cocoa intake 
correlated with the cocoa intake that was estimated 5 and 10 years later (Spearman r = 0.45 and 
r = 0.43, respectively; P < .001 for both). The reproducibility of total calorie intake was about 
r = 0.80 after 3 and 12 months (13).  
Collection of risk factor and morbidity data 
Systolic and diastolic blood pressure (Korotkoff phase V) were measured twice at the end of the 
physical examination by 1 of 5 physicians using a random-zero sphygmomanometer (Hawksley 
& Sons Ltd, West Sussex, United Kingdom) while participants were in the supine position. The 
mean values of the 2 blood pressure measurements are presented herein. Body mass index (BMI) 
was calculated as weight in kilograms divided by the square of height in meters.  
Total and high-density lipoprotein cholesterol levels were measured in nonfasting serum 
samples using standard validated methods (17). Remaining serum samples were stored at –20°C. 
Serum homocysteine levels were determined in stored samples 10 years after the examination 
(18).  
The history of myocardial infarction, angina pectoris, and intermittent claudication was 
ascertained using the Dutch translation of the questionnaire formulated by Rose and Blackburn 
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(19). For history of heart failure, diabetes mellitus, and cancer, a standardized questionnaire was 
developed and the physicians' conclusion was used in the present analyses. Physical activity was 
estimated using a validated questionnaire originally designed for retired men (20). This 
questionnaire asks about the frequency and duration of different activities, such as walking, 
cycling, and gardening. The time spent on each activity was summed to yield minutes of physical 
activity. Information on cigarette smoking, socioeconomic status, and the use of antihypertensive 
drugs, aspirin, and anticoagulants was also collected by questionnaire.  
Ascertainment of follow-up events 
Municipal registries provided information on vital status and were checked at 5-year intervals. 
Two men were lost to follow-up during the study and were censored after their last physical 
examination. Information on the cause of death was obtained from hospital discharge data and/or 
general practitioners, and up to 1990 also from Statistics Netherlands, Voorburg. The final 
causes of death were ascertained by one clinical epidemiologist and coded according to the 
International Classification of Diseases, Ninth Revision (ICD-9). Cardiovascular diseases refer 
to ICD-9 codes 390 to 459. Because the underlying cause of death in elderly people is often 
difficult to ascertain, we included CVDs coded as primary (n = 118), secondary (n = 30), and 
tertiary (n = 4) cause of death in our analysis. Information on the cause of death was lacking for 
1 man, and his follow-up was censored at the date of death. 
Statistical analysis 
Cocoa intake was related to blood pressure cross-sectionally, combining data from 470 men at 
baseline and data from 324 men who were repeatedly examined in 1990, composing 794 total 
observations. A random intercept model (SAS Proc Mixed; SAS Institute Inc, Cary, NC, USA) 
was used to calculate adjusted means and 95% confidence intervals (CIs) of blood pressure for 
each tertile of cocoa intake. In addition to an age-adjusted model, we used 3 multiple regression 
models to adjust for other factors that are associated with cocoa intake or are well-known 
determinants of blood pressure. Dietary covariates were adjusted for total calorie intake 
according to the residual method (21).  
Relative risks (RRs) and 95% CIs for the association between cocoa intake and 
cardiovascular and all-cause mortality were estimated using Cox proportional hazards models in 
which the middle and the highest tertiles of cocoa intake were compared with the lowest tertile. 
In the time-dependent analyses, mortality between 1985 and 1990 was related to cocoa intake 
estimated in 1985; mortality between 1990 and 1995 was related to the mean cocoa intake in 
1985 and 1990; and mortality between 1995 and 2000 was related to the mean cocoa intake in 
1985, 1990, and 1995 (22). Besides an age-adjusted model, we used a multivariate-adjusted 
model that included lifestyle factors related to CVD risk and BMI as an indicator of calorie 
balance (model A). This model was extended with diet prescription, total calorie intake, and 
calorie-adjusted consumption of foods (model B). In model C, we also adjusted for dietary 
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intake using calorie-adjusted intake of nutrients instead of foods. Adjustment for continuous 
distributed covariates was done time dependently; for discrete variables, we used baseline data. 
Stratified analyses were performed for major cardiovascular risk factors. All statistical tests were 
2-sided. 
Results 
Cocoa intake and baseline characteristics 
In 1985, one third of the study population did not use cocoa. The median intake in the middle 
tertile was 0.92 g/d; in the highest tertile, this was 4.18 g/d. All cocoa-containing foods that were 
consumed at baseline are listed in Table 1. Plain chocolate and chocolate bars contributed two 
thirds to the total intake of cocoa.  
 
Table 1: Cocoa containing food items consumed by elderly men in Zutphen at baseline* 
Cocoa containing food Cocoa content (g/100g) Contribution to total cocoa 
intake (%) 
Chocolate confectionary   
Plain chocolate, dark 43.0 28.4 
Plain chocolate, milk 30.0 21.8 
Chocolate bar with nuts 22.5 3.3 
Chocolate candy bar† 15.0 9.5 
Chocolates (bonbons) 18.0 2.3 
M&Ms, chocolate 28.5 <0.1 
M&Ms, peanuts 16.5 0.4 
Chocolate cookies 9.0 1.1 
Cocoa sandwich filling   
Chocolate spread 13.5 0.6 
Chocolate nut spread 6.0 0.6 
Chocolate confetti, dark 38.7 10.9 
Chocolate confetti, milk 27.0 4.3 
Cocoa desserts   
Chocolate custard 8.3 4.4 
Chocolate pudding 2.5 0.6 
Chocolate pudding with sauce 2.1 0.1 
Chocolate mousse 22.6 0.1 
Drinks   
Cocoa drink, full fat 1.5 2.4 
Cocoa drink, skimmed 1.5 1.9 
Miscellaneous   
Cocoa powder 100.0 5.9 
Cocoa powder sweetened 25.0 0.3 
Nutritional supplement‡ 42.0 1.2 
*Data are given for men free of chronic diseases and not using antihypertensive medication at baseline. †Bounty, Mars, Milky Way 
(Mars Inc, McLean, Va, USA), Nuts (Nestlé, Vevey, Switzerland). 
‡Ovomaltine (cocoa flavor) (Novartis, Basal, Switzerland). 
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Men who consumed cocoa-containing foods used more low- and medium-fat dairy foods, 
sugar confectionary foods, and cookies and savory foods, and were more likely to consume 
alcohol and nuts and seeds (Table 2). Cocoa intake was inversely associated with the 
consumption of meat and coffee. Furthermore, cocoa intake was positively related with calorie 
intake, and with intake of calcium (P = .03) and magnesium (P = .04). The median cocoa intake 
among users was 2.11 g/d in 1985, 2.30 g/d in 1990, and 2.36 g/d in 1995. 
Cocoa intake and blood pressure 
After adjustment for potential confounders, cocoa intake was inversely associated with systolic 
and diastolic blood pressure (Table 3). The mean systolic blood pressure was 3.7 mm Hg lower 
(95% CI, –7.1 to –0.3 mm Hg; P = .03) in the highest tertile of cocoa intake compared with the 
lowest tertile after multivariate adjustment, including consumption of foods (model B). This 
difference was –3.1 mm Hg (95% CI, –6.5 to 0.2 mm Hg; P = .07) after adjustment according to 
model C, which included intake of nutrients rather than foods. The mean diastolic blood pressure 
was 2.1 mm Hg lower in the highest tertile of cocoa intake compared with the lowest tertile 
(95% CI, –4.0 to –0.2 mm Hg; P = .03; model B). Adjustment for covariates in model C yielded 
similar estimates. 
Additional multivariate-adjusted analysis showed that neither systolic nor diastolic blood 
pressure was related to the consumption of sugar confectionary (P = .84 and P = .16 for linear 
trend, respectively), and to the consumption of cookies and savory foods (P = .31 and P = .20 for 
linear trend, respectively). After multivariate adjustment, the mean systolic blood pressure did 
not differ between consumers and nonconsumers of nuts and seeds (P = .44), whereas the 
diastolic blood pressure was higher among consumers (P = .02). 
Cocoa intake and mortality 
During the 4908 person-years of follow-up between 1985 and 2000, 314 (66.8%) of the 470 men 
died. Cardiovascular diseases were the cause of death for 152 men. The results of the time-
dependent Cox proportional hazards regression model showed that cocoa intake was inversely 
related to cardiovascular mortality (Table 4). After adjustment for age, BMI, lifestyle factors, 
drug use, and food and calorie intake (model B), the RR for cardiovascular mortality for men in 
the highest tertile of cocoa intake was 0.50. 
Adjustment for intake of nutrients (model C) instead of foods resulted in similar risk 
estimates. Analyzing baseline cocoa intake rather than cumulative average cocoa intake in time-
dependent analysis yielded similar results (multivariate-adjusted RR of cardiovascular death for 
the highest vs the lowest tertile, 0.51; 95% CI, 0.33-0.78; P = .006 for linear trend). 
The consumption of sugar confectionary was not significantly associated with 
cardiovascular mortality (P = .54 for linear trend), nor was the consumption of cookies and 
savory foods (P = .45 for linear trend), nor the consumption of nuts and seeds (P = .12). 
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Table 2: Selected characteristics of elderly men in 1985 in Zutphen, free of chronic diseases and not using 
antihypertensive drugs, by tertiles of cocoa intake 
Tertiles of cocoa intake  
 
Characteristic 
Lowest tertile 
(n=165) 
Medium tertile 
(n=149) 
Highest tertile 
(n=156) 
 
P value* 
Cocoa intake, g/day† 0 (0-0) 0.92 (0.60-1.45) 4.18 (2.90-6.10)  
Demographics. lifestyle, risk factors, 
and drug use 
    
Age, y 72.1 (5.6) 72.0 (5.4) 71.3 (4.4) .38 
High socioeconomic status, % 33.3 30.2 31.4 .83 
Positive family CVD history, % 17.0 19.5 17.9 .85 
Leisure time physical activity, h/wk† 10.5 (4.5, 20.5) 9.8 (4.5, 18.9) 10.7 (6.3, 20.4) .40 
Current cigarette smoking, % 35.8 31.5 33.3 .73 
Alcohol consumer, % 70.9 77.2 83.3 .03 
Prescribed diet, % 15.2 12.8 9.0 .24 
Use of vitamin supplements, % 15.2 12.8 14.1 .83 
Body mass index, kg/m2 25.9 (3.2) 25.4 (3.0) 25.3 (2.7) .24 
Resting heart rate, beats/min‡ 70.7 (10.8) 70.9 (11.9) 70.8 (10.6) .97 
Serum total cholesterol, mmol/L 6.1 (1.1) 6.0 (1.2) 6.1 (1.1) .53 
Serum HDL cholesterol, mmol/L 1.2 (0.3) 1.1 (0.3) 1.1 (0.3) .46 
Serum homocysteine, μmol/L 14.8 (8.1) 14.8 (5.9) 14.8 (8.1) .96 
Aspirin use, % 13.9 12.1 7.7 .20 
Anticoagulant use, % 15.2 10.7 10.9 .39 
Food intake, g/day     
Bread and cereal products 165 (72) 162 (61) 158 (63) .66 
Potatoes 182 (96) 165 (84) 181 (88) .17 
Vegetables 181 (77) 173 (65) 169 (61) .27 
Fruits† 157 [100, 243] 189 [116, 271] 167 [112, 263] .13 
Low- and medium-fat dairy† 250 [124, 461] 321 [165, 493] 330 [212, 490] .03 
Meat 122 (50) 113 (40) 109 (37) .02 
Fish 18 (21) 20 (23) 19 (24) .82 
Butter and hard margarine 49 (37) 55 (39) 54 (35) .35 
Vegetable oil and soft margarine† 5 [0, 22] 2 [0, 23] 3 [0, 21] .26 
Sugar confectionary other than 
chocolate 
47 (37) 53 (34) 61 (38) <.001 
Cookies and savory products 31 (29) 40 (29) 50 (34) .003 
Coffee† 428 [288, 624] 396 [226, 496] 400 [284, 517] .05 
Tea† 372 [201, 590] 392 [180, 600] 400 [223, 610] .60 
% nuts and seeds consumers 32.1 40.3 55.1 <.001 
Energy intake, kJ§ 8795 (2207) 9345 (1914) 10011 (2149) <.001 
Data are given as mean (SD), unless otherwise indicated. Abbreviations: CVD, cardiovascular diseases; HDL, high-density 
lipoprotein. 
*Based on analysis of variance, Kruskal-Wallis, or Chi-square test. 
† Median [interquartile range]. 
‡ Based on 461 observations because of missing data. 
§Energy contributed by alcohol is not included. 
 
To explore whether blood pressure contributed to the lower cardiovascular mortality risk 
observed in cocoa users, we also adjusted for baseline blood pressure in model B. Neither 
systolic nor diastolic blood pressure, however, affected our risk estimates. 
Cocoa intake, blood pressure, and cardiovascular mortality 
 84 
Table 3: Systolic and diastolic blood pressure according to cocoa intake among elderly men in Zutphen, free of 
chronic diseases and not using antihypertensive drugs, by tertiles of cocoa intake 
 Tertiles of cocoa intake  
Blood pressure Lowest (<0.36 g/d) Middle (0.36-2.30 g/d) Highest (>2.30 g/d) P for trend 
Systolic     
Crude 149.7 (147.3-152.2) 148.8 (146.5-151.1) 147.0 (144.6-149.5) .08 
Age-adjusted 149.6 (147.2-152.0) 148.8 (146.4-151.1) 147.0 (144.6-149.5) .09 
Model*     
A 149.9 (147.4-152.4) 148.9 (146.6-151.2) 146.9 (144.4-149.4) .07 
B 150.2 (147.7-152.8) 149.0 (146.7-151.3) 146.5 (144.0-149.1) .03 
C 150.0 (147.5-152.6) 148.8 (146.5-151.2) 146.9 (144.4-149.4) .06 
Diastolic     
Crude 84.4 (82.9-85.8) 83.6 (82.3-85.0) 82.2 (80.8-83.6) .02 
Age-adjusted 84.5 (83.1-85.9) 83.7 (82.3-85.0) 82.2 (80.8-83.6) .01 
Model*     
A 84.2 (82.8-85.6) 83.8 (82.5-85.1) 82.5 (81.1-83.8) .05 
B 84.4 (83.0-85.8) 83.8 (82.5-85.1) 82.3 (80.9-83.7) .03 
C 84.3 (82.9-85.7) 83.8 (82.5-83.7) 82.3 (80.9-83.7) .03 
Data are given as mean (95% confidence interval) blood pressure values, in mm Hg. 
* Model A was adjusted for age (continuous), body mass index (continuous), alcohol intake (yes or no), physical activity 
(continuous), cigarette smoking (yes or no), diet prescription (yes or no), aspirin use (yes or no), anticoagulant use (yes or no), and 
the physician who measured blood pressure (categorical); B, variables given for A and further adjusted for the consumption of 
vegetables, fruit, meat, low- and medium fat dairy, nuts and seeds, sugar confectionary other than chocolate, cookie and savory 
foods, coffee, and energy intake (all continuous); and C, those variables given for A and further adjusted for intake of potassium, 
sodium, calcium, magnesium, and total energy intake (all continuous). 
 
Cocoa intake was also inversely related to all-cause mortality in time-dependent analysis 
(Table 4). Similar results were obtained when baseline cocoa intake was related to 15-year all-
cause mortality (multivariate-adjusted RR for the highest vs the lowest tertile, 0.59; 95% CI, 
0.44-0.79; P = .003 for trend). 
The association between cocoa intake and cardiovascular mortality did not differ 
significantly between strata of BMI, cigarette smoking, physical activity, calorie intake, alcohol 
consumption, or socioeconomic status (P > .30 for all) (Table 5). 
The consumption of sugar confectionary was not significantly associated with 
cardiovascular mortality (P = .54 for linear trend), nor was the consumption of cookies and 
savory foods (P = .45 for linear trend), nor the consumption of nuts and seeds (P = .12).  
To explore whether blood pressure contributed to the lower cardiovascular mortality risk 
observed in cocoa users, we also adjusted for baseline blood pressure in model B. Neither 
systolic nor diastolic blood pressure, however, affected our risk estimates.  
Discussion 
In the present study, usual daily cocoa intake was inversely related to blood pressure in cross-
sectional analysis. In prospective analysis, usual cocoa intake was associated with a 45% to 50% 
lower risk of cardiovascular and all-cause death.  
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Table 4: Relative risks for the association between cocoa intake and 15-year mortality among elderly men in 
Zutphen, free of chronic diseases and not using antihypertensive drugs at baseline 
 Tertiles of cocoa intake 
Mortality Lowest (<0.36 g/d) Middle (0.36-2.30 g/d) Highest (>2.30 g/d) 
 
P for trend 
Number of men 161 147 162  
Person-years 1481 1573 1854  
CVD mortality     
Cases, n (%) 58 (36.0) 50 (34.0) 44 (27.2)  
Mortality rate* 39.2 31.8 23.7  
RR (95% CI)     
Age-adjusted 1.00 0.79 (0.54-1.15) 0.58 (0.39-0.86) .008 
Model†     
A 1.00 0.84 (0.57-1.24) 0.67 (0.45-1.01) .05 
B 1.00 0.70 (0.47-1.05) 0.50 (0.32-0.78) .004 
C 1.00 0.79 (0.53-1.19) 0.50 (0.32-0.78) .004 
All-cause mortality     
Cases, n (%) 122 (75.8) 100 (68.0) 92 (56.8)  
Mortality rate* 82.4 63.6 49.6  
RR (95% CI)     
Age-adjusted 1.00 0.76 (0.58-0.99) 0.57 (0.43-0.75) <.001 
Model†     
A 1.00 0.81 (0.62-1.05) 0.65 (0.49-0.86) <.001 
B 1.00 0.73 (0.55-0.97) 0.53 (0.39-0.72) <.001 
C 1.00 0.79 (0.60-1.05) 0.52 (0.38-0.71) <.001 
Abbreviations: CI, confidence interval; CVD, cardiovascular diseases; RR, relative risk.  
* Mortality rate is given per 1000 person-years.  
†Model A was adjusted for age (continuous), body mass index (continuous), alcohol intake (yes or no), physical activity 
(continuous), cigarette smoking (yes or no), diet prescription (yes or no), aspirin use (yes or no), anticoagulant use (yes or no); B, 
those variables given for A and further adjusted for the consumption of vegetables, fruit, meat, low- and medium fat dairy, nuts and 
seeds, sugar confectionary other than chocolate, cookie and savory foods, coffee, and energy intake (all continuous); and C, those 
variables given in model A and further adjusted for intake of potassium, sodium, calcium, magnesium, and total energy intake (all 
continuous). 
 
To our knowledge, the present study is the first epidemiological study reporting inverse 
relationships of cocoa intake with blood pressure and with cardiovascular and all-cause 
mortality. In the Harvard Alumni Study (23), consumers of candy had a lower risk of all-cause 
mortality compared with subjects who almost never consumed candy. However, the 
investigators were not able to differentiate between consumption of chocolate and sugar candy. 
In the Nurses' Health Study, the frequency of consumption of chocolate bars and chocolate 
pieces was not associated with a lower risk of coronary heart disease after 14 years of follow-up 
(24). Because cocoa is not only present in chocolate, this association may have been 
underestimated in this study.  
A major concern in observational studies is the possibility of residual confounding. In 
our study, cocoa users consumed less meat and coffee; consumed more dairy, sugar 
confectionary, cookies, and savory foods; and were more likely to use alcoholic drinks and nuts 
and seeds. Consequently, cocoa intake was positively associated with calorie intake. However, 
we did not observe a positive association of cocoa intake with BMI or physical activity. Because  
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Table 5: Relative risks for the association between cocoa intake and 15-year cardiovascular mortality among elderly 
men in Zutphen, free of chronic diseases and not using antihypertensive drugs at baseline, stratified by major risk 
factors* 
 Tertiles of cocoa intake 
Variable Lowest (<0.36 g/d) Middle (0.36-2.30 g/d) Highest (>2.30 g/d) 
 
P for trend 
Body mass index     
≥25 1.00 0.90 (0.53-1.51) 0.55 (0.31-0.98) .03 
<25 1.00 0.63 (0.31-1.25) 0.40 (0.20-0.79) .01 
Cigarette smoking     
Yes 1.00 0.59 (0.29-1.22) 0.42 (0.18-0.95) .06 
No 1.00 0.76 (0.45-1.30) 0.52 (0.30-0.92) .03 
Physical activity     
High 1.00 1.31 (0.41-4.20) 0.40 (0.11-1.54) .07 
Low 1.00 0.67 (0.42-1.05) 0.50 (0.31-0.81) .009 
Energy intake     
High 1.00 0.54 (0.28-1.06) 0.48 (0.26-0.87) .04 
Low 1.00 0.95 (0.56-1.63) 0.54 (0.28-1.05) .06 
Alcohol consumption     
Yes 1.00 0.65 (0.41-1.02) 0.51 (0.32-0.84) .02 
No 1.00 1.29 (0.45-3.74) 0.18 (0.04-0.73) .01 
Socioeconomic 
status 
    
High 1.00 0.59 (0.23-1.48) 0.42 (0.16-1.13) .12 
Low 1.00 0.75 (0.46-1.21) 0.46 (0.27-0.78) .004 
Abbreviations: CI, confidence interval; CVD, cardiovascular diseases; RR, relative risk.  
* Adjusted for age (continuous), body mass index (continuous), alcohol intake (yes or no), physical activity (continuous), cigarette 
smoking (yes or no), diet prescription (yes or no), aspirin use (yes or no), anticoagulant use (yes or no), consumption of vegetables, 
fruit, meat, low- and medium fat dairy, nuts and seeds, sugar confectionary other than chocolate, cookie and savory foods, coffee, 
and energy intake, and total energy intake (all continuous). 
 
BMI was measured accurately, we cannot rule out that residual confounding by physical activity, 
and by dietary factors, may partly explain our results.  
Chocolate confectionary contributed about two thirds to the total intake of cocoa in our 
study. We considered the possibility of reverse causation, i.e., that healthy subjects consume 
more chocolate confectionary than those who are not healthy. However, we limited our study to 
subjects without chronic diseases and to those not using antihypertensive drugs at baseline. Also, 
the association between cocoa intake and cardiovascular mortality did not differ between 
subjects with a high and low level of physical activity, which can also be considered as a marker 
of general health. Finally, the consumption of sugar confectionary other than chocolate, cookies 
and savory foods, and nuts and seeds, which were all strongly related to cocoa intake, was not 
associated with cardiovascular mortality, suggesting a specific effect of cocoa on cardiovascular 
mortality.  
A few small short-term intervention studies have evaluated the effect of dark chocolate 
consumption on blood pressure. In hypertensive and normotensive persons, daily consumption 
of 100 g of dark chocolate for 2 weeks reduced the average systolic blood pressure between 4.1 
and 11.9 mm Hg and the average diastolic blood pressure between 1.8 and 8.5 mm Hg (6,8). 
However, daily consumption of 46 g of dark chocolate did not affect blood pressure after 2 
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weeks in healthy subjects (10). In summary, these studies suggest that large amounts of dark 
chocolate lower blood pressure, whereas a smaller amount appears to have no effect.  
The present study indicates that men with a usual daily cocoa intake of about 4.2 g, 
which is equal to 10 g of dark chocolate per day, had a lower systolic and diastolic blood 
pressure compared with men with a low cocoa intake. Although this amount is one tenth of the 
dose that is used in most intervention studies, it suggests that long-term daily intake of a small 
amount of cocoa may lower blood pressure.  
Mechanistic studies suggest that the flavan-3-ols in cocoa-containing foods are likely to 
be responsible for the reduction in blood pressure and the improvement of endothelial function. 
Consumption of flavan-3-ol–rich chocolate or cocoa is shown to increase arterial (9,11) and 
peripheral vasodilation (10), whereas this effect is less (10) or absent (9,11) after consumption of 
flavan-3-ol–low chocolate or cocoa. An increased activity of nitric oxide is likely to play a major 
role in this process (9,10). This is supported by the observation that polymeric procyanidins 
increased endothelial nitric oxide synthase activity in cultured endothelial cells (25). Although 
there is little doubt that flavan-3-ols have a beneficial effect on endothelial function and blood 
pressure, other bioactive substances in cocoa, including theobromine (26), may also contribute to 
its effects.  
The lower cardiovascular mortality risk associated with cocoa intake could not be 
attributed to the lower blood pressure observed with cocoa use. An explanation may be that 
blood pressure itself was not a risk factor for cardiovascular and all-cause mortality in the 
Zutphen Elderly Study (27). Our findings, therefore, suggest that the lower cardiovascular 
mortality risk related with cocoa intake is mediated by mechanisms other than lowering blood 
pressure. The improvement of endothelial function by flavan-3-ols in cocoa may be a plausible 
candidate (8–11). Dark chocolate also exhibits several metabolic effects (7,8). Daily 100 g of 
dark chocolate for 2 weeks reduced fasting insulin and glucose levels and decreased glucose and 
insulin responses after an oral glucose load (7,8). Cocoa-containing foods and flavan-3-ols may 
also reduce cardiovascular risk by the inhibition of platelet function (28–30) and low-density 
lipoprotein oxidation (31–33), the modulation of cytokine production (24–36), and the beneficial 
effect on serum cholesterol levels (8,33,37).  
To explore whether possible misclassification of cardiovascular mortality occurred in our 
study, we also studied the association of cocoa intake with all-cause mortality. We observed a 
similar risk for all-cause mortality as for cardiovascular mortality. This may implicate that cocoa 
intake is also associated with noncardiovascular mortality. Because cocoa is a rich source of 
antioxidants, it may also be related to other diseases that are linked to oxidative stress (e.g., 
pulmonary diseases, including chronic obstructive pulmonary disease (38), and certain types of 
cancer) (39). However, this merits further investigation.  
In conclusion, to our knowledge, this is the first observational study that found that 
habitual cocoa intake was inversely associated with blood pressure in cross-sectional analysis 
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and with cardiovascular and all-cause mortality in prospective analysis. Before drawing 
conclusions, confirmation by other observational and experimental studies is needed. 
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Serum Glutathione Peroxidase 3 
Activity in Relation to Cardiovascular 
Mortality: the Minnesota Heart Survey 
 
 
Brian Buijsse, Jordan L. Holtzman, Lyn Steffen, Duk-Hee Lee, Richard R. 
Erickson, John H. Eckfeldt, Russell V. Luepker, and David R. Jacobs Jr. 
 
Background: Oxidative stress has been proposed as an initiating factor in the development of 
atherosclerosis. If true, then glutathione peroxidase-3 (GPx-3) activity may be inversely related to 
cardiovascular disease, but prospective studies have not been reported. 
Methods and Results: In a case-control study nested within the Minnesota Heart Survey, we assayed 
serum GPx-3 activity in 130 cardiovascular deaths and 240 controls identified after 5 to 12 years of follow-up. 
Participants were predominantly of white race and aged 26 to 85 years. Logistic regression models were used 
to calculate odds ratios adjusted for age, sex, baseline year, body mass index, smoking, alcohol intake, 
physical activity, serum total and high-density lipoprotein (HDL) cholesterol, systolic blood pressure, serum 
non-fasting glucose, and serum activity of gamma glutamyltransferase. Odds ratios [95% confidence intervals 
(CIs)] for cardiovascular mortality for increasing quartiles of serum GPx-3 activity were 1.00, 0.90 (0.48 to 
1.68), 0.77 (0.40 to 1.49), and 0.42 (0.21 to 0.86) (P for trend = .02). This inverse association was confined to 
those with below median serum HDL cholesterol concentration (P for interaction = .006), with odds ratios 
(95% CIs) for increasing quartiles of 1.00, 0.82 (0.36 to 1.88), 0.60 (0.23 to 1.59), and 0.17 (0.06 to 0.47) (P 
for trend = .001). GPx-3 was not related in subjects with above median HDL cholesterol (P for trend = .82). 
Conclusions: A high serum GPx-3 activity in those with a low serum HDL cholesterol concentration may 
contribute to reduced cardiovascular mortality. 
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Introduction 
Glutathione peroxidases (GPx) form a superfamily that consists of different isoforms which vary 
in cellular location. GPx-1 is solely found in the cytosol, whereas GPx-3 is present mainly in 
circulating high-density lipoprotein particles (1,2). This enzyme’s main biological function is to 
catalyze the reactions of glutathione to reduce lipid hydroperoxides to their corresponding 
alcohols and to reduce hydrogen peroxide to water (2), thereby contributing to overall reduction 
of oxidative stress. 
The activity of GPx-1 in erythrocytes predicted incident cardiovascular death, infarction, 
or stroke in a 6.5 year followup study of angiographically studied patients (3).  Also, a low 
activity of erythrocyte GPx-1 has been associated with an increased risk of cardiovascular events 
in patients with coronary heart disease (4). Although a recent case-control study found that 
several single nucleotide polymorphisms in the GPx-3 gene promoter region were associated 
with early strokes (5), no prospective studies on GPx-3 activity in serum and cardiovascular 
diseases have been published. 
A nested case control design within the Minnesota Heart Survey presented an 
opportunity for a pilot prospective assessment of the concept that serum GPx-3 activity is 
inversely related to cardiovascular disease. Consistent with its presumed role in reducing 
oxidative stress, we hypothesized that a higher activity of GPx-3 would be associated with a 
lower cardiovascular mortality. An inverse relation was anticipated to be stronger in those with a 
low HDL cholesterol concentration, as these subjects are likely to need additional antioxidant 
activity to protect LDL from oxidation. 
Methods 
Minnesota Heart Survey and selection of cases and controls 
Methods of the Minnesota Heart Survey (MHS) have been published previously (6-8). Briefly, 
the MHS, initiated in 1980, is an ongoing population-based surveillance on trends of risk factors 
for coronary heart disease in residents of the 7 county Minneapolis-St. Paul metropolitan area. A 
two-stage self-weighting cluster design was used selecting households at random. Within each 
household, one individual was randomly selected to participate in the survey except for surveys 
1980-1981, 1995-1997, and 2000-2002 when all age-eligible household members were invited 
to participate (9). Mortality follow-up was accomplished by matching with Minnesota death 
certificates on or before December 31, 2002. Written consent was obtained from all study 
participants. Consent and data collection procedures for each survey were approved by the 
University of Minnesota Research Subjects’ Protection Programs Institutional Review Board. 
Given 5-12 years of followup for mortality, these data presented an opportunity to test 
the concept that GPx-3 activity can protect against cardiovascular disease.  Nevertheless, the 
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study was regarded as a pilot because MHS was not designed to study this question and there 
were several known disadvantages. Specifically, participants were not fasting, clinic blood 
handling was differential between the two surveys, and there were an unknown number of 
missing blood samples.   
For the current analysis, we used data and stored blood samples from the surveys 
conducted in 1990-1992 and 1995-1997. We identified 173 cardiovascular disease deaths 
(International Classification of Diseases ninth revision codes 390-459 or tenth revision codes 
I00-I99) and 2 age and sex  matched controls per case (n = 346). Serum was available for 137 of 
the participants who had died and for 250 of the controls. Three of the controls had died during 
follow-up from non-cardiovascular disease.  The subjects ranged in age from 26 to 85 years. 
Absence of blood sample occurred more often in the 1995-1997 survey: 96 cases and 198 
controls were seen in 1990-1992, while 41 cases and 51 controls were seen in 1995-1997. 
Complete covariate data were available in 130 cases 95 in 1990 and 35 in 1995) and 240 
controls (197 in 1990 and 43 in 1995). Findings were barely altered if the 16 missing covariate 
values were imputed from the participant’s sex, age, body mass index (BMI), and diabetes 
status. Nevertheless, we report on those with complete data because 12 of the missing values 
were in high-density lipoprotein (HDL) cholesterol, and this variable played a central role in 
these analyses. 
Clinical assessment  
Height was measured in stocking feet with a wooden triangle and a rigid ruler attached to a wall. 
Weight was measured without coat and shoes with a beam balance; the balance was calibrated 
daily with a 22.7-kg (50-lb) weight. BMI was calculated as weight (kg) divided by the square of 
height (m2).  
Systolic and fifth phase diastolic blood pressure were measured with a random zero 
sphygmomanometer (Hawksley, West Sussex, United Kingdom) throughout the study by trained 
technicians according to a standard procedure (9). The average of two blood pressure 
measurements taken 1 minute apart is presented.  
Information on age, sex, leisure-time physical activity, smoking, and the consumption of 
alcoholic beverages was obtained by interviewer administered questionnaires. For leisure-time 
physical activity, four questions were asked about the intensity, duration, and frequency of 
exercise sessions and a physical activity score (in MET-hr/day) was derived (10). 
Laboratory assays in serum 
Non-fasting blood was drawn according to standardized protocols that differed in one respect 
(typical duration of refrigeration in clinic at 4ºC) between the 1990 and 1995 surveys. After 
clotting, serum was isolated and refrigerated up to several days in the 1990 survey but generally 
within 24 hours in the 1995 survey. Upon receipt in the laboratory, all serum samples were 
stored at –70ºC, and serum was used for all subsequent laboratory analyses. 
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Total cholesterol was assayed with an AutoAnalyzer II (Technicon Corporation) with a 
nonenzymatic method between 1990 and 1992 and with an enzymatic method thereafter. HDL 
cholesterol was measured with an enzymatic method after precipitation of non-HDL cholesterol 
with heparin and Mn2+ (1990-1992) (11) or magnesium dextran sulfate (1995-1997) (12). 
Glucose, urea nitrogen, aspartate aminotransferase, alanine aminotransferase and gamma 
glutamyltransferase were measured using a Vitros 950 multi-channel analyzer (Ortho Clinical 
Diagnostics, Raritan, NJ) using their standard thin-layer reflectance spectrophotometric 
methods. Average analytical CV’s for these assays at the high end of the normal reference range 
were, <3% for all analytes. 
GPx-3 activity in all samples was determined in 2006 by a modified kinetic assay as 
previously described (1). Briefly, the serum samples, glutathione and glutathione reductase were 
aliquoted in quadruplicate into a 96 well microtitre plate, with a phosphate buffer. The plate was 
warmed to 37ºC and nicotinamide adenine dinucleotide phosphate (NADPH) was added and the 
plate was shaken. The decrease in absorbance at 340 nm was determined in a microtitre plate 
reader (FLUOstar, BMG, Offenberg, Germany). The coefficient of variation was 5% within 
plate.  
The GPx-3 activity was generally lower in samples collected in 1990 than in those 
collected in 1995. During characterization of the GPx-3 assay (work associated with, but not 
reported in Chen et al (1)), we observed a loss of serum GPx-3 activity in samples stored for 48 
hours at 4ºC compared to aliquots of the same samples that had quickly been frozen at -70ºC. 
This difference presumably occurred because of the longer pre-freezing refrigeration time in 
1990. To rule out a difference between plates as the source of the difference in GPx-3 activity 
between surveys, we investigated whether 1990 and 1995 samples run on the same plate had 
widely differential values. Because the samples were run in the order received, there was only 
one such plate, for which GPx-3 mean activity (SD) was 0.36 (0.13) U/ml in thirteen 1990 
samples versus 0.76 (0.07) U/ml in eight 1995 samples (P for difference <.0001).  
Data analysis 
Case-control differences were similar within participants in the 1990 survey as within 
participants in the 1995 survey and the primary findings pool data from the two surveys.  
However, given GPx-3 differences and case/control differences in blood sample availability 
between years, we also present survey specific data to demonstrate this consistency. In the 
pooled analyses, we adjusted for baseline year and used baseline year-specific quartiles based on 
the distribution in controls in assessing the association between GPx-3 activity and 
cardiovascular mortality. Relative risks for cardiovascular mortality were studied by calculating 
odds ratios (ORs) and 95% confidence intervals (CIs) in logistic regression models. The lowest 
quartile was the reference.  
All analyses were adjusted for age, sex, and baseline year (model 1). In multivariable 
analysis, we first included BMI, cigarette smoking, physical activity, and the intake of alcohol 
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(model 2). This model was then extended with serum total and HDL cholesterol, systolic blood 
pressure, non-fasting serum glucose, and serum gamma glutamyltransferase (model 3). Trends 
across quartiles of GPx-3 activity were assessed by modeling one variable for quartiles of GPx-3 
activity as a continuous variable.  
Stratified analyses for HDL cholesterol were conducted to assess whether the relation 
between serum GPx-3 and cardiovascular mortality differed in those below vs. above sex-
specific median values for HDL cholesterol. The sex-specific median values for HDL 
cholesterol were similar for 1990-1992 and 1995-1997. A product term of GPx-3 (quartiles) and 
HDL cholesterol (continuous) was entered into the multivariable model to assess the statistical 
significance of this interaction. All analyses were conducted with SAS version 9.1 (SAS 
Institute Inc., Cary, NC, USA). The authors had full access to the data and take responsibility for 
its integrity. All authors have read and agree to the manuscript as written. 
Results 
Baseline characteristics 
Of the 130 cardiovascular mortality cases included in the analyses, 66 (51%) had died of 
coronary heart disease, 25 (19%) of atherosclerotic stroke, 22 (17%) of other atherosclerotic 
cardiovascular diseases and 17 (13%) of non-atherosclerotic cardiovascular diseases. 95% of 
cases and 97% of controls were of white race. Overall, cases were more likely to smoke, had 
higher average systolic blood pressure, non-fasting serum glucose and serum gamma 
glutamyltransferase, and lower average serum HDL cholesterol than did controls (Table 1). 
Furthermore, cases were more likely to use medication for hypertension and hyperlipidemia, and 
to self-report having diabetes. These differences were mutually independent, apart from higher 
prevalent diabetes in the cases, which lost statistical significance after regression adjustment for 
other risk factors for cardiovascular diseases. The GPx-3 activity was lower in cases than 
controls, but varied between surveys, with mean (SD) activity for samples collected in 1990 0.32 
(0.12) U/ml, while those collected in 1995 had mean 0.51 (0.19) U/ml. Case-control difference 
were generally similar between surveys, although, like GPx-3, aspartate aminotransferase and 
alanine aminotransferase activities were higher in both cases and controls in 1995 than in 1990, 
while gamma glutamyltranferase activity and serum lipid, glucose, and urea nitrogen 
concentrations were comparable between the two surveys (data not shown). Among controls, 
GPx-3 activity was unrelated or inconsistently related to the covariates studied (Table 2) and 
there were no notable differences in GPx-3 associations with covariates between the 1990 and 
1995 surveys (data not shown).  
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Table 1: Baseline (1990-1992 or 1995-1997) characteristics of the total study population by case-control status, the 
Minnesota Heart Survey 
 
Characteristic 
Cases  
(n=130) 
Controls  
(n=240) 
P* 
Male sex, %† 57.7 56.7 .85 
Age, y† 69.2 (11.9) 67.9 (12.2) .33 
BMI, kg/m2 27.8 (5.1) 27.3 (4.3) .16 
Current smoker, %  20.8 8.3 <.001 
Alcohol, drinks per week 5.6 (12.8) 3.4 (6.8) .07 
Physical activity, MET-hr/day 8.5 (12.7) 7.8 (10.7) .60 
Serum cholesterol, mg/dl    
Total 220 (43) 216 (38) .43 
High-density lipoprotein (HDL) 41 (14) 45 (15) .03 
Lipid-lowering medication, % 13.8 6.7 .02 
Hypercholesterolemia, %‡ 41.5 32.1 .06 
Blood pressure, mm Hg    
Systolic 135.9 (18.5) 130.1 (18.9) .005 
Diastolic 75.7 (12.7) 74.6 (10.6) .37 
Antihypertensive use, % 40.8 25.4 .002 
Hypertension, %§ 66.9 43.8 <.001 
Self-reported diabetes, % 19.2 7.5 <.001 
Aspirin use, % 39.2 35.0 .52 
Enyme activities in serum    
Glutathione peroxidase-3, U/mL║ 0.34 (0.01) 0.37 (0.01) .02 
Gamma glutamyltransferase, U/L 43.3 (69.7) 25.9 (18.3) .006 
Serum glucose, mg/dL¶ 130 (62) 109 (36) <.001 
Urea nitrogen, mg/dL 19.7 (9.2) 18.1 (4.9) .07 
Data are given as mean (SD), unless otherwise indicated.  
*Based on 2-sample t-test, Mann-Whitney U test, or Chi-square test. 
†Matching factor. 
‡Defined as a serum total cholesterol >200 mg/dl. 
§Defined as a blood pressure of ≥140/90 mm Hg or the use of antihypertensive medication. 
║Given are mean (standard error) glutathione peroxidase-3 activities adjusted for baseline year in covariance analysis. 
¶Glucose concentrations were measured in non-fasting sera. 
 
Serum activity of GPx-3 and cardiovascular mortality 
Serum GPx-3 activity was inversely and dose-dependently related to cardiovascular mortality 
after controlling for the matching factors age and sex, and baseline year (Table 3). Additional 
adjustment for conventional cardiovascular risk factors and the activity of gamma 
glutamyltransferase had little effect on the strength of the association. The regression coefficient 
predicting the case-control logit per standard deviation of GPx-3 was -0.48 (P = .02) in 1990 and 
was -0.1 (P = .70) in 1995.   
The association between GPx-3 and cardiovascular mortality was restricted to subjects 
with below sex-specific median concentration of serum HDL cholesterol (cutpoints were 38 
mg/dl in men and 48 mg/dl in women), whereas GPx-3 was not significantly related in those 
with higher HDL cholesterol concentration (P for interaction, .006). For those below median 
HDL cholesterol, the multivariable adjusted regression coefficient predicting the case-control
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Table 2: Cross-sectional relation between glutathione peroxidase 3 activity and characteristics at baseline: the 
Minnesota Heart Survey* 
Characteristic Baseline serum glutathione peroxidase 3 activity† 
 Q1 Q2 Q3 Q4 
P trend‡ 
Number of controls 59 60 61 60  
Male sex, % 49.2 61.7 55.7 60.0 .81 
Age, y 68.5 (11.1) 68.1 (12.8) 68.4 ±13.5) 66.6 (11.3) .52 
BMI, kg/m2 27.8 (4.8) 26.9 (3.4) 26.8 (4.6) 27.7 (4.4) .46 
Current smoker, % 8.5 11.7 6.6 8.3 .86 
Alcohol, drinks per week 3.1 (5.6) 4.7 (9.4) 3.2 (5.1) 2.5 (6.1) .33 
Physical activity, MET-hr/day 8.2 (11.4) 6.8 (9.5) 7.0 (9.8) 9.1 (12.2) .63 
Serum cholesterol, mg/dL      
Total 219 (39) 213 (43) 219 (34) 214 (36) .73 
High-density lipoprotein 42 (15) 45 (14) 50 (14) 43 (14) .03 
Lipid-lowering medication, % 5.1 11.7 0.0 10.0 .04 
Hypercholesterolemia, %║ 33.9 35.0 31.1 28.3 .89 
Blood pressure, mm Hg      
Systolic 127.8 (18.4) 128.2 (16.9) 130.6 (19.4) 133.9 (20.7) .26 
Diastolic 73.5 (11.3) 74.0 (9.6) 75.4 (11.6) 75.3 (10.0) .71 
Antihypertensive use, % 27.1 20.0 24.6 30.0 .64 
Hypertension, %§ 39.0 33.3 50.8 51.7 .11 
Self-reported diabetes, % 8.5 6.7 4.9 10.0 .74 
Aspirin use, % 42.4 23.3 36.1 33.3 .17 
Gamma glutamyltransferase, 
U/L 
25.7 (19.8) 23.6 (14.0) 26.2 (17.2) 28.1 (21.6) .61 
Serum glucose, mg/dL¶ 108 (26) 105 (24) 110 (30) 115 (55) .47 
Urea nitrogen, mg/dL 19.6 (6.8) 17.8 (3.8) 17.7 (4.4) 17.4 (3.9) .05 
Data are given as mean (SD), unless otherwise indicated.  
†Shown are year-specific (1990-1992 and 1995-1997) quartiles of glutathione peroxidase 3 activity, based on the distribution in 
controls. Ranges of glutathione peroxidase 3 activity in U/ml for increasing quartiles were 0.09-0.23, 0.24-0.30, 0.31-0.42, and 0.43-
0.76 in 1990-1992, and 0.17-0.35, 0.36-0.47, 0.48-0.56, and 0.57-1.03 in 1995-1997. 
‡Based on modeling quartiles of glutathione peroxidase 1 activity as a continuous variable. 
§Defined as a blood pressure of ≥140/90 mm Hg or the use of antihypertensive medication. 
║Defined as a serum total cholesterol >200 mg/dL. 
¶Glucose concentrations were measured in non-fasting sera. 
 
logit per standard deviation of GPx-3 was -0.67 (P = .01) in 1990 and was -0.62 (P = .10) in 
1995, compared to values for those at or above median HDL cholesterol, namely -0.08 in 1990 
and 0.43 in 1995, neither significantly different from zero. We also displayed the association of 
GPx-3 activity and HDL cholesterol with cardiovascular mortality with the joint lowest GPx-3 
quartile / below median HDL cholesterol as the single reference category. Compared to this 
reference, the multivariable-adjusted risk of cardiovascular mortality decreased across 
increasing quartiles of GPx-3 in those with below median HDL cholesterol concentration 
(Figure). In contrast, in those at or above the median HDL cholesterol concentration, the 
cardiovascular mortality risk across quartiles of GPx-3 was nearly constant and similar to the 
risk seen in those with a low HDL cholesterol concentration and high GPx-3 activity. 
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Table 3: Odds ratios and 95% confidence intervals (CIs) of cardiovascular mortality by serum glutathione peroxidase-3 activity: the Minnesota Heart Survey 
 Quartiles of baseline serum glutathione peroxidase-3 activity* 
 Q1 Q2 Q3 Q4 
Regression coefficient 
(SE)‡ 
 
P 
All subjects       
Number of cases/controls 43/59 35/60 32/61 20/60   
Odds ratio (95% CI)       
Model A§ 1.00 0.79 (0.44-1.40) 0.69 (0.38-1.25) 0.44 (0.23-0.83) -0.30 (0.14) .03 
Model B║ 1.00  0.79 (0.43-1.43) 0.70 (0.38-1.30) 0.44 (0.23-0.86) -0.28 (0.14) .05 
Model C¶ 1.00 0.90 (0.48-1.68) 0.77 (0.40-1.49) 0.42 (0.21-0.86) -0.30 (0.15) .04 
Low HDL cholesterol**       
Number of cases/controls 35/35 20/26 15/20 9/33   
Odds ratio (95% CI)       
Model A§ 1.00 0.74 (0.35-1.57) 0.72 (0.32-1.65) 0.26 (0.11-0.64) -0.52 (0.19) .005 
Model B║ 1.00  0.78 (0.36-1.71) 0.71 (0.29-1.69) 0.23 (0.09-0.58) -0.57 (0.20) .004 
Model C¶ 1.00 0.82 (0.36-1.88) 0.60 (0.23-1.59) 0.17 (0.06-0.47) -0.68 (0.22) .002 
High HDL cholesterol**       
Number of cases/controls 8/24 15/34 17/41 11/27   
Odds ratio (95% CI)       
Model A§ 1.00 1.28 (0.46-3.58) 1.15 (0.42-3.14) 1.16 (0.39-3.42) 0.09 (0.22) .67 
Model B║ 1.00  1.33 (0.44-4.02) 1.34 (0.45-4.00) 1.29 (0.39-4.26) 0.15 (0.23) .53 
Model C¶ 1.00 1.38 (0.44-4.35) 1.34 (0.43-4.16) 1.22 (0.35-4.27) 0.12 (0.24) .62 
*Shown are year-specific (1990-1992 and 1995-1997) quartiles of glutathione peroxidase 3 activity, based on the distribution in controls. Ranges of glutathione peroxidase 3 activity in U/ml for 
increasing quartiles were 0.09-0.23, 0.24-0.30, 0.31-0.42, and 0.43-0.76 in 1990-1992, and 0.17-0.35, 0.36-0.47, 0.48-0.56, and 0.57-1.03 in 1995-1997. 
‡Shown are regression coefficients (standard errors) predicting the case-control logit per standard-deviation (0.16 U/ml) increase of glutathione peroxidase 3 activity. 
§Adjusted for matching factors age (continuous) and sex, and baseline year. 
║Adjusted as in model 1, but with additional adjustment for body mass index (continuous), current cigarette smoking, alcohol use (dummy variables in drinks per week: 1-6, 7-14, >14), and physical 
activity (continuous). 
¶Adjusted as in model 2, but with additional adjustment for total cholesterol (continuous), high-density lipoprotein (HDL) cholesterol (continuous), systolic blood pressure (continuous), non-fasting 
glucose (continuous), and gamma glutamyltransferase (continuous). In stratified analysis, adjustment for HDL cholesterol was omitted. 
** Low high-density lipoprotein (HDL) cholesterol was defined as lower than the median serum value of 38 mg/dl for men and 48 mg/dl for women, high serum HDL as greater or equal than 38 mg/dl in 
men and greater or equal than 48 mg/dl in women. 
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Figure: Odds ratios for cardiovascular mortality for joint levels of glutathione peroxidase 3 activity and high-density 
lipoprotein (HDL) cholesterol, adjusted for age, sex, baseline year, body mass index (continuous), current cigarette 
smoking, alcohol use (dummy variables in drinks per week: 1-6, 7-14, >14), and physical activity (continuous), total 
cholesterol (continuous), high-density lipoprotein (HDL) cholesterol (continuous), systolic blood pressure 
(continuous), non-fasting glucose (continuous), and gamma glutamyltransferase (continuous). Glutathione 
peroxidase 3 activities were year-specific quartiles, based on the distribution among controls. For HDL cholesterol, 
sex-specific median values were used as cutpoints; the median value was 38 mg/dl in men and 48 mg/dl in women. 
Those in the lowest quartile of glutathione peroxidase-3 activity and with below median HDL cholesterol served as 
the reference. The interaction tested was between quartiles of glutathione peroxidase-3 activity (as a continuous 
variable coded 1 to 4) and HDL cholesterol (continuous). * denotes P < 0.05 as compared to the reference. 
 
 
After excluding cases that had died of non-atherosclerotic cardiovascular diseases 
(n=13), the relation in those with below median HDL cholesterol concentration remained 
essentially similar, with multivariable-adjusted odds ratios (95% CIs) for increasing quartiles of 
GPx-3 activity of 1.00, 0.83 (0.35 to 1.95), 0.58 (0.21 to 1.62), and 0.20 (0.07 to 0.57) (P for 
trend = .003). Additional adjustment for the use of aspirin or medication for hyperlipidemia or 
hypertension, or the prevalence of diabetes mellitus did not influence the estimates. The relation 
between GPx-3 activity and cardiovascular mortality did not differ significantly between 
smokers and non-smokers (P for interaction = .52), or alcohol intake (P for interaction = .08) or 
age (P for interaction = .14). 
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Discussion 
In the current nested case-control study, the activity of GPx-3 in serum was inversely associated 
with cardiovascular mortality in a linear fashion, especially in subjects with low serum HDL 
cholesterol concentration. This relation was independent of conventional risk factors of 
cardiovascular diseases and gamma glutamyltransferase activity. 
It is widely accepted that oxidized plasma lipids initiate and promote cardiovascular 
disease (13). GPx-3, which is the form found in HDL particles, is one enzyme that catalyzes the 
reduction of plasma lipid hydroperoxides. Although no population based studies have been 
published on the role of GPx-3  in cardiovascular disease, a few basic studies suggest that it may 
have a protective role (14,15). One study found that homocysteine decreased the concentration 
of nitric oxide through inhibition of GPx-1 (14), which was supported by an in vitro observation 
that homocysteine inhibited GPx-3 activity (1). Porter et al. (16) and Dogru-Abbasoglu et al. 
(17) in small cross-sectional studies have observed that patients with cardiovascular diseases 
have lower plasma, platelet, and erythrocyte (16) and plasma (17) GPx-3 activities than do 
normals. GPx-1 activity was inversely related to incident atherosclerotic events in the 
ATHEROGENE study in CAD patients with coronary artery disease (3,4).  The 
ATHEROGENE study also found that the prediction of new events from homocysteine was 
stronger in those with low GPx-1 than in those with higher values (18). Similarly, Voetsch et al. 
(5) reported that the presence of several genetic variants in the promoter region of the GPx-3 
gene were associated with an increased risk of premature arterial ischemic strokes. Finally, a 
case-control study (19) found that serum glutathione concentrations in the adolescent sons of 
recent myocardial infarction victims were significantly lower than those of sons of age-matched 
controls. Our finding of an inverse association between the activity of GPx-3 and cardiovascular 
mortality is consistent with these observations.  
In the current study, the inverse relation was confined to those with low HDL cholesterol 
concentration. This may suggest that GPx-3 is an important antioxidant enzyme in persons with 
low HDL cholesterol concentration. In the Veterans Affairs High-Density Lipoprotein 
Cholesterol Intervention trial (VA-HIT) (20), patients with coronary heart disease and low HDL 
cholesterol concentrations were treated with the fibric acid derivative gemfibrozil. Although 
gemfibrozil significantly increased the HDL cholesterol concentrations and reduced coronary 
heart disease as compared to placebo, the increase in HDL cholesterol could only explain 23% 
of the reduction in coronary heart disease (21). This suggests that mechanisms other than HDL 
cholesterol are involved in the reduction of coronary heart disease, perhaps an increase in GPx-3 
activity (2). This hypothesis is supported by the finding that treatment of dyslipidemia with 
fenofibrate for 120 days was accompanied by an increase of the activity of GPx in erythrocytes 
by 80% (22). Another study of fenofibrate (23) failed to observe such an increase, but red cells 
do not form new protein once in circulation, and the treatment duration of 30 days was 
insufficient for much red cell turn over. 
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This study has several limitations, mostly arising from the fact that the MHS was not 
designed to study the question posed here. Many scheduled blood samples were not collected, 
especially in 1995, and for unknown reasons this differentially affected those selected as 
controls in 1995.  The number of cardiovascular deaths was relatively small, resulting in a 
sample size limitation, which limited the power to study the associations of GPx-3 activity in 
more detail. There was a systematic difference in GPx-3 activity for samples collected in 1990 
versus 1995, probably accounted for by differential prefreezing refrigeration time.  It is unlikely 
that any deterioration in samples would have affected cases and controls differentially, but the 
1995 survey GPx-3 activity values are likely to be more representative of general population 
levels than are those reported here from the 1990 survey. Because we also noted systematically 
lower activity values for samples collected in 1990 compared to those collected in 1995 for the 
serum activity of aspartate aminotransferase and alanine aminotransferase, but not for gamma 
glutamyltranferase or for serum levels of lipids, glucose, and urea nitrogen, we therefore could 
not rule out some deterioration during the 5 years longer storage time at –70ºC as contributory, 
although such deterioration seems unlikely at this storage temperature. We removed any effect 
of this difference in GPx-3 by verifying that the case-control difference was similar between 
baseline years, computing year-specific quartiles for the activity of GPx-3, and adjusting all 
analyses for baseline year. Despite all these problems, this MHS nested case-control study 
provided an important opportunity for prospective study of GPx-3 and cardiovascular disease 
incidence. 
In conclusion, our nested case control study indicates that a high activity of GPx-3 is 
related to a lower risk of cardiovascular mortality, particularly in persons with low concentration 
of HDL cholesterol. A high serum GPx-3 activity in those with low serum HDL cholesterol 
concentration may contribute to reduced cardiovascular mortality.  
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General Discussion: 
The Antioxidant Paradox, Oxidative 
Stress, and Cardiovascular Diseases 
 
 
 
 
The research described in this thesis aimed to elucidate the role that antioxidants and oxidative stress play in 
the development of cardiovascular diseases from an epidemiological perspective. Specifically, the objectives 
were to confirm previous observational studies on beta-carotene and vitamin E in relation to CVD, and to 
evaluate emerging antioxidants and indicators of oxidative stress in relation to CVD. The main findings were 
a three-fold lower 40-year mortality from coronary heart disease (CHD) in the Cretan cohort (Greece) 
compared with the Zutphen cohort (The Netherlands; Chapter 3) of the Seven Countries Study. This lower 
CHD mortality was paralleled by a higher intake of carotenoids from fruits and vegetables, particularly 
tomotoes, and a higher intake of alpha-tocopherol from olive oil. Also, the Cretan men had lower intakes of 
saturated and trans fatty acids than did the Zupthen men. These differences in intake were confimed at the age 
of 80 years and older, when the Cretan cohort had higher plasma concentrations of major dietary antioxidants 
such as lycopene and alpha-tocopherol, lower levels of iron status, lower levels of oxidative stress and 
inflammation, and a more favorable plasma fatty acid composition (Chapter 2). Earlier prospective cohort 
studies that found inverse associations between antioxidants and risk of cardiovascular diseases (CVD) were 
confirmed for dietary and blood concentrations of (beta-)carotene, but not for vitamin E (Chapters 4 and 5). 
Novel findings were the inverse association between the intake of cocoa, a rich source of flavanol 
antioxidants, with blood pressure and 15-year CVD and all-cause mortality (Chapter 6), and the inverse 
relation of serum glutathione peroxidase-3, an antioxidant enzyme, with CVD mortality, particularly in 
persons with low HDL cholesterol concentrations (Chapter 7). This chapter puts these findings into 
perspective and gives suggestions for future research. 
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The antioxidant paradox: no clear-cut answer yet 
The antioxidant paradox refers to the sharp contrast that exists in evidence concerning the 
cardiovascular benefits of antioxidants (1), primarily vitamin E and beta-carotene, obtained from 
experimental animal studies and human observational studies (generally suggesting beneficial 
effects) on the one hand, and large-scale randomized trials (finding no or even harmful effects) 
on the other hand. There is yet no clear-cut answer for this apparent paradox, although a plethora 
of possible explanations exists. 
In retrospect, the first large prospective cohort studies for vitamin E showed consistently 
strong associations (2-5) which were considered too large to be explained by confounding 
(relative risks for CHD were between 0.4-0.6 in (3-5)). However, the results of later published 
studies on vitamin E were less consistent (6), and two prospective cohort studies described in 
this thesis did not find an association of either vitamin E intake or vitamin E concentrations in 
blood with CVD mortality.  
An all-embracing explanation for the first positive cohort studies is lacking. One of the 
reasons may be that subjects with a high intake of vitamin E, in particular vitamin E supplement 
users, differ in a multitude of aspects from those with a low intake. By definition, observational 
studies do not randomize participants with respect to exposure as is done in clinical trials. 
Although differences between subjects in observational studies are usually accounted for by 
statistical adjustments, it is sometimes not certain whether these adjustments are sufficient (7). 
Residual confounding arises when a factor related to both exposure and disease, while not 
involved in the causal pathway, is not at all or (due to measurement error or improper 
categorization) poorly accounted for. This is a major threat to the validity of observational 
studies. 
Multiple factors have been suggested to be inadequately accounted for in observational 
studies on antioxidants and CVD. First, multiple social and behavioral factors acting across the 
course of life have been proposed (8). In the British Women’s Heart and Health Study, Lawlor 
et al. (8) showed that adulthood plasma concentrations of vitamin C, and to a lesser extent also 
vitamin E, are inversely related to multiple measures of socioeconomic status from childhood 
through adulthood. They propose that observational studies should account for a wide range of 
socioeconomic and behavioral factors and demonstrated in the same population that plasma 
vitamin C is not longer associated with coronary heart disease after adjustment for these factors 
(9). However, this approach has been criticized by others (10,11), due to a lack of biological and 
quantitative plausibility and because many of the proposed measures, such as adulthood leg-
length as marker for early life exposure, have multifactorial causes (12). 
A second possible factor that has been proposed to induce residual confounding is (low-
grade) systemic inflammation. Because inflammation itself has consistently been shown a risk 
factor for coronary heart disease (13), and plasma levels of antioxidants have been inversely 
related to measures of inflammation (14-17), it may be that plasma antioxidants are simply a 
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surrogate for inflammation. Alternatively, it may also be possible that inflammation lies within 
the biological pathway in which antioxidants lower CVD risk. This is supported by the 
observation that supplementation with antioxidants reduces measures of inflammation in various 
populations (18-21). If antioxidants truly lower inflammation, then observational studies on 
antioxidants and CVD can evaluate the contribution by the reduction in inflammation by 
adjusting for it in the statistical analysis. However, the observational studies on antioxidants and 
CVD risk that accounted for inflammation did not show substantial attenuation of the risk 
estimates (16,22,23), which suggests that the inverse associations between antioxidants and 
CVD are explained by other factors than inflammation. 
A third factor, smoking, was initially proposed as confounder in the relation between 
beta-carotene and lung cancer (24). However, it may also be relevant in the relation between 
antioxidants and CVD as smoking is a strong CVD risk factor and has been related to lower 
blood concentrations of antioxidants (17,25). These lower concentrations are at least partly due 
to smoking-induced destruction of antioxidants (26-28). Low blood concentrations of 
antioxidants may therefore simply reflect the risk of cigarette smoking.  However, without a few 
exceptions (4,29), the inverse relation between antioxidants and CVD has been shown, also in 
this thesis, in both smokers and non-smokers (4,5,30). This makes it unlikely that smoking is a 
major confounding factor. It can, however, not be excluded that residual confounding by several 
factors together partly explain the inverse association between antioxidants and CVD. 
Perhaps the most likely explanation is that other dietary antioxidants and compounds 
with bioactive potential are responsible for the apparent protective effects of single antioxidants 
in observational studies. For ages, the human body has been exposed to a wide array of 
antioxidants and bioactive compounds from plant foods, among which tocopherols, tocotrienols, 
carotenoids, and polyphenols. The Zutphen Elderly Study, in which dietary intake was 
repeatedly assessed by means of the dietary history method and intake of antioxidants were 
estimated by using a detailed food composition table, confirms earlier studies that found an 
inverse association of CVD mortality with alpha- and beta-carotene in the diet (Chapter 3). This 
inverse relation was also confimed with concentrations of carotene in blood in SENECA 
(Chapter 4). An explanation for these findings is that carotene (31), like vitamin C (32), is a 
marker for fruit and vegetable consumption and, thus, for their total antioxidant and bioactive 
potential. Taking a single antioxidant in the form of a supplement in dosages beyond dietary 
intake may disrupt the delicate biochemical balance between all these compounds (33,34). This 
may explain the increased risk of CVD and mortality that is related with the use of antioxidant 
supplements (35-38), as it is thought that high dosages of antioxidants exhibit pro-oxidant rather 
than antioxidant effects (39).  
Apart from observational studies, the large-scale trials on antioxidants and CVD have 
been criticized too (1,40-43), including [A] the choice to test a single antioxidant instead of 
multiple, [B] in the synthetic form rather than the natural one with higher activity (vitamin E), 
[C] in a dose that was either too low or too high, [D] for a period that was too short, [E] in 
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patients with established CVD or high risk groups, but without any proven oxidative stress, [F] 
and lack of monitoring therapy compliance. Concerning the dose, it might be that antioxidants 
within the normal dietary range offer protection, whereas amounts beyond that (i.e., from 
supplement use) increase CVD risk (44). Although the total evidence, i.e. from all studies 
together, may suggest such a curvilinear association, this has not been shown within a single 
population.  
Finally, the negative results from the trials might also suggest that the oxidation 
modification hypothesis is incorrect (45). However, the lack of benefit shown by the large-scale 
trials does not necessarily disprove the oxidation hypothesis. Rather, it shows that the type and 
dosage of antioxidants tested in the trials lack benefit. As long as the precise underlying 
mechanisms of in vivo lipoprotein oxidation are unknown, it remains uncertain which 
antioxidants, if any, at what dosages, would be most effective (40). 
In summary, despite many possible explanations, the antioxidant paradox remains 
unsolved. The most likely explanation is that single antioxidants as studied in observational 
studies, were not only reflecting the actual intake of the antioxidant itself, but rather of multiple 
antioxidants and bioactive compounds. 
Cocoa, a food component recently discovered to be rich in 
antioxidants 
Although cocoa has only recently been proposed as a healthy food component, the interest in the 
beneficial health effects of cocoa is not new. Already three centuries ago, it was thought that 
cocoa relieved angina pectoris (46). The empirical research on cocoa and cardiovascular health, 
however, started only a decade ago, after the finding that chocolate is a rich source of 
antioxidants, in particular flavanols (47,48). The first observational data in humans came from 
the island-dwelling Kuna Indians in Panama. While living off Panama’s coast, they consume 
large amounts of cocoa drink and rarely develop hypertension, whereas this apparent protection 
by cocoa is lost upon migration to Panama city (49). 
An important biological mode of action by which cocoa is thought to exert its beneficial 
effects, is by improving endothelial function. The vasodilator nitric oxide (NO) plays an 
essential role in maintaining endothelial function. Endothelial dysfunction is recognized as an 
early event in the development of atherosclerosis (50) and occurs when the bioavailability of NO 
decreases. Consumption of cocoa and chocolate rich in flavanols improves vasodilation (51-54) 
likely by improving NO bioavailability (54,55). Apart from improving endothelial function, 
other possible mechanisms of action include inhibition of platelet function (56,57), increase in 
HDL cholesterol concentrations (58), modulation of cytokine production (59), improvement of 
glycemic control (60,61), and inhibition of LDL oxidation (62). 
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One of the possible effects of improving endothelial function is a lower blood pressure. 
Previous experimental studies have tested the blood pressure lowering potential of dark 
chocolate (53,60,61,63) or cocoa drink (61). In a meta-analysis (64), 100 grams of dark 
chocolate per day for at least 7 days was shown to lower systolic blood pressure by 4.7 (95% CI, 
-7.6 to -1.8) mm Hg and diastolic blood pressure by 2.8 (95% CI, -4.8 to -0.8) mm Hg. The 
findings of the Zutphen Elderly Study indicate that blood pressure can be lowered with already 4 
grams of cocoa per day, comparable to about 10 grams of regular dark chocolate (Chapter 6). 
Indeed, a more recently published intervention study found that 6.3 grams of dark chocolate per 
day for 18 weeks lowered systolic blood pressure with 2.9 mm Hg (P < .001) and diastolic blood 
pressure with 1.9 mm Hg (P < .001), as compared to an isocaloric amount of white chocolate 
(65). 
Apart from the inverse association between habitual cocoa intake and blood pressure, the 
Zutphen Elderly Study also indicates that a daily consumption of 4 grams of cocoa lowers CVD 
mortality by 50% as compared to those not consuming cocoa. Up to present, only two other 
observational studies have published results on cocoa and incident CVD. Chocolate 
consumption was prospectively related to a lower CVD mortality in the Iowa Women’s Health 
Study (66) and to a lower odds of non-fatal myocardial infarction in an Italian case-control study 
(67). 
Taken together, evidence is accumulating that cocoa and its flavanols improve 
endothelial function and lower blood pressure by increasing the bioavailability of NO. Whether 
this translates to a reduced CVD incidence is tempting, but so far there is insufficient evidence 
in this emerging area of research. 
Oxidative stress 
Oxidative stress can be defined as a higher rate of oxidant production compared to the rate of 
their inhibition and degradation. This definition makes oxidative stress a theoretical model and 
more conceptual than operational in biomedical research (68). There is still much to learn about 
the oxidative mechanisms in vivo. Together with the lack of validated indicators of oxidative 
stress and the difficulty in distinguishing oxidative stress as a cause or consequence of disease, 
this makes many scientists skeptical about the role of oxidative stress in disease etiology.   
Oxidative stress in humans can be monitored by [A] measuring products of oxidative 
damage, [B] by challenging the potential of individuals or their tissue (usually blood) to 
withstand in vivo or in vitro oxidation, and by [C] measuring activities of antioxidant enzymes. 
This thesis describes only two of a wide range of measureable products of oxidative processes, 
i.e. concentrations of serum hydroperoxides and malondialdehyde (MDA). In addition, activities 
of two enzymes involved in the metabolism of glutathione were described, i.e. gamma-
glutamyltransferase, of which high activities have been related to an increased CVD risk, and 
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glutathione-peroxidase 3, of which high activities have been related to a lower CVD risk. There 
is, however, little agreement about which is the best indicator of oxidative stress.  
Ideally, a biomarker of oxidative stress should be predictive for and reflect biological 
events related to the pathogenesis of CVD; should be stable over a period of time in individuals; 
should provide identical results when assayed in the same laboratory as well as in different 
laboratories; and should be stable (at least in its ranking) during specimen collection, freezing 
storage, processing and assaying (69). Additional criteria apply for the use in large-scale 
observational studies: the biomarker should also be measurable by an assay that performs well in 
the lower concentration range; the measurement should be feasible on a large scale (reasonable 
costs and high throughput), and utilize a minimum of specimen.  
For most biomarkers, however, there is currently no sufficient information available 
necessary to evaluate these criteria (70). Various products of low-density lipoprotein (LDL) 
oxidation can be measured in blood, but many lack precision (71), and a reduction in LDL 
oxidation by vitamin E supplementation does not substantially lower the progression of 
atherosclerotis (72). MDA is an extensively studied product of polyunsaturated fatty acid 
peroxidation and its concentration was nonsignificantly lower among elderly men in Crete than 
in Zutphen (Chapter 3). Although there has been much concern about the sensitivity and 
specificity (73,74), MDA has also been found an stable and effective marker of smoking related 
oxidative stress (75). Serum hydroperoxides and activity of gamma-glutamyltransferase, were 
much lower in Crete compared to Zutphen, though need to be related to clinical CVD end points 
in future studies.  
The biomarker of oxidative stress that meet most criteria for use in large-scale 
observational studies at present are the isoprostanes, which have become the gold standard for in 
vivo oxidative stress, at least with respect to lipid peroxidation (76). Isoprotanes are stable, 
specific, and unique end products of arachidonic acid oxidation (77). Although isoprostanes may 
be a valid biomarker of lipid peroxidation, measures of lipid peroxidation alone do not represent 
overall oxidative stress, due to a lack of correlation with oxidative stress measures in other 
molecules, including DNA and protein (78). Therefore, it is recommended to measure multiple 
biomarkers of oxidative stress and also concurrently measure markers of inflammation, as 
oxidative stress and inflammation often parallel each other (70).  
Future epidemiological research 
Antioxidants and oxidative stress in relation to CVD form a controversial topic that has been 
extensively studied in the past two decades. Hopeful signs come from studies on foods rich in 
flavonoids and their effects on endothelial function and blood pressure. On the other hand, 
extensive research on beta-carotene and vitamin E has led to the antioxidant paradox.  
Given the evidence that a diet rich in plant foods, including fruit and vegetables, lowers 
CVD risk, and that beta-carotene and vitamin E alone are not responsible for this effect, suggests 
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that multiple antioxidants and other compounds with bioactive potential may synergistically 
offer cardiovascular protection. Therefore, it is worthwhile to study multiple antioxidants 
simultaneously. Since 1941 it has been suggested that vitamin C recycles vitamin E (79,80). Yet, 
the first direct evidence that vitamin C and vitamin E work together in vivo has only recently 
been published (81). More of these studies are needed to indentify which antioxidants are 
working in concert. Up to present, nutritional epidemiology has heavily relied on studying one 
nutrient at a time, by using the so called ‘single-nutrient approach.’ Although this approach is 
powerful and the first to recommend for not commonly studied components in the diet, there is a 
need for additional study designs that address multiple dietary compounds (nutrients or foods) 
simultaneously. The research in this thesis continues to suggest an inverse association between 
beta-carotene and CVD, and also that alpha-carotene intake is related to a lower CVD risk. 
However, beta-carotene itself is not likely to be a causal factor, and the finding for alpha-
carotene merits further study. It may be that beta-carotene, and perhaps also alpha-carotene, are 
just markers of a healthy diet. One relatively new approach in nutritional epidemiology is 
studying patterns of dietary intake by using different analytical techniques (82-85). By using 
these designs, patterns of dietary antioxidants can be studied.  
But perhaps we should go one step further backwards. It has even been suggested that 
studying nutrients is too simplistic and that foods rather than nutrients should be the unit of 
nutritional research (86). By estimating the intake of, for example, beta-carotene from fruit and 
vegetables, researchers will lose information about the food sources of beta-carotene and its 
interactions with other bioactive compounds. During the past few years, results on food and food 
pattern analyses have become a topic of interest in observational studies (87-89). However, there 
is a lack of randomized trials on the effects foods on CVD. Compared to randomized 
intervention trials testing the efficacy of beta-carotene, trials on foods, such as fruit and 
vegetables, are only sparingly published (90-93) and need to be encouraged. Specifically, trials 
with an increased intake of plant foods rich in carotene or flavanols and other flavonoids need to 
be conducted. Studying hard end points, such as incident CVD, might be difficult as long-term 
compliance to a high fruit and vegetable diet is difficult. Therefore, surrogate end points for 
CVD, including blood pressure, inflammation, blood lipids, atherosclerotic progression, and 
oxidative stress should be used. 
In order to measure the efficacy of (foods rich in) antioxidants in reducing oxidative 
stress and inhibiting lipoprotein oxidation, observational and intervention studies should use 
valid biomarkers. Measuring the ability of an antioxidant to lower the ex vivo lipoprotein 
oxidation is widely used, but may not be satisfactory enough. Thus, there is a need for new 
biomarkers. Apart from isoprostanes, the serum concentration of hydroperoxides may be 
worthwhile to consider. Currently, it is recommended to measure multiple measures of oxidative 
stress (70), together with measures of inflammation (94). Also, the use of information on 
antioxidant capacity of foods (95) or redox-active compounds in the diet (96) may be useful in 
observational epidemiology. The incorporation of relevant biomarkers and nutrigenomics (97) 
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may enable researchers to investigate molecular interactions, influences of genetic 
polymorphism, new valid intermediate endpoints, and differentiate persons who are more 
susceptible for oxidative stress from those who are not. In the future, the use of genetic 
epidemiology may be helpful in underpinning the causal inference of antioxidants in 
observational studies. For example, by using the variance in functional genes, researchers may 
differentiate subjects with a high and low antioxidant status or oxidative stress, independent 
from behavioral, social, and environmental factors (98). 
The research on the cardiovascular health effects of cocoa has only just begun. Although 
evidence is accumulating that cocoa may improve CVD risk factors and lower CVD risk itself, 
much research still needs to be done before any recommendations can be made (99). At present, 
only two prospective cohort studies have been published on cocoa and incident CVD, with 
promising results (Chapter 6 and (66)). More of such studies on both intermediate and clinical 
end points are needed to confirm these findings. A biomarker of cocoa or flavanol intake would 
be very useful to estimate the intake accurately. Intervention studies need to increase their 
duration and use lower, more realistic amounts of chocolate or cocoa; use an appropriate placebo 
for chocolate that, apart from having no flavanols, is difficult to distinguish from the 
experimental flavanol-rich chocolate; properly assess and publish the content of flavanols as 
well as other nutrients and bioactive components; and, attempt to publish null or negative results 
to prevent publication bias. Also, although nearly all scientific interest is going out to flavanols 
(100), cocoa also contains other compounds with bioactive potential, including flavonols (101), 
another flavonoid subclass, and methylxanthines such as theobromine (102). Finally, the 
dominance of industry-funded human intervention studies on the health effects of cocoa is 
worrisome. Of 28 identified studies (99), 19 had industrial involvement by either sponsorship or 
authorship, whereas 9 can be classified as industry-independent. Though the interest of the food 
industry in this new area of research is understandable, studies without involvement of the 
industry, funded by governmental and other non-profit organizations, should be encouraged. 
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Summary 
Cardiovascular diseases (CVD) remain the number one cause of death worldwide. During the 
past 20 y, there has been a great interest in the role of antioxidants in the prevention of CVD. 
Antioxidants are proposed to lower CVD risk by reducing oxidative stress in general and the 
oxidation of low-density lipoproteins (LDL) in particular. In this thesis, the role of antioxidants 
and oxidative stress in the development of CVD was investigated from an epidemiological 
perspective. The aim was to confirm previous observational studies on antioxidants and CVD 
risk and to investigate the association of emerging antioxidants and oxidative stress with CVD. 
These objectives were evaluated in cross-cultural and prospective cohort studies. 
 
In Chapters 2 and 3, the Cretan (Greece) and Zutphen (The Netherlands) cohorts of the Seven 
Countries Study were compared cross-culturally with respect to coronary heart disease (CHD) 
mortality, diet, lifestyle, and biomarkers of nutrient intake. At baseline in 1960, 676 men in 
Crete and 878 men in Zutphen (age, 40-59 y), were examined. After 40 y of follow-up, the 
median survival time for all-cause mortality was 32 y in Crete (95% confidence interval [CI]: 31 
to 33 y) compared to 26 y in Zutphen (95% CI: 24 to 27 y; P for difference <0.0001). The CHD 
mortality rate was 3 times lower in Crete. Compared to Zutphen, the Cretan diet was higher 
consumption of fruit, tomatoes, and olive oil, amongst others, and a lower intake of meat, dairy, 
poultry, solid fats and sugar products. Consequently, the intake of carotenoids, alpha-tocopherol, 
and vitamin C was higher, and that of saturated and trans fatty acids lower in Crete. 
At the age of ~80 y and older, the survivors of the Cretan and Zutphen cohorts were 
compared with respect to their antioxidant status, iron status, and level of oxidative stress. This 
analysis included 105 men in Crete and 139 men in Zutphen (age range, 79-98 y). Two 
previously proposed indicators of oxidative stress, i.e. serum hydroperoxides and the activity of 
gamma-glutamyltransferase, were on average lower in Cretan men than men in Zutphen (P < .01 
for both). The most pronounced difference in iron status was a twofold lower mean serum 
ferritin concentration in men in Crete (P < .0001), a marker of the amount of stored iron. Finally, 
Cretan men had consistently higher plasma concentrations of major antioxidants, including a 
higher mean concentration of beta-carotene (P = .001) and even a nearly fourfold higher mean 
concentration of lycopene (P < .0001), a carotenoid exclusively found in tomatoes. Given the 
cross-cultural design and the old age of the survivors, it is difficult to judge the strength the 
relation between these factors and CHD risk.  
 
The Zutphen cohort was used to investigate whether dietary antioxidants were related to CVD 
mortality (Chapter 4). In this study, about 500 men (age, 65-84 y) participated since 1985 and 
were followed for 15 years. Of six dietary carotenoids, only alpha- and beta-carotene were 
inversely related to CVD mortality [relative risk (RR) for 1 standard deviation increase in intake 
of both carotenoids: ~0.80; P for both <.05]. Carrots were the dietary source of these carotenes, 
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and its consumption was also inversely related to CVD mortality (0.83; 95% CI: 0.68–1.00). 
Vitamin E from dietary sources was not related to CVD mortality, nor was dietary vitamin C. 
Also, the total intake of vitamin E and vitamin C as estimated from dietary intake and the use of 
vitamin supplements were not associated with CVD mortality. Finally, multiple dietary 
antioxidants were investigated by constructing an ‘antioxidant score.’ This score was weakly 
inversely related to CVD mortality, and this association was driven by alpha- and beta-carotene. 
 
In the ‘Survey in Europe on Nutrition and the Elderly: a Concerted Action’ (SENECA), the 
association between serum concentrations of carotene and alpha-tocopherol with mortality was 
evaluated (Chapter 5). In this study, 1168 men and women (age, 70-75 y) from eight European 
countries were examined and followed for 10 y. Plasma concentrations of carotene were 
inversely related to mortality [RR for 1 standard deviation increase in plasma concentration: 
0.83 (95% CI: 0.70-1.00) for CVD mortality and 0.79 (95% CI: 0.70-0.89) for all-cause 
mortality]. Plasma concentrations of vitamin E were not related to CVD and all-cause mortality. 
For both antioxidants, the findings on all-cause mortality were confirmed by a meta-analysis of 
5 observational studies, including SENECA. 
 
Data from the Zutphen Elderly Study was also used to address a food component naturally rich 
in certain flavonoids, which became more recently a topic of intensive scientific interest: cocoa 
(Chapter 6). The intake of cocoa from cocoa-containing foods was cross-sectionally related to 
blood pressure, and prospectively to 15-y CVD mortality. As compared to men who did not use 
cocoa, the intake of 4 g of cocoa per day was related to a 3.7 (95% CI: –7.1 to –0.3) mm Hg 
lower mean systolic blood pressure and a 2.1 (95% CI: –4.0 to –0.2) mm Hg lower mean 
diastolic blood pressure (for both P trend < .05). The relative risk of CVD mortality was also 
50% lower in these men (RR: 0.50; 95% CI: 0.32-0.78; P trend = .004).  
 
In the Minnesota Heart Survey, a nested case-control study was conducted on the association 
between CVD mortality and the serum activity of glutathione peroxidase 3 (GPx-3), a scarcely 
studied antioxidant enzyme but considered important in lowering oxidative stress (Chapter 7). 
This analysis included data of 130 CVD deaths and 240 control subjects (age, 26-85 y), from 
who blood was earlier collected, either in 1990-1992 or 1994-1997. Persons in the highest 
quartile of serum activity of GPx-3 had on odds ratio of CVD mortality of 0.42 (95% CI: 0.21-
0.86; P trend = .02). This inverse association was only evident in persons with below median 
concentrations of HDL cholesterol (odds ratio: 0.17; 95% CI: 0.06-0.47; P trend = .001); no 
association was observed in those with median or higher concentrations of HDL cholesterol (P 
interaction = .006). These findings may indicate that having a low concentration of HDL 
cholesterol may not increase the risk of CVD mortality as long as the activity of GPx-3 is high. 
However, due to small numbers and a systematic difference in GPx-3 activity between samples 
from the two used baseline periods, these findings need to be confirmed in other studies. 
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The results described in this thesis were put into perspective in Chapter 8. There is a sharp 
contrast between the favorable results on beta-carotene and vitamin E from observational studies 
and the null-findings or even harmful effects of these antioxidants found in large-scale 
randomized trials (the ‘antioxidant paradox’). The research described in this thesis continous to 
suggest an inverse relation between beta-carotene and CVD mortality, but supports no favorable 
or harmfull role of vitamin E. Altough the interpretation of the findings on beta-carotene 
remains ambiguous, it may be that beta-carotene reflects a diet rich in multiple bioactive 
compounds, including alpha-carotene. The inverse relation of cocoa with blood pressure and 
CVD described in this thesis are supported by short-term intervention studies on intermediate 
risk factors for CVD. However, the research on cocoa and its flavanols has only just started and 
it is too early for drawing firm conclusions.  
Oxidative stress is a term that is more conceptual than operational. Its evaluation as a 
CVD risk factor is hampered by the current lack of validated biomarkers. Criteria for an ideal 
biomarker of oxidative stress are described. Until such biomarkers are not available, it is 
recommended to measure multiple indicators of oxidative stress, together with indicators of 
inflammation. 
Future epidemiological research should evaluate multiple antioxidants simultaneously, 
for example by applying new analytical methods to study food patterns. Also, more intervention 
studies on foods rich in antioxidants such as carotene and flavanols are needed. Such studies 
should use established intermediate CVD end points. Intervention studies on the cardiovascular 
health effects of cocoa should increase in duration, use more realistic amounts of cocoa and a 
suitable placebo, and should publish the content of flavanols and other nutrients. The few 
published prospective cohort studies on cocoa or chocolate and CVD need to be confirmed by 
others. A biomarker of flavanol or cocoa intake would be very useful in this respect.  
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Samenvatting 
Hart- en vaatziekten (HVZ) vormen wereldwijd nog steeds de belangrijkste doodsoorzaak. In de 
afgelopen 20 jaar was er grote belangstelling voor de rol van antioxidanten in de preventie van 
HVZ. Antioxidanten worden verondersteld het risico op HVZ te verkleinen via het verlagen van 
oxidatieve stress, in het bijzonder de oxidatie van het low-density lipoprotein (LDL) cholesterol. 
In dit proefschrift is de rol van antioxidanten en oxidatieve stress op het ontstaan van HVZ 
onderzocht vanuit epidemiologisch perspectief. Het doel was om eerder gepubliceerde 
observationele onderzoeken over antioxidanten in de voeding en HVZ te bevestigen en de relatie 
van nieuwe antioxidanten en indicatoren van oxidatieve stress met HVZ te bestuderen. Hiervoor 
werden cross-culturele en prospectieve cohortstudies gebruikt. 
 
In Hoofdstuk 2 en 3 zijn twee cohorten van de Zeven Landen Studie, namelijk het cohort op 
Kreta (Griekenland) en het cohort in Zutphen (Nederland) met elkaar vergeleken wat betreft 
sterfte aan coronaire hartziekte (CHZ), voeding, leefstijl en biomarkers voor nutriëntinname. 
Tijdens het eerste onderzoek in 1960 werden hiervoor 676 mannen in Kreta en 878 mannen in 
Zutphen (leeftijd 40-59 jaar) onderzocht. Na 40 jaar follow-up was de mediane overlevingsduur 
voor totale sterfte 32 jaar in Kreta (95% betrouwbaarheidsinterval [BI]: 31 tot 33 jaar), 
vergeleken met 26 jaar in Zutphen (95% BI: 24 tot 27 jaar; P < .0001). De sterfte aan CHZ was 
3 keer lager in Kreta. Vergeleken met Zutphen bevatte het Kretenzer voedingspatroon onder 
andere meer fruit, tomaten en olijfolie, en minder vlees, zuivel, gevogelte, zogenaamde ‘harde’ 
vetten en suikerprodukten. Daarom was de inname van carotenoiden, alfa-tocoferol en vitamine 
C hoger, en dat van verzadigde en transvetzuren lager in Kreta. 
Op de leeftijd van ~80 jaar en ouder werden de overlevenden van het Kreta- en 
Zutphencohort vergeleken wat betreft hun antioxidantstatus, ijzerstatus, en mate van oxidatieve 
stress. Dit onderzoek had betrekking op 105 mannen in Kreta en 139 mannen in Zutphen 
(leeftijdsrange 79-98 jaar). Twee veronderstelde indicatoren voor oxidatieve stress in serum, te 
weten de concentratie hydroperoxides en de activiteit van gamma-glutamyltransferase, waren 
gemiddeld lager in de Kretenzer mannen (P < .01 voor beide). Het meest opvallende verschil in 
ijzerstatus was een twee keer zo laag gemiddeld serumferritinegehalte in de Kretenzer mannen 
(P <  .0001). Tenslotte hadden zij ook hogere plasmaconcentraties van antioxidanten in de 
voeding, waaronder een hoger gemiddelde concentratie van beta-caroteen (P =  .0001) en een 
bijna vier keer zo hoog gemiddelde concentratie van lycopeen (P < .0001), een carotenoid dat 
alleen in tomaten voorkomt. Gezien het cross-culturele design van dit onderzoek en de hoge 
leeftijd van de overlevenden is de sterkte van de relatie tussen deze factoren en het CHZ-risico 
moeilijk vast te stellen. 
 
Het cohort in Zutphen werd gebruikt om de relatie tussen antioxidanten in de voeding 
gerelateerd en sterfte aan HVZ te onderzoeken (Hoofdstuk 4). Hiervoor werden gegevens 
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gebruikt van ongeveer 500 mannen (leeftijd 60-80 jaar) die vanaf 1985 werden onderzocht. Van 
in totaal zes verschillende carotenoiden in de voeding waren alleen alfa- en beta-caroteen invers 
gerelateerd aan sterfte door HVZ [relatief risico (RR) voor een toename van 1 standaarddeviatie 
in inname voor beide carotenoiden: ~0,80; P voor beide <.05] . Wortels waren de belangrijkste 
bron van deze carotenoiden in de voeding en de consumptie ervan was ook invers gerelateerd 
aan sterfte door HVZ (RR: 0,83; 95% CI: 0,68–1,00). Vitamine E in de voeding was niet 
gerelateerd aan sterfte door HVZ, evenals vitamine C. Ook de gecombineerde inname van deze 
antioxidant-vitamines in de voeding en voedingssupplementen was niet gerelateerd aan sterfte 
door HVZ. Tenslotte werden verschillende antioxidanten samengevat in een ‘antioxidantscore.’ 
Deze score was zwak invers gerelateerd aan HVZ-mortaliteit, wat verklaard kon worden door de 
belangrijke bijdrage van alfa- en beta-caroteen aan deze score. 
 
In de ‘Survey in Europe on Nutrition and the Elderly: a Concerted Action’ (SENECA) werden 
de relaties tussen serumconcentraties van carotene en alfa-tocoferol met sterfte bestudeerd 
(Hoofdstuk 5). In dit onderzoek werden 1168 mannen en vrouwen (leeftijd  70-75 jaar) uit acht 
verschillende Europese landen onderzocht en gevolgd voor 10 jaar. Plasmaconcentraties van 
caroteen waren invers gerelateerd aan sterfte door HVZ [RR voor een toename van 1 
standaarddeviatie in plasmaconcentratie: 0,83; 95% betrouwbaarheidsinterval (BI): 0,70-1,00] 
en aan totale mortaliteit (RR: 0,79; 95% BI: 0,70-0,89). Plasmaconcentraties van vitamine E 
waren niet gerelateerd aan HVZ- en totale sterfte. Voor beide antioxidanten werden de 
bevindingen voor totale sterfte bevestigd in een meta-analyse van 5 observationele onderzoeken, 
waaronder SENECA. 
 
Gegevens van de Zutphen Studie werden ook gebruikt voor een onderzoek naar een 
voedingsingrediënt dat van nature rijk is aan bepaalde flavonoiden en recentelijk in 
wetenschappelijke belangstelling is komen te staan: cacao (Hoofdstuk 6). De inname van cacao 
uit voedingsmiddelen werd cross-sectioneel onderzocht in relatie tot bloeddruk en prospectief in 
relatie tot 15-jaars sterfte aan HVZ. Ten opzichte van mannen die geen cacao gebruikten, was de 
inname van 4 g cacao per dag geassocieerd met een 3,7 (95% BI: –7,1 to –0,3) mm Hg lager 
gemiddelde systolische bloeddruk en een 2,1 (95% BI: –4,0 to –0,2) mm Hg lagere diastolische 
bloeddruk (P trend voor beide  < .05). Het relatief risico voor sterfte aan HVZ bij mannen die 
dezelfde hoeveelheid cacao gebruikten was de helft van het risico voor mannen die geen cacao 
aten (RR: 0,50; 95% BI: 0,32-0,78; P voor trend =  .004).  
 
In de Minnesota Heart Survey werd een genest patiënt-controleonderzoek uitgevoerd naar de 
relatie tussen de serumactiviteit van glutathioneperoxidase 3 (GPx-3), een weinig onderzocht 
maar belangrijk verondersteld antioxidantenzym, en sterfte ten gevolge van HVZ (Hoofdstuk 
7). Dit onderzoek had betrekking op gegevens van 130 sterfgevallen van HVZ en 240 
controlepersonen (leeftijd 26-85 jaar), van wie op een eerder tijdstip bloed was afgenomen, 
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ofwel in de periode 1990-1992, ofwel tussen 1994-1997. De odds ratio voor sterfte aan HVZ 
voor personen in het hoogste kwartiel van GPx-3-activiteit bedroeg 0,42 (95% BI: 0,21-0,86; P 
trend = .02). Deze inverse associatie werd alleen waargenomen voor personen met een HDL-
concentratie beneden de mediane waarde (RR: 0,17; 95% BI: 0,06-0,47; P trend = .001); er werd 
geen associatie gevonden voor degenen met HDL-concentraties gelijk of hoger dan de mediaan 
(P interactie = .006). Deze bevindingen suggereren dat een lage HDL-concentratie niet gepaard 
hoeft te gaan met een verhoogd risico op sterfte aan HVZ zolang de activiteit van GPx-3 hoog 
is. Echter, door de kleine omvang van het onderzoek en een systematisch verschil in GPx-3-
activiteit tussen samples van de twee verschillende baselineperioden, is bevestiging van deze 
resultaten in andere onderzoeken noodzakelijk. 
 
De resultaten die beschreven zijn in dit proefschrift werden in perspectief geplaatst in 
Hoofdstuk 8. Er is een groot verschil tussen de gunstige resultaten van beta-caroteen en vitamin 
E uit observationeel onderzoek en de nulbevindingen of zelfs schadelijke effecten van deze 
antioxidanten uit grootschalige gerandomiseerde interventiestudies (de ‘antioxidantparadox’). 
Het onderzoek dat in dit proefschrift beschreven is, blijft duiden op een inverse relatie tussen 
beta-caroteen en sterfte aan HVZ, maar ondersteunt geen gunstige of schadelijke rol voor 
vitamin E. Hoewel de resultaten van beta-caroteen niet eenduidig geïnterpreteerd kunnen 
worden, is het mogelijk dat beta-caroteen een voedingspatroon weerspiegelt dat rijk is aan 
meerdere bioactieve componenten, waaronder alfa-caroteen. De in dit proefschrift beschreven 
inverse associatie van cocoa met bloeddruk en sterfte aan HVZ wordt ondersteunt door 
kortdurende interventiestudies met intermediaire eindpunten voor HVZ. Het onderzoek naar 
cacao en flavanolen is echter pas van start gegaan en het is nog te vroeg om definitieve 
conclusies te trekken. 
Oxidatieve stress is een term die meer conceptueel dan operationeel is. Onderzoek naar 
oxidatieve stress als risicofactor voor HVZ wordt bemoeilijkt door het ontbreken van 
gevalideerde biomarkers. Criteria voor een ideale biomarkers worden beschreven. Zonder 
dergelijke biomarkers verdient het de aanbeveling om meerdere indicatoren van oxidatieve 
stress tezamen met indicatoren van ontstekingprocessen te onderzoeken. 
Toekomstig epidemiologisch onderzoek dient meerdere antioxidanten tegelijkertijd te 
bestuderen. Dit kan bijvoorbeeld door het toepassen nieuw ontwikkelde analysemethoden die 
het mogelijk maken voedingspatronen te bestuderen. Tevens zijn meer interventiestudies 
noodzakelijk met voedingsmiddelen die rijk aan antioxidanten zijn zoals caroteen en flavanolen. 
Dergelijke studies dienen onderbouwde risicofactoren voor HVZ als eindpunt te gebruiken. 
Interventieonderzoek naar de effecten van cocoa op risicofactoren voor HVZ moet zich richten 
op de lange-termijn effecten van realistische hoeveelheden cocoa, een geschikte placebo 
gebruiken, en gehaltes van flavanolen en andere nutriënten in de publicatie vermelden. Meer 
prospectief cohortonderzoek naar de relatie tussen de inname van cocoa en HVZ is 
noodzakelijk. 
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